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The persistence of high global mortality rates directly attributable to 
cardiovascular disease drives ongoing research into novel approaches for improved 
diagnosis and treatment of its primary underlying cause, atherosclerosis. Combined 
intravascular ultrasound and photoacoustic (IVUS/IVPA) imaging is one such modality, 
actively being developed as a tool for improved characterization of high-risk 
atherosclerotic plaques. The pathophysiology associated with progression and 
destabilization of atherosclerotic plaques leads to characteristic changes in arterial 
morphology and composition. IVUS/IVPA imaging seeks to expand upon the ability of 
clinically utilized intravascular ultrasound (IVUS) imaging to assess vessel anatomy by 
adding improved sensitivity to image the underlying cellular and molecular composition 
through intravascular photoacoustic (IVPA) imaging of either endogenous chromophores 
(e.g. lipid) or exogenously delivered contrast agents.  
This dissertation focuses on the expansion of IVUS/IVPA imaging using 
exogenous contrast agents to enable the detection and subsequent optically-triggered 
therapy of atherosclerotic plaques. The passive extravasation and aggregation of 
systemically injected plasmonic gold nanorods absorbing within the near infrared tissue 
optical window within plaques of atherosclerotic rabbit models is first demonstrated, 
 viii 
along with the ability to localize the contrast agents using ex vivo IVUS/IVPA imaging. 
The motivation for nanoparticle labeling of atherosclerosis is then expanded from that of 
purely image contrast agents to vehicles for image-guided, dual-modality phototherapy. 
The integrated IVUS/IVPA imaging catheter is utilized for photothermal delivery with 
simultaneous IVPA temperature monitoring using the high optical absorption of gold 
nanorod contrast agents to enable localized heating. Subsequently, the potential role for 
IVUS/IVPA-guided phototherapy is further expanded through the characterization and in 
vitro assessment of novel multifunctional theranostic nanoparticles comprised of a gold 
nanorod core with a degradable, photosensitizer-doped silica shell. Together, the results 
presented within this dissertation provide a framework for ongoing research into the 
expansion of IVUS/IVPA imaging as a platform for complimentary diagnosis and local 
treatment of atherosclerotic plaques using multifunctional theranostic nanoparticle 
contrast agents.
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Chapter 1: Introduction- The Motivation for Atherosclerotic Plaque 
Characterization and Novel Therapy Guidance Using Intravascular 
Photoacoustics  
The persistence of high global mortality rates which can be directly attributed to 
cardiovascular disease continues to motivate ongoing research into a more complete 
understanding of biological mechanisms for disease progression as well as novel 
approaches for improved diagnosis and treatment of its primary underlying cause, 
atherosclerosis. Coronary heart disease alone is responsible for an estimated 7.3 million 
annual deaths throughout the world and greater than one in six deaths within the United 
States, with estimated related domestic costs well in excess of one hundred billion dollars 
[1,2]. Together, these statistics clearly demonstrate the ongoing need for improved 
preventative, diagnostic, and therapeutic interventions. While several notable risk factors 
are well known, such as high blood pressure or cholesterol levels, smoking, obesity, and 
physical inactivity, their monitoring alone remains insufficient for reliable diagnosis of 
high risk patients. Therefore, improved clinical strategies are needed to aid in the 
diagnosis of atherosclerosis at the level of both the patient and their individual high-risk 
lesion(s).  
Diagnostic imaging, particularly intravascular imaging modalities, represents an 
area of active research with potential to help meet the clinical demand for improved 
localization and characterization of coronary atherosclerosis. However, conventional 
imaging techniques within interventional cardiology provide an incomplete assessment of 
coronary artery plaque, particularly with regard to their ability to differentiate specific 
cellular and molecular biomarkers of atherosclerotic lesion vulnerability. To this end, a 
number of emerging intravascular imaging modalities are currently in development, 
utilizing differing technologies to supplement anatomical images of existing imaging 
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modalities with improved compositional information. Such techniques seek to take 
advantage of the increased understanding of the pathophysiology of atherosclerotic 
plaques, particularly those most prone to induce acute cardiac events. 
1.1. PATHOPHYSIOLOGY AND DESTABILIZATION OF CORONARY ATHEROSCLEROSIS 
Continued molecular biology research over the past several decades has provided 
increased understanding of the fundamental pathophysiological pathways involved in the 
development and destabilization of coronary atherosclerosis. Plaque progression is a 
process involving disordered cholesterol metabolism, compromised endothelial function, 
and loss of vessel patency, with systemic and local inflammatory events occurring 
throughout its growth (Fig. 1.1A). Atherosclerosis develops from endothelial 
dysfunction, causing monocyte recruitment and eventual progression towards an 
advanced, thrombotic plaque [3]. High levels of low density lipoprotein (LDL), or 
infectious agents and toxins can cause endothelial dysfunction and expression of 
adhesion molecules and selectins. High levels of these molecules, in turn, promote the 
accumulation of monocytes, which subsequently form macrophage foam cells and an 
associated amplified inflammatory response with secretion of extracellular matrix 
proteins [4-6]. Ultimately, production of matrix metalloproteinases can weaken a 
plaque’s fibrous cap, leaving the prothrombotic core prone to erosion, fissure, or rupture 
with subsequent thrombus formation which can result in acute complications. 
Together, atherosclerotic lesions which have advanced to the point of being at 
high risk of acute thrombus formation are referred to as ‘vulnerable plaques’. As high as 
60% or more of acute coronary syndromes - a term which encompasses unstable angina, 
acute myocardial infarction, and sudden cardiac death – are the result of thrombi 
formation following atherosclerotic plaque rupture [7]. Several studies investigating the 
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underlying mechanisms and plaque compositions which lead to plaque rupture have led 
to modified classification schemes for staging atherosclerotic lesions, with thin-cap 
fibroatheroma (TCFA) being identified as the most common culprit lesions for plaque 
ruptures [7,8]. TCFA are defined as exhibiting a thin fibrous cap, with thickness <65 µm, 
overlaying a large, lipid-rich necrotic core and an increased infiltration of macrophages 
relative to healthy arterial tissue and more stable atherosclerotic plaque categories (Fig. 
1.1B) [9-16]. Longitudinal sectioning of cadaver coronary arteries has also enabled an 
estimation of the occurrence and distribution of these high-risk plaques, finding that the 
majority of TCFA occur within the proximal third of the major coronary arteries and at 
focal sites within the arteries rather than diffusely spread of over long distances [17]. 
Together, this understanding of the local anatomy and composition lends itself to the 
implementation of targeted diagnostic imaging and localized therapeutic strategies. 
 
 
Figure 1.1: Anatomy and composition of vulnerable atherosclerotic plaques. (A) 
Schematic representation of vulnerable plaque cellular and molecular 
composition. Reprinted with permission from [8]. (B) Histology of a 
vulnerable plaque revealing a thin fibrous cap and high macrophage cell 
density. Reprinted with permission from [18]. 
A B
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The primary biological hallmarks of TCFA plaques include the presence of a 
necrotic core with acellular regions surrounded by elevated macrophage density. Both of 
these characteristics are indicative of an imbalance between intra-plaque apoptosis and 
the clearance of apoptotic cells or necrotic cell debris. In fact, while it is believed that the 
fate of most cells within atheroma is apoptosis, a form of programmed cell death in which 
caspases gradually dismantle the cells in a cascade which signals for their engulfment by 
phagocytes, the level number density of apoptotic cells within a plaque has been shown 
to closely related to its lesion stage and likelihood of plaque rupture [19]. The 
consequences of apoptosis within atheroma are highly dependent on both cell type and 
the plaque stage. In the case of macrophages, experimental models of atherosclerosis 
have shown that increasing apoptosis can lead to a stabilizing effect, with reduced plaque 
size, for early lesions, but result in increased plaque size in older lesions [20]. The driving 
mechanisms for this divergence in effect of macrophage apoptosis has been linked to the 
extent of efferocytosis, engulfment of apoptotic cells by phagocytes and other 
surrounding cells, within the plaques. In advanced lesions, delayed or compromised 
efferocytosis pathways allow apoptotic macrophages to become secondarily necrotic cells 
which, in turn, contribute to the expansion of the necrotic core of vulnerable plaques [21]. 
It has additionally been hypothesized that the predominant cause of compromised 
efferocytosis within advanced plaques is the transition of macrophages into foam cells, 
which yields them inefficient in engulfing nearby apoptotic cells [21]. As a result, the 
presence and biochemical state of macrophages within advanced atherosclerotic plaques 
play an important role in determining and, in many respects, driving the vulnerability of 
the lesion to rupture and induce acute coronary syndromes. Therefore, the ability to 
detect and differentiate macrophages in addition to other anatomical and compositional 
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biomarkers of TCFA plaques is of great interest for both the improved experimental 
understanding and the clinical diagnosis of vulnerable plaques. 
1.2. INTRAVASCULAR IMAGING TECHNIQUES FOR DIAGNOSIS AND 
CHARACTERIZATION OF CORONARY ATHEROSCLEROSIS 
Despite the growing fundamental understanding of the pathophysiology involved 
in atheroma progression and destabilization, its translation into reliable clinical diagnoses 
remains limited by the capabilities of current imaging modalities. For example, the 
traditional gold standard for coronary imaging during percutaneous coronary 
interventions (PCI), contrast coronary angiography, provides only a two dimensional 
projection of vessel patency. While heavily used during intervention to guide catheter 
placement, the resulting images provide a primarily morphological characterization of the 
coronary tree, with little information gained beyond the verification of a local stenosis 
within a coronary artery region. Similarly, coronary computed tomography either utilizes 
contrast injections to obtain projections of the coronary artery patency or detects the 
presence of higher-density calcifications within the coronary arteries. While the amount 
of calcium within the coronary tree has been shown to be correlated with total plaque 
burden, the most vulnerable plaques frequently do not contain significant calcium and, 
therefore, the absence of coronary calcification detected by computed tomography does 
not exclude the potential for vulnerable plaques [22]. Additionally, both angiography and 
computed tomography techniques are fundamentally limited by using contrast to image 
the coronary lumen diameter. Positive remodeling enable preservation of the lumen 
diameter with plaque areas up to 40%, as was first shown by Glagov, through 
compensatory expansion of the arterial wall [23]. This phenomenon has clearly limiting 
implications for imaging techniques which detect only the luminal diameter.  
Furthermore, each of these techniques suffers from inadequate resolution and contrast to 
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detect critical characteristics of plaque stability, such as the thickness of a fibrous cap and 
underlying lipid and macrophage distribution. 
Therefore, there remains a need for improved diagnostic imaging which provide 
interventional cardiologists with greater information regarding the morphology as well as 
the cellular and molecular composition of atheroma to help guide accurate lesion 
characterization and to monitor therapy delivery. Numerous intravascular imaging 
techniques, including those which have already been translated into clinical practice as 
well as those in preclinical development, are poised to help bridge this gap between 
diagnostic imaging capabilities and the fundamental understanding of disease pathology 
[24]. These techniques are briefly introduced below, with an emphasis on the benefits of 
each as an imaging tool for detecting and staging atherosclerotic plaques. 
1.2.1. Intravascular Ultrasound 
Intravascular ultrasound (IVUS) imaging has provided a tool for arterial 
assessment within the catheterization laboratory for several decades, particularly within 
Japan, Europe and the United States. At the time of intervention, an IVUS catheter is 
advanced into the coronary arteries and scanned using a high center frequency ultrasound 
transducer (20-60 MHz) which is rotated to provide real-time, cross-sectional images of 
arterial morphology to aid in diagnosis and therapy guidance during percutaneous 
coronary intervention. Volumetric renderings of coronary artery segments can also be 
obtained if the catheter is mechanically pulled back during rotation. IVUS is commonly 
used for the characterization of atherosclerotic lesions of unclear severity based on 
angiographic assessment to guide selection of the appropriate transcatheter therapy option 
through its ability to delineate the full vessel wall thickness and echogenicity to provide 
metrics associated with lesion severity (Fig. 1.2A) [25]. Despite its ongoing clinical 
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applications, however, IVUS provides limited histopathological information about the 
imaged artery, and histological studies have reported a generally low sensitivity of the 
technique’s ability to differentiate thrombotic and lipid-rich lesions [26,27]. Efforts to 
overcome these fundamental limitations of IVUS have led to the investigation of 
numerous imaging techniques intended to supplement the morphological view provided 
by IVUS imaging with greater information regarding the compositional or mechanical 
characteristics of the interrogated arteries. Among these techniques are virtual histology 
IVUS (VH-IVUS) and integrated backscatter IVUS (IB-IVUS), both of which involve 
analysis of the spectral content of backscattered US signals as a means of predicting 
tissue composition.  Although VH-IVUS and IB-IVUS are clinically available methods 
intended to improve the ability of IVUS to detect plaque composition, the reliability of 
these approaches has recently been questioned [28,29]. Additionally, IVUS palpography, 
a technique which involves the assessment of vessel wall deformation at variable 
intravascular pressures (e.g. systole and diastole) to detect soft versus hard lesions, has 
also been investigated [30]. 
1.2.2. Optical Coherence Tomography 
Intravascular optical coherence tomography (OCT) has also been introduced as an 
alternative to IVUS imaging. OCT is conceptually analogous to IVUS imaging in that 
images from both modalities are generated based on signals reflected from tissue 
structures. However, whereas IVUS signals are received by the direct detection of time of 
flight of the propagating ultrasound pressure transients, in the case of OCT, 
interferometry techniques are used to detect either time delays or frequency shifts in 
received optical echoes, which travel five orders of magnitude faster than ultrasound 
waves. As a result, OCT is able to achieve a higher axial resolution than IVUS imaging 
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and can therefore provide greater ability to differentiate vessel wall and atherosclerotic 
plaque microstructures, with adequate axial resolution to detect the thin cap of TCFA 
plaques (Fig. 1.2B) [31]. In addition to general detection of vessel morphology and 
identification of atherosclerotic plaques, fibrous cap thickness, microcalcifications, 
neovascularization, thrombus, and macrophage infiltration have all been interrogated by 
OCT [32]. The modality is not without its own limitations, however, as it requires saline 
flushing to eliminate blood during signal acquisition, and is capable of providing a 
limited tissue penetration depth of less than approximately 1.25 mm, or even less in lipid-
rich regions [33]. 
1.2.3. Near Infrared Spectroscopy 
While both IVUS and OCT imaging provide clinicians with information primarily 
related to coronary artery morphology, each modality is limited in its ability to 
definitively diagnose arterial composition due to potential ambiguities and artifacts in 
their respective backscattered signals. Intracoronary diffuse reflectance near-infrared 
spectroscopy (NIRS) represents an additional, clinically approved, imaging technique 
which is capable of detecting lipid-rich plaques. NIRS relies on variations in the 
molecular overtone and combination vibrations of endogenous molecules, which result in 
molecular composition-specific optical absorption and scattering within the near-infrared 
region of the electromagnetic spectrum (approximately 1000 nm to 2400 nm). During 
intravascular NIRS imaging, a broadband NIR source is emitted into the arterial wall and 
the returned light is received to extract chemical compositional information of the 
illuminated region. First demonstrated as a tool for assessing atherosclerotic plaques in an 
animal model of atherosclerosis in the early 1990s [34], the capability of NIRS to detect 
several plaque risk indicators, including lipid pools, fibrous cap and inflammatory cells 
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was demonstrated nearly a decade later [35], and the modality was first utilized for in 
vivo human imaging for lipid detection soon thereafter [36]. Commercialized by 
Infraredx, Inc. (Burlington, Massachusetts), and approved by the Food and Drug 
Administration (FDA) in 2008, clinical intravascular NIRS provides a chemogram 
representing the likelihood of a lipid-rich plaque within an angular region of an arterial 
cross-section. A notable advantage of the technique is that this chemogram can be 
obtained through blood, thus avoiding the need for luminal flushing which is required for 
most other optical imaging modalities. However, because NIRS detects remitted light 
from within highly optically scattering blood and tissue, the received signal is not depth-
resolved [37]. Therefore, while the absence or presence of a lipid-rich plaque can be 
detected using NIRS, it alone cannot provide corresponding morphological context 
without being coupled with IVUS or OCT. 
The current clinical NIRS system couples the technique with IVUS imaging, 
providing a dual modality approach to coronary assessment (Fig. 1.2C). Both NIRS and 
IVUS image acquisition are performed simultaneously with a conventional IVUS image 
display encompassed within a chemogram revealing the likelihood of lipid-rich plaque 
within an angular region. In addition to a demonstrated general improvement in the 
ability to characterize high-risk, lipid-rich plaques [36,38], the hybrid NIRS/IVUS 
imaging technique is also being used to generate a database through the Chemometric 
Observations of Lipid Core Plaque of Interest in Native Coronary Arteries (COLOR) 
registry to be used for assessment of the varieties of lipid-rich plaques and their long-term 
clinical significance and responses to available therapies [39]. Additionally, a recently 
launched 9,000 patient Lipid-Rich Plaque Study trial is intended to assess whether this 
hybrid imaging technique can be utilized as a predictor of future coronary events.  
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Early clinical adoption of NIRS/IVUS has been found through its inclusion as an end 
point for lipid-lowering clinical trials [40] and is actively being investigated as a tool to 
help reduce risk of periprocedural complications during PCI through the Coronary 
Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow (CANARY) trial 
[41,42].  As results of the ongoing clinical trials come out, the true clinical impact of 
NIRS/IVUS imaging will be further clarified. 
 
Figure 1.2: Representative images from clinical intravascular imaging systems: (A) IVUS 
and (B) OCT. Reprinted with permission from [43]. (C) NIRS with 
accompanying IVUS; source: infraredx.com. 
1.2.4. Angioscopy 
Coronary angioscopy (CAS) represents an alternative approach for intravascular 
imaging, enabling clear visualization of the luminal arterial wall. Originally introduced as 
early as the mid-1980s [44,45], CAS is a clinically approved, endoscopic technique 
which utilizes a fiber bundle to deliver a white light illumination source as well as to 
collect and return reflected light to a charge-coupled-device, color camera [39]. The 
generated CAS images have been demonstrated to enable the differentiation of atheroma 
composition based, in part, on the color of identified lesions. Fibrous lesions tend to 
appear as white lesions, whereas lipid-rich plaques tend to exhibit a yellow color upon 
CAS visualization, likely due to the carotenoid content of intimal cholesterol [46]. 
Furthermore, the intensity of the detected yellow color has also been associated with the 
A B C
 11 
prevalence of thrombosis on the atheroma, suggesting a potential indicator of lesion 
vulnerability [47]. 
Despite its regulatory approval and ability to distinguish different arterial surface 
compositions, however, the utilization of CAS remains limited to research applications, 
and there are currently no clinical indications for the use of CAS over other imaging 
modalities during coronary intervention.  Limitations of the technique include the 
inability to image beyond the surface of the arterial wall, the requirement of flushing 
luminal blood during imaging, and catheter diameters which are too large to enable 
imaging beyond the proximal regions of main coronary arteries. As a research tool, 
however, CAS continues to be refined and is commonly utilized to help evaluate the 
efficacy of both pharmacological treatment regimes, such as statin therapies [48,49], and 
evaluation of arterial wall response following stent placement [50,51]. Additionally, due 
to its limitation to imaging the arterial surface, CAS has been utilized in combination 
with IVUS [52,53] and OCT [54], as well as the combination of all three modalities [31] 
to provide a more comprehensive evaluation of atherosclerotic lesions.  Despite these 
pairings, however, integrated intravascular probes combining CAS with other 
intravascular modalities have not yet been developed, and co-registration of CAS images 
with those obtained from the same arterial cross-section with different techniques 
remains a challenge for these dual- and tri-modality applications. 
1.2.5. Investigational Intravascular Imaging Techniques  
In addition to the aforementioned clinical approved imaging modalities for 
diagnosis atherosclerotic plaques and guiding their subsequent treatment, several novel 
approaches are currently being investigated within preclinical settings. These 
investigational intravascular techniques include fluorescence techniques, Raman 
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spectroscopy, magnetic resonance, and nuclear imaging.  Each of the modalities offers 
the potential for improvement(s) over existing clinical intravascular imaging modalities, 
particularly enhanced capabilities for assessment of plaque composition or biomarkers. 
1.2.5.1. Fluorescence Imaging Techniques 
Fluorescence imaging techniques have also been introduced as a means of 
enhancing the ability to detect atherosclerotic plaque composition. Several distinct 
fluorescence imaging techniques are underway, including time resolved fluorescence 
spectroscopy (TRFS) and near-infrared fluorescence spectroscopy (NIRF). Initial studies 
were able to differentiate normal arterial tissue from atherosclerotic lesions by assessing 
the tissue molecular components, including lipid, elastin, and collagen based on their 
respective autofluorescence characteristics [55-57]. Increased molecular specificity, 
however, has been achieved through the introduction of TRFS, a technique which relies 
on the temporal profile of remitted photons following excitation with a pulsed optical 
source. TRFS has been demonstrated for the ex vivo classification of atherosclerotic 
plaques into three subtypes; intimal thickening, fibrotic and fibrocalcific, and inflamed 
and necrotic lesions [58]. The ability to detect the presence of macrophage foam cells 
was also demonstrated [59].  Further improvements were subsequently made through the 
introduction of fluorescence lifetime imaging microscopy (FLIM), a TRFS technique 
which enables the recording of two-dimensional lifetime information in an image format, 
compatible within an endoscopic design which permitted an improved imaging depth of 
approximately 4 mm [60,61]. The FLIM catheter was utilized for ex vivo characterization 
of 11 human aorta sections at a total of 48 locations, demonstrating that the technique can 
be used to distinguish clinically relevant plaque features with sensitivities as high as 86% 
and an all case specificity of 87% [62]. Notably, a hybrid imaging probe combining 
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fluorescence spectroscopy with reflectance spectroscopy and Raman spectroscopy has 
also been described [63] and utilized to characterize plaque composition [64]. 
As FLIM and, more generally, TRFS continue development towards clinical 
translation, they suffer from two primary drawbacks, a limited penetration depth of 
approximately 250 µm due to the high absorption and scattering of the excitation light 
and the inability to provide arterial morphology to compliment the compositional 
assessment [61]. 
1.2.5.2. Raman Spectroscopy 
Raman spectroscopy, an alternative method for detecting the molecular signatures 
of biological tissues, has also been investigated as a potential intravascular imaging 
modality. Rather than molecular absorption spectra, as is the basis for NIRS assessment, 
Raman spectroscopy relies on frequency shifts of emitted light which are generated by an 
energy exchange between photons and molecular components of tissues. The magnitude 
of this energy exchange, and thus the extent of the frequency shift of received photons, is 
a function of a given molecule’s vibrational and rotational energies. Raman spectroscopy, 
therefore, offers the potential for very high molecular specificity. Whereas NIRS is used 
to differentiate lipid-rich plaques, Raman spectroscopy offers the potential to differentiate 
specific chemical components such as triglycerides, cholesterol, cholesterol esters, 
elastin, and collagen [65-69]. Several intravascular Raman imaging catheter prototypes 
have been developed and utilized for arterial characterization, including in the presence 
of luminal blood [69-72].   
Irrespective of the potential for high intravascular molecular sensitivity, Raman 
spectroscopy as a stand-alone modality suffers from similar limitations as NIRS, namely 
its inability to detect arterial morphology. To this end, offline approaches coupling the 
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modality with either IVUS or OCT have been investigated [73-77]. While these proof-of-
concept demonstrations of hybrid Raman techniques are still in early stages, they offer 
the potential for development into an intravascular system analogous to that of 
NIRS/IVUS.  
Despite early demonstrations of hybrid modalities combining Raman 
spectroscopy with IVUS or OCT, Raman spectroscopy has failed to be translated into the 
clinic. In comparison to NIRS, Raman spectroscopy typically yields low intensity signals, 
and the resulting low signal-to-noise ratio (SNR) is exacerbated by noise introduced 
within the optical fibers of Raman catheters. While high-wavenumber Raman 
spectroscopy techniques and new catheter designs have provided hope that the technical 
challenges preventing commercialization of a hybrid Raman-based approach to plaque 
assessment will be attained, significant validation is still required [71,75]. 
1.2.5.3. Magnetic Resonance Imaging 
Noninvasive magnetic resonance imaging (MRI) has been utilized to image lipid 
within arterial walls, as well as other biomarkers of atherosclerotic plaque vulnerability 
or rupture through the use of contrast agents, based on the biochemical response of 
protons following the application of an electromagnetic radiofrequency pulse within the 
presence of a static magnetic field [78]. Noninvasive MRI, however, is ill-suited for such 
imaging of the coronary arteries due to a lack of adequate signal to noise ratio (SNR) and 
motion artifacts. To this end, various designs of intravascular MRI approaches have been 
developed for imaging coronary arteries, including the use of receiver coils and self-
contained probes [79-82]. Utilizing a self-contained probe consisting of a magnet as well 
as transmitting and receiving coils, intravascular MRI was able to differentiate TCFA 
plaques from in situ coronary arteries with high sensitivity and specificity and no 
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complications arising in a first-in-man study of 29 patients [83,84]. However, 
intravascular MRI enables a limited penetration depth of only 250 µm, a circumferential 
view of only 120° with poor angular resolution, and an inability to produce a true image 
[85].  Instead, a map of chemical composition analogous to that utilized for NIRS 
imaging is created, with no corresponding anatomical context about the imaged arterial 
cross-section. Together, these drawbacks have largely limited the continued development 
of intravascular MRI as a viable solution to improve upon existing techniques, despite the 
high sensitivity of MRI for lipid detection. 
1.2.5.4. Positron Emission Tomography 
Conventional scintigraphic techniques, including positron emission tomography 
(PET) and single photon emission computed tomography (SPECT), have a wide array of 
applications within cardiovascular imaging. These techniques utilize radionuclide 
contrast agents to detect and monitor physiological processes, thus enabling functional 
imaging. However, in the case of coronary atherosclerosis, these noninvasive modalities 
suffer as a result of substantial physiological motion and provide insufficient resolution 
and sensitivity to effectively characterize functional activity within atherosclerotic 
lesions.  Efforts to circumvent those limitations, however, have resulted in the 
development and ex vivo characterization of several prototype intravascular radiation 
detection catheters [86-90]. For such catheters, it is desirable to detect beta radiation, due 
to its short path length of only a few millimeters, rather than gamma and x-radiation, 
which have much longer path lengths and could increase undesirable background signal 
from tissue beyond the coronary adventitia. The distal ends of these intravascular 
catheters have typically utilized plastic scintillating fibers for beta detection, resulting in 
improved sensitivity radionuclide detection over noninvasive nuclear imaging techniques.   
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Intravascular positron detection alone, however suffers from a lack of anatomical 
information.  Therefore, to compliment the functional information obtained from arterial 
lesions, a dual positron detection and OCT probe has been developed [91]. The hybrid 
probe was demonstrated on ex vivo arteries from animal models of atherosclerosis, 
demonstrating the complimentary functional and microstructure information offered by 
the two modalities. Despite this initial demonstration of the feasibility to combine these 
two modalities, intravascular positron detection has not continued to make advances 
towards a clinical catheter, likely a result of its limited resolution. Additional challenges 
include the need for improved catheter design and the optimization of radionuclide 
delivery and detection protocols, owing to their limited half-life and inherent circulation 
times. 
1.2.6. Summary of Intravascular Imaging Modalities 
Each of these clinical and investigational intravascular imaging modalities offers 
both distinct advantages and disadvantages for the assessment of coronary 
atherosclerosis, ranging from the high superior anatomical context provided by IVUS and 
OCT to the chemical compositional assessment enabled through many of the 
investigational techniques (Table 1.1). As a result, efforts to commercialize multimodal, 
hybrid imaging systems which strategically combine such benefits for improved plaque 
characterization are under way. However, none of these systems are capable of providing 
co-registered views of the arterial anatomy and its underlying composition, two key 
determinants of atherosclerotic plaque vulnerability.  To this end, an additional hybrid 
intravascular imaging modality, combined intravascular ultrasound and photoacoustic 
(IVUS/IVPA) imaging, has recently been developed to provide inherently co-registered 
anatomical and cellular/molecular compositional information regarding the imaged 
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arterial tissue through the combination of conventional IVUS and photoacoustic imaging, 
a form of optically-induced ultrasound generation. 
1.3. PHOTOACOUSTIC IMAGING PRINCIPLES 
Photoacoustic (PA) imaging, also referred to as optoacoustic imaging or, more 
generally, thermoacoustic imaging, relies on the detection of acoustic pressure transients 
generated as a result of rapid thermal expansion following absorption of optical pulses. 
Although reported by Alexander Graham Bell in 1880 [92], widespread research into 
potential applications of PA imaging did not commence until after the development of 
laser-based technologies in the 1960s and 1970s. Even then, early PA applications 
predominantly focused on spectral characterization of gases or thin film solids and liquids 
[93,94]. It was more than a decade later before the PA effect was first applied for soft-
tissue imaging [95] and began to be introduced as a biomedical imaging modality 
[96,97]. 
For PA imaging, the optically induced pressure amplitude is proportional to the 
delivered optical fluence, the absorption coefficient of the absorber(s) and the Grüneisen 
parameter, which accounts for the efficiency of conversion from optical to acoustic 
energy. Due to the dependence of the PA signal amplitude on the optical absorption 
properties of the illuminated medium, it is possible to differentiate particular absorbers of 
interest based on their unique spectral signatures. In this respect, PA imaging is similar to 
optical spectroscopy techniques such as NIRS. However, PA imaging offers a distinct 
advantage in comparison to purely optical-based techniques. Because the signal detection 
is achieved ultrasonically, locating the origin of the signal (i.e., optical absorber) can be 
achieved based on the ultrasound time-of-flight. As a result, PA signals can be readily 
depth-resolved to reveal the spatial distribution of absorbers. Furthermore, when coupled 
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with pulse-echo ultrasound imaging, combined ultrasound and PA imaging is well-suited 
to provide complimentary morphology as well as cellular and molecular compositional 
information using shared instrumentation and signal processing algorithms. 
The combination of IVUS with intravascular photoacoustic (IVPA) imaging was 
recently introduced as a potential hybrid imaging modality for improved characterization 
of coronary arteries. Combined IVUS/IVPA imaging provides a means of supplementing 
the morphological information provided by IVUS with additional capability for assessing 
the composition of atherosclerotic lesions based on unique optical absorption properties 
of specific plaque components or delivered imaging contrast agents [98]. The 
mechanisms for this synergistic nature of the combined imaging modality are rooted in 
the fundamental principles of photoacoustic imaging. 
1.3.1. Photoacoustic Pressure Generation 
Photoacoustic imaging relies on absorption of optical energy, subsequent thermal 
expansion of the absorber, and the generation of a resultant pressure wave which can be 
detected and localized using acoustic imaging techniques. The application of modulated 
electromagnetic radiation, such as in the form of pulsed laser illumination, can lead to the 
generation of acoustic waves via five distinct processes, including dielectric breakdown, 
vaporization, thermal expansion, electrostriction, and radiation pressure [99,100]. The 
vast majority of biomedical applications of PA imaging utilize the mechanism of thermal 
expansion, a process by which optical absorption from a pulsed laser source induces a 
mechanical expansion and relaxation of the absorbing chromophore [95,101].  
In order for highly efficient PA signal generation, both the thermal and stress 
confinement conditions should be satisfied. Thermal and stress confinement conditions 
are defined by Equations 1.1 and 1.2, respectively, where τ0 is the optical pulse duration, 
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τth is the thermal diffusion time, τs is the stress relaxation time, dc is a characteristic 
dimension of the excited region (determined by the size of an absorber or the penetration 
depth of light within an absorber), αth is the thermal diffusivity, and vs is the speed of 
sound [102].  
              𝜏0 ≪ 𝜏𝑡ℎ =
𝑑𝑐
2
𝛼𝑡ℎ
     Eq. 1.1 
         𝜏0 ≪ 𝜏𝑠 =
𝑑𝑐
𝑣𝑠
     Eq. 1.2 
In effect, under thermal confinement, the laser pulse duration should be significantly 
shorter than the thermal diffusion time, thus meaning that thermal dissipation from the 
absorbing region is negligible during the excitation pulse and PA transient generation 
process. Similarly, under stress confinement, propagation of the acoustic wave which is 
generated as a result of the thermoelastic expansion and mechanical relaxation can be 
considered to be negligible over the duration of the optical pulse. While αth and vs are 
tissue-dependent and temperature-dependent parameters, typical values for soft tissues 
are on the order of approximately 1.3×10-3 cm2/s and 1.5 mm/µs, respectively [103]. As 
an example, to resolve an absorber with a characteristic dimension of 100 µm, τth and τs 
would be approximately 77 ms and 67 ns, respectively, meaning that efficient PA signal 
generation is achieved if the pulse duration is less than 67 ns. Overall, the confinement 
conditions are satisfied for micrometer-sized absorbers through the use of nanosecond 
pulsed laser sources (< 10 ns/pulse) for PA imaging of endogenous biological tissues. 
Examples and descriptions of such sources are provided below in section 1.3. 
Under thermal confinement, τth, the PA pressure, p, generated within a non-
viscous and acoustically homogenous medium is described by Equation 1.3 [104,105]. 
The heating function, H(r,t), represents a spatial position, r, and time, t, dependent 
conversion of the applied electromagnetic radiation to thermal energy, β represents the 
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isobaric volume expansion coefficient, and Cp represents the isobaric specific heat 
capacity.  
∇2𝑝 −
1
𝑣𝑠
2
𝜕2
𝜕𝑡2
𝑝 = −
𝛽
𝐶𝑝
𝜕
𝜕𝑡
𝐻(𝑟, 𝑡)    Eq. 1.3 
Considering a pulsed optical illumination heating source, the heating function, H(r,t), can 
be expressed in terms of the local optical absorption coefficient of the medium, µa, and 
the local laser fluence, Φ (Equation 1.4). 
𝐻(𝑟, 𝑡) = µ𝑎(𝑟)𝛷(𝑟, 𝑡)     Eq. 1.4 
Further assuming that the stress confinement condition is satisfied, τs, the temporal 
component of the heating function can be approximated as a delta function, δ, effectively 
isolating the spatial dependency of the heating profile (Equation 1.5). 
𝐻(𝑟, 𝑡) = 𝐻(𝑟)𝛿(𝑡)     Eq. 1.5 
Therefore, given a sufficiently short laser pulses and a large enough spot size to achieve 
both thermal and stress confinement conditions, the peak PA pressure, po, generated is 
defined by Equation 1.6, from which it can be seen that the generated pressure is defined 
by only the local optical fluence, Φ, the optical absorption coefficient, µa, and the 
Grüneisen parameter, Γ, which is itself dependent on the thermal coefficient of volume 
expansion, β, the speed of sound, and the isobaric specific heat capacity.  
𝑝0 =
𝛽𝑣𝑠
2
𝐶𝑝
𝐻(𝑟) =
𝛽𝑣𝑠
2
𝐶𝑝
µ𝑎(𝑟)𝛷(𝑟) = 𝛤µ𝑎(𝑟)𝛷(𝑟)   Eq. 1.6 
In the case of imaging biological tissues with nanosecond pulsed lasers, Equation 
3 is widely utilized as the fundamental, albeit simplified, PA equation, whereby the 
generated PA signal magnitude is dependent on only three local parameters: light 
delivery, optical absorption, and efficiency of converting the absorbed energy into a 
pressure wave. Figure 1.3A schematically illustrates the generation of PA signal from 
within an artery using a catheter design to illuminate the tissue and receive an induced 
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acoustic response. The light delivery can be controlled, in part, by adjusting the delivered 
light energy. Typically, PA differentiation of specific absorbers of interest is achieved 
through the careful selection of imaging wavelength(s) which correspond to optical 
absorption peaks of the desired imaging target while reducing background signal and 
light attenuation. Such optical wavelength selection is highly tissue and target specific, as 
discussed below.  
While PA imaging of endogenous tissues has several key applications within 
cardiovascular medicine, preclinical research also relies heavily on the utilization of 
exogenous absorbers for improved molecular imaging capabilities and enhanced contrast. 
PA contrast agents under investigation include dyes, carbon nanotubes and metallic 
nanoparticles. In the case of utilizing these nanometer-sized agents for PA imaging, 
however, it is important to note that the above equations describing generated PA 
pressure must be reconsidered because the thermal and stress confinement conditions are 
often not maintained using optical sources most commonly used for PA imaging. This 
ultimately means that, despite the high absorption, both the thermal confinement and 
stress confinement conditions may not be valid when using a nanosecond pulsed laser for 
nanoparticle-enhanced PA imaging applications. Under these conditions, it has been 
shown that the applied laser pulse-induced stress is quickly converted to heat, and that the 
heat rapidly diffuses throughout the nanoparticle and to the interface with the surrounding 
environment where the acoustic pressure wave is induced, shown schematically in Figure 
1.3B [106]. This indicates that both the optical properties of the contrast agent and the 
efficiency of the heat transfer into the surrounding environment will significantly affect 
the generated acoustic pressure. To account for the lack of stress and thermal 
confinement in the case of imaging nanoparticle contrast agents, the simplified PA 
pressure equation can be modified as indicated in Equation 1.7, where η is the heat 
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transfer efficiency from the particle to its surroundings, Γeff is an effective Grüneisen 
parameter of the nanoparticle-environment mixture, and σ is the absorption cross-section 
of the nanoparticle [107]. 
𝑝0 ∝ 𝜂𝛤𝑒𝑓𝑓𝜎𝛷             Eq. 1.7 
Additionally, whereas variations in optical absorption spectra of either 
endogenous absorbers or exogenous contrast agents provide the most common means of 
PA imaging tissue characterization, it is important to note that the Grüneisen parameter 
offers a separate means for PA imaging and sensing. The terms comprising the Grüneisen 
parameter are tissue and temperature specific. Therefore, PA imaging performed at a 
single optical wavelength, and at a constant optical fluence, can also be utilized as a 
means to remotely monitor temperature change, thus providing a potential means of 
therapy guidance. As an example, in water based tissue, the Grüneisen parameter, and 
therefore the PA conversion efficiency, scales linearly with temperature, a characteristic 
which has been utilized for monitoring temperature rise during cancer photothermal 
therapy  in preclinical studies [108,109]. The relationship between the Grüneisen 
parameter and temperature is also tissue-dependent. In an extreme case, it has been 
shown that the parameters comprising the Grüneisen parameter- the speed of sound, the 
thermal coefficient of volume expansion and the isobaric specific heat capacity- all 
exhibit opposite temperature-dependent trends for lipid than they do for water-based 
tissues [110]. As a result, lipid deposits may be differentiated from water-based tissue by 
monitoring the direction of PA signal intensity change with changing temperature [111]. 
 23 
 
Figure 1.3: Photoacoustic signal generation from (A) endogenous lipid (yellow) within an 
atherosclerotic plaque using an intravascular imaging catheter, and (B) an 
exogenous plasmonic nanoparticle. Reprinted with presmission from [106]. 
1.3.2. Fundamental Photoacoustic Imaging Techniques 
PA imaging is increasingly investigated as a modality capable of augmenting both 
preclinical and clinical imaging modalities. A multitude of different imaging techniques 
are possible using PA imaging, whereby adjustments in the instrumentation set-up, 
imaging procedure, and targeted signal sources can all be tailored to specific imaging 
needs. In particular, PA imaging can be categorized according to the physical parameter 
which is modified in order to induce photoacoustic signal changes- adjustment of optical 
wavelength(s) or induced local temperature changes during PA imaging. 
1.3.2.1. Spectroscopic Photoacoustic Imaging 
The amplitude of a generated photoacoustic signal is proportional to the optical 
absorption, the local laser fluence, and the efficiency of thermo-acoustic transfer within 
the local environment (the Grüneisen parameter), evident by Equations 1.6 and 1.7. 
Therefore, provided that the Grüneisen parameter does not vary during PA imaging, one 
major advantage of PA imaging is that it enables the detection of specific chromophores 
B
BA
PA
Time (µs)
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of interest based on analysis of PA signal intensity when the optical excitation 
wavelength is varied and the local laser fluence is held constant. Using this approach, 
wavelength-dependent optical absorption spectral characteristics are exploited as an 
independent variable to enable PA detection of specific absorbers of interest, including 
both endogenous tissues and exogenous contrast agents.  
This technique, termed spectroscopic photoacoustic (sPA) imaging or 
multispectral optoacoustic tomography, is widely utilized for both identifying the 
location of one or more absorber(s) as well as estimating their relative concentrations. 
Using sPA, differentiation of absorbers of interest, such as lipid or nanoparticle contrast 
agents can be achieved using a variety of spectral unmixing algorithms, ranging from a 
simple analysis of the spectral slope [112-114] or a ratiometric analysis [115] of the 
obtained PA signal to more computationally intensive methods which enable calculation 
of the relative contribution of multiple absorbers such as interclass correlation [116] or 
linear least squares algorithms [117]. Regardless of the approach, however, sPA provides 
a means of capitalizing on the compositional specificity which makes PA imaging an 
attractive modality to combine with the more limited molecular contrast, but improved 
anatomical contrast, of US imaging. In the case of imaging atherosclerosis, lipid is 
particularly well-suited for sPA differentiation from other plaque components based on 
unique optical peaks within the wavelength regions of approximately 1210 nm and 1720 
nm, as are cellular- or molecular-targeted contrast agents. Each of these applications is 
discussed in greater detail below. 
1.3.2.2. Photoacoustic Temperature Monitoring 
In addition to sPA, the Grüneisen parameter provides for an alternative means of 
contrast during PA imaging. All components of the Grüneisen parameter, the thermal 
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coefficient of volume expansion, the speed of sound, and the isobaric specific heat 
capacity, are temperature sensitive and tissue-specific. Therefore, whereas sPA imaging 
techniques assume that the Grüneisen parameter remains constant during imaging, the 
deliberate modification of temperature within the imaged tissue provides an additional 
PA imaging technique, termed thermal photoacoustic (tPA) imaging. Using the tPA 
technique, the PA signal acquisition performed with the optical fluence and wavelength 
held constant and the obtained signal intensity is monitored over time as the temperature 
of the target tissue is modified. As a result, the magnitude of the tPA signal at each 
location within the tissue is linearly proportional to the local temperature within the 
tissue, thus allowing for temperature distribution mapping throughout the imaging field. 
Therefore, tPA has been investigated for applications in the non-invasive monitoring of 
the delivered thermal dosage during targeted hyperthermia or cryogenic treatments, with 
reported temperature resolutions as high as 0.15 °C have been reported in ex vivo studies 
[118]. Relative to other temperature monitoring techniques, tPA offers an advantage in 
that the signal is depth-resolved, meaning that the temperature at each location within the 
arterial wall can be monitored rather than merely the intimal surface. It is also noteworthy 
that ultrasound is capable of temperature monitoring as well, using temperature-
dependent changes in the speed of sound to map changes in the time-of-flight to 
temperature changes. However, this technique relies on the detection of a shift in 
ultrasound signal temporal shift, which can be challenging to monitor in vivo due to 
motion artifacts. In contrast, tPA imaging utilizes a linear dependence of the PA signal 
intensity with temperature, meaning that the magnitude of the PA signal is monitored 
rather than its arrival time. This technique offers unique implications for potential image 
guidance during hypo- or hyper-thermic interventions during coronary interventions, both 
of which have been previously investigated [119,120].  
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1.4. COMBINED INTRAVASCULAR ULTRASOUND AND PHOTOACOUSTIC IMAGING  
Recently, combined intravascular ultrasound and photoacoustic (IVUS/IVPA) 
imaging was introduced as a potentially clinically-translatable hybrid technique to help 
improve diagnostic accuracy of vulnerable atherosclerotic lesions by providing a means 
of supplementing the morphological information provided by IVUS with additional 
ability to assess atherosclerotic lesion cellular and biochemical composition based on 
unique optical absorption properties of specific plaque components or delivered contrast 
agents [98]. Custom fabricated integrated IVUS/IVPA catheters and imaging systems 
enable the acquisition of spatially co-registered and temporally consecutive IVUS and 
IVPA images, therefore allowing for complimentary IVUS/IVPA imaging of arterial 
cross-sections with shared signal detection hardware.  
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Table 1.1: Comparison of IVUS/IVPA with Clinical Intravascular Imaging Systems. 
Modified with permission from [121]. 
 
1.4.1. Integrated Intravascular Ultrasound and Photoacoustic Imaging Catheter 
and System 
In addition to the complimentary nature of the received information from the two 
modalities, there is an added benefit of shared hardware between IVUS and IVPA.  
Because the received signals for both modalities are acoustic pressures, a hybrid 
Image Grayscale IVUS VH-IVUS/iMap NIRS IVOCT IVUS/IVPA*
Image Type/ 
Content
Cross-section 
structure
Cross-section 
tissue type
Lipid-core plaque 
map (chemogram)
Cross-section 
structure
Cross-section 
tissue type
Type of radiation Ultrasound Ultrasound Near-IR light Near-IR light
(Near-IR) light + 
ultrasound
Axial resolution 
(µm)
100-200 >250 N/A 10-15 100
Lateral resolution 
(µm)
300-500 300-500 1000 30-40 400-500
Penetration (mm) 10 5 unknown 1 5
Contrast 
mechanism
Acoustic 
Backscattering
Acoustic    
Backscatter 
Frequency 
Content
Optical absorption Optical scattering Optical absorption
Pullback rate 0.5 mm/s 0.5 mm/s 0.5 mm/s 20-40 mm/s
TBD               
0.5 mm/s ?
Flushing No No No Yes No
Current status CS/CA CS/CA CS/CA CS/CA PCS
Lumen area ++ ++ - ++ ++
Plaque burden ++ ++ - - ++
Positive 
remodeling
++ ++ - - ++
Necrotic core ± ++ ++ - ++
Fibrous-cap 
thickness
- - - + TBD
TCFA - ± - + TBD
Plaque rupture + + - ++ -
Erosion - - - + -
Thrombus ± ± - + ±
Inflammation - - - ± ±
Calcium ++ ++ - + ++
IVUS = intravascular ultrasound; VH = virtual histology; NIRS = near-infrared spectroscopy; IVOCT = intravascular 
optical coherence tomography; IVUS/IVPA = combined intravascular ultrasound and photoacoustics; 
CA = clinically, commercially available; CS = clinical studies; PCS = pre-clinical studies; N/A = not applicable; TBD 
= to be determined; TCFA = thin-cap fibroatheroma.
++excellent. +good. ±possible. −impossible.
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IVUS/IVPA system can use a single ultrasound transducer, analog-to-digital converter 
(ADC), and many of the same signal processing algorithms. A schematic block diagram 
of an IVUS/IVPA imaging set-up designed for interrogation of vessel mimicking 
phantoms and freshly excised artery sections, is provided in Figure 1.4 [122]. Briefly, the 
distal end of an integrated IVUS/IVPA imaging catheter is inserted into the lumen of the 
imaging target. Output from a nanosecond pulsed laser is focused into a multimode 
optical fiber at the proximal end of an integrated IVUS/IVPA imaging catheter which 
also housed a single element IVUS transducer. The laser source is a Q-switched 
neodymium-doped yttrium aluminum garnet (Nd:YAG) which provides a pulse duration 
of approximately 5 -7 ns at a fundamental wavelength of 1064 nm.  The output can be 
easily frequency doubled, tripled and quadrupled to obtain 532, 355 and 266 nm, 
respectively, and used to pump optical parametrical oscillators (OPOs) which are capable 
of generating output wavelengths across a wide spectral range (e.g. 680 nm to >2000 
nm), thus providing versatility for IVPA imaging applications in which wavelength 
tunability remains critical for differentiation of target chromophores. During imaging, 
each pulse of the laser provides a trigger for collecting radio frequency (RF) signals from 
a pulser/receiver connected to the IVUS transducer within the integrated catheter. The 
received RF signals are digitized, resulting in a single IVPA A-line signal, a depth-
resolved IVPA signal at from a single azimuthal angular position within an arterial cross-
section. Following a user-defined delay, approximately 9 µs, the pulser/receiver is then 
triggered in order to acquire a conventional pulse-echo IVUS A-line. Therefore, the 
resulting acquired RF data is composed of spatially co-registered and temporally 
consecutive IVPA and IVUS signals. For generation of two-dimensional images of a 
vessel cross section, the integrated IVUS/IVPA catheter is rotated using a stepper motor. 
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Additionally, for three-dimensional imaging, a second motor was utilized to translate the 
image target.  
 
 
Figure 1.4: High level block diagram of experimental IVUS/IVPA imaging system 
Reprinted with permission from [122]. 
There are several unique challenges associated with the design of an integrated 
IVUS/IVPA imaging catheter, particularly the need to maintain a small profile for the 
catheter while ensuring that the optical and ultrasound beams overlap and are projected 
sideways onto the arterial wall from within the lumen. This has been achieved using a 
thin optical fiber as a waveguide to transfer optical energy, coupled from the external 
laser source at the proximal end of the integrated IVUS/IVPA catheter, to the distal end 
of the catheter where it is reflected towards the artery wall. Also located at the distal wall 
is an IVUS transducer. Commercial IVUS catheter designs utilize either a cylindrical 
array based transducer operating at a center frequency of approximately 20 MHz or a 
single element transducer which is mechanically rotated and typically have a center 
frequencies ranging from 30-60 MHz. To date, all integrated IVUS/IVPA catheters have 
utilized single element transducers, using either commercial IVUS transducers or custom 
fabricated elements.  
 30 
Integrated IVUS/IVPA catheter prototypes utilize multimode optical fibers with 
core diameters ranging from 200 to 600 micrometers [123-125]. The redirection and 
alignment of light with the ultrasound beam has been realized using both micro-optics 
such as mirrors [124,126,127] or prisms [128] and side-fire fibers utilizing total internal 
reflection [123,125]. The mirror-based optical reflection approach is suitable to redirect 
light with lower energy lose and offers greater variability in the reflected angle compared 
to the side fire fiber approach. However, the small core diameter of the optical fibers 
results in high light intensity which can damage the mirror. This problem can be partially 
overcome by increasing the distance between the fiber and the mirror and using the same 
mirror to redirect both the ultrasound and light beams [124], but the rigid part of the 
catheter becomes elongated using this approach, potentially sacrificing the achievable 
catheter flexibility. To-date, most experimental achievements using integrated 
IVUS/IVPA catheters have been demonstrated using side-fire fiber-based light delivery 
systems and single-element transducers, a schematic and photograph of which is provided 
in Figure 1.5 [129]. The smallest integrated imaging catheter has the outer diameter of 
1.25 mm with approximately 3.5-mm-long rigid part [125]. However, further 
miniaturization of integrated IVUS/IVPA catheters is likely to be achieved with future 
design modifications, to less than 1 mm outer diameter, resulting in more clinically 
acceptable catheter size and flexibility. 
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Figure 1.5: Integrated intravascular ultrasound and photoacoustic (IVUS/IVPA) imaging 
catheter. (A) Schematic design and (B) prototype photograph. Reprinted 
with permission from [129]. 
A 10 µm carbon fiber was used to simulate an impulse response received using 
such an IVUS/IVPA imaging system in order to characterize its resolution. The axial 
resolution was calculated based on the full width half maximum (FWHM) of the 
frequency response, whereas the lateral resolution was calculated based on the -6 dB 
lateral beam profile from the carbon fiber. The axial resolution for IVUS and IVPA 
imaging were measured to be 54 µm and 38 µm, respectively, whereas the lateral 
resolutions were measured to be 3.2° and 5.5°. In a separate experiment, demonstrating 
the complimentary nature of combined IVUS/IVPA imaging, a vessel mimicking 
phantom composed of a polyvinyl alcohol (PVA) cylindrical mold with a highly optically 
absorbing graphite inclusion was imaged [98]. Figure 1.6 shows obtained IVUS, IVPA 
and combined IVUS/IVPA images of the phantom, clearly demonstrating how IVPA 
imaging provides compositional information based on optical absorption properties 
within the context of the overall morphology demarcated by the corresponding IVUS 
image. These examples highlight the feasibility and characteristics of combined 
IVUS/IVPA imaging. 
A B
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Figure 1.6: Vessel mimicking phantom images demonstrating complimentary nature of 
IVUS/IVPA imaging. (A) IVUS, (B) IVPA, (C) IVUS/IVPA. Reprinted 
with permission from [122]. 
 
1.4.2. Applications of Intravascular Photoacoustic Imaging 
IVUS/IVPA imaging has been most heavily investigated for two distinct 
applications, the localization of lipid-rich atherosclerotic plaques and the detection of 
exogenous contrast agents. Both lipid and contrast agent localization using IVUS/IVPA 
offer the potential for improved atherosclerotic lesion characterization and therapy 
guidance over clinically available intravascular imaging modalities. 
1.4.2.1. Intravascular Lipid Imaging 
Due in large part to its correlation with atherosclerotic lesion instability, lipid has 
been a major focus of IVPA imaging. Endogenous lipid contains unique optical 
absorption peaks, relative to other endogenous absorbers within the arterial environment, 
at approximately 1210 nm and 1720 nm. Thus, spectroscopic IVPA (sIVPA) imaging has 
been utilized to identify the distribution of lipid within atherosclerotic plaques of excised 
arteries using combined IVUS/IVPA systems (Figure 1.7A,B) [114,130,131]. A direct 
comparison between results obtained from performing sIVPA imaging over the two 
spectral bands found similar results, with a lower pulse energy required for detection of 
A B C
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lipid at the 1720 nm spectral band but with a reduced achievable imaging depth [114]. 
IVUS/sIVPA has also been expanded to go beyond localizing lipid within plaques to the 
differentiation of specific cholesterol compositions as a way of further characterizing 
lesions and potentially differentiating lipid within plaques from adventitial fat [114]. For 
the absorption peak located at 1720 nm, the IVPA signal obtained using only a single 
wavelength was shown to correlate well with regions identified as lipid by both the 
sIVPA approach and subsequent histological staining [130]. In fact, this single 
wavelength lipid-detection technique was the approach utilized for the first in vivo 
IVUS/IVPA demonstration, which was performed on a rabbit model of atherosclerosis 
(Fig. 1.7C) [131]. 
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Figure 1.7: IVUS/IVPA imaging of lipid-rich atherosclerosis. (A) Ex vivo IVUS/IVPA 
image of human coronary atherosclerosis, with (B) corresponding 
spectroscopic validation of lipid signals. Reprinted with permission from 
[132]. (C) In vivo IVUS/IVPA detection of lipid in a rabbit model of 
atherosclerosis at 1720nm. Reprinted with permission from [133]. 
Continued development of IVUS/IVPA imaging as a system for localizing lipid 
within atherosclerotic plaques is a likely first application for the hybrid intravascular 
imaging technique. While the correlation between lipid-rich plaques and adverse 
coronary events is well established, continued investigation as to how the knowledge of 
lipid content and location within a plaque can improve patient diagnosis and 
A C
B
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interventional outcomes are critical to the ultimate motivation for clinical adoption of the 
technique. An improved understanding of the relationships between clinical outcome and 
lipid-rich plaques, such as the aforementioned COLOR registry, CANARY trial, and the 
Lipid-Rich Plaque study, as well as future trials specific to IVUS/IVPA imaging the 
results are, therefore, critical in driving clinical adoption of IVUS/IVPA imaging. 
1.4.2.2. Exogenous Contrast Agents for Intravascular Photoacoustic Imaging 
While limited number of relevant tissues, particularly lipids, are well-suited for 
localization within arterial plaques using IVPA imaging, many critical cellular and 
molecular biomarkers of atherosclerotic plaque vulnerability cannot be differentiated 
using IVUS/IVPA imaging based on endogenous contrast alone. Therefore, the 
introduction of exogenous contrast agents with strong and unique optical absorption 
spectral characteristics provides a means of significantly increasing the potential imaging 
targets. It is important that the contrast agents provide IVPA signal within an optical 
region where background signal from endogenous chromophores, such as hemoglobin, is 
minimized. The near-infrared (NIR) tissue optical window, spanning from approximately 
700 – 1100 nm, provides an optimal spectral region in which endogenous tissue optical 
absorption and scattering is sufficiently reduced to contrast-enhanced IVPA imaging.   
A wide array of contrast agents have been developed and evaluated using 
photoacoustic imaging, many of which exhibit characteristics which make them of 
particular interest for IVPA imaging applications (Table 1.2) [134]. In general, PA 
contrast agents which have been widely investigated to date fall into three main 
categories- dyes, single-walled carbon nanotubes (SWNTs), and noble metal 
nanoparticles. Examples of dyes which have been utilized for PA imaging include 
indocyanine green (ICG) [135] and methylene blue [136], each of which are already 
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clinical approved for limited applications, as well as IRDye800CW [137], AlexaFluor750 
[138], and the enzymatically-activated MMPSense680 [115]. Beyond molecular dyes, 
SWNTs and noble metal nanoparticles have also been utilized as PA contrast agents. 
SWNTs exhibit a high optical absorption over a broad wavelength range, supporting their 
ability to efficiently generate PA signals [139]. Additionally, both dyes and SWNTs can 
be modified to enabled conjugation of molecular targeting moieties [137-140]. However, 
both dyes and SWNTs have limitations as PA contrast agents. Dyes are prone to 
instability in biological and PA imaging conditions, which can cause photobleaching, 
quenching, or shifts in their optical absorption spectra. SWNT exhibit a broad absorbance 
spectrum without distinct peaks to detect using spectroscopic PA imaging techniques. 
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Table 1.2: Exogenous photoacoustic contrast agents of particular relevance to 
intravascular imaging applications. Modified, with permission, from [134]. 
Contrast agent Description Size 
(nm) 
Peak 
absorption 
wavelength 
(nm) 
Notable Prior 
Applications 
MMPSense 680 Activatable fluorescent dye < 2 620, 680 Imaging MMP activity within 
atherosclerotic plaque 
Gold nanospheres Solid gold spheres 2-60 520-540 Molecular PA imaging for 
identifying macrophages 
Gold nanorods Solid rice-shaped gold particles 10 by 40-
60 650-1100 
Cancer imaging, photothermal 
therapy 
Gold nanoshells Silica core and gold shell spheres 50-500 700-1100 Brain vascular imaging, 
photothermal therapy 
Silver nanoplates Thin triangular silver discs 6-20 by 
100-200 600-1200 PA imaging at 1064 nm 
Single-walled carbon 
nanotubes 1-atom thick cylinders of graphene 
1 by 50-
300 690 
Cancer imaging with αvβ3 
targeting 
Nanobeacons Liposomes containing plasmonic 
nanoparticles 100-200 520-1100 
Cancer imaging with αvβ3 
targeting 
Photoacoustic 
nanoDroplets 
Liquid perfluorocarbon droplets loaded 
with plasmonic nanoparticles 200 520-1200 
Optically triggered, combined 
contrast in US and PA 
Radiolabeled gold 
nanorods 
Gold nanorods labeled with the 
radioisotope iodine-125 
10 by 40-
60 650-1100 
Sensitive whole-body detection 
using SPECT 
Gold nanoclusters 4-nm nanospheres connected with a 
biodegradable polymer 50-100 700-900 
PA imaging with subsequent 
high clearance 
 
Noble metal nanoparticles represent a widely investigated category of PA contrast 
agents. Metallic nanoparticles are of particular interest to researchers because they exhibit 
localized surface plasmon resonance (LSPR) coupling, a process in which free electrons 
at the nanoparticle surface oscillate with the applied electromagnetic field, which enables 
very high, tunable optical absorption properties based on modifications to the 
nanoparticles size and shape [141,142]. As a result of the LSPR effect, an individual 
nanoparticle exhibits optical absorption up to five orders of magnitude greater than that 
of a dye molecule, resulting in efficient PA signal generation [143]. Similar to the other 
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classes of PA contrast agents, the surface of plasmonic nanoparticles can be readily 
conjugated with targeting moieties for molecular imaging applications [144] or otherwise 
modified to improve their stability in biological environments [145] and PA signal 
generation efficiency [146]. Additionally, the size and shape of these plasmonic 
nanoparticles can be tailored, resulting in changes to their optical absorption spectrum 
and the ability to use sPA imaging for their detection over background endogenous 
tissues. In fact, a significant number of gold nanoparticle PA contrast agents have been 
developed, including spherical gold nanoparticles [116,147], gold nanoshells [148,149], 
gold nanorods [146,150-152], gold nanoplates [153], gold nanocages [154] and 
aggregated gold nanoclusters [155], each with their own unique physical and optical 
absorption properties. As a result, plasmonic nanoparticle delivery followed by sPA 
imaging can be employed to greatly expand cellular and molecular imaging capabilities 
from that which can be achieved based solely on endogenous absorbers. Gold nanorods 
(AuNR) are particularly applicable as PA imaging contrast agents because the location of 
their longitudinal peak absorbance can be readily adjusted within the NIR optical window 
by tuning the particles’ aspect ratios [156,157]. Using a seed mediated growth method, 
tuning the concentration of silver ions during gold nanorod growth can be utilized adjust 
the nanoparticles’ aspect ratio, thereby selectively tuning the location of the longitudinal 
optical absorption peak over a range from 600 nm to over 1000 nm, as demonstrated in 
Figure 1.8 [157]. 
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Figure 1.8: Demonstration of the tunability of the optical extinction properties of gold 
nanorods by adjusting the relative number of amount of silver ions present 
during their synthesis as a way of changing the resulting aspect ratio. 
Reprinted with permission from [157]. 
In the case of IVPA imaging, macrophages provide a clear target for contrast-
enhanced, cellular-specific imaging. An indicator of the local inflammatory status of an 
atherosclerotic plaque, macrophage are scavenger cells which phagocytose foreign 
bodies. To this end, both in vitro phantom studies and ex vivo IVUS/sIVPA imaging 
performed on animal models of atherosclerosis following systemic injection of non-
targeted, polymer-stabilized spherical gold nanoparticles was shown to enable 
localization of aggregated particles based on a broadening and red shift which occurs 
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upon aggregation of spherical gold nanoparticles. Figure 1.9 demonstrates, in an in vitro 
vessel mimicking phantom model, the ability to use sIVPA imaging to differentiate gold 
nanospheres aggregated within macrophage endosomes from background signal as well 
as from colloidal particles. Histological staining of atherosclerotic animal models 
following systemic injection of gold nanospheres confirmed the co-localization of sIVPA 
signal with regions of high macrophage density (RAM 11 stain) and the presence of the 
gold nanoparticles (silver stain), supporting the hypothesis that the particles are 
phagocytosed and concentrated within intraplaque macrophages [147]. One limitation of 
this approach, however, is that spherical gold nanoparticles yield a peak absorbance of 
approximately 520 nm, which overlaps with a strong absorption peak of oxygenated 
hemoglobin, the most abundant endogenous chromophore during IVPA imaging.  While 
broadening and red shifting of the peak occurs upon aggregation of the particles, due to 
plasmon resonance coupling, IVUS/IVPA imaging of the gold nanoparticle-labeled 
macrophages was still not achieved in the presence of luminal blood. In order for 
contrast-enhanced IVUS/IVPA imaging using gold nanospheres to be demonstrated in 
vivo, the inability to image through luminal blood would necessitate saline flushing of the 
imaged artery, a technique which reduces image acquisition time and has been associated 
with increased risk of intra-procedural ischemia or pulmonary edema [158]. 
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Figure 1.9: Vessel mimicking phantom demonstrating sIVPA detection of gold 
nanoparticles. (A) Phantom design schematic, (B) IVUS/IVPA image 
obtained at 532 nm, revealing the presence of gold nanospheres, (C) 
IVUS/IVPA image obtained at 680 nm revealing only the gold nanospheres 
aggregated within macrophage endosomes. Reprinted with permission from 
[147]. 
The introduction of metallic nanoparticle contrast agents, in combination with the 
optical delivery system of an integrated IVUS/IVPA catheter, for localizing cellular or 
molecular targets of interest within atherosclerotic plaques also opens the door for novel 
therapeutic strategies. As a result, one can conceive a theranostic strategy in which 
plasmonic nanoparticles are first localized within the context of atherosclerotic lesions 
using IVUS/IVPA imaging and then utilized to deliver a therapeutic effect which might 
include the release of a therapeutic compound or delivering thermal therapy through the 
direct heating of the nanoparticles and their surrounding tissue. Such a strategy is 
analogous, in many respects, to phototherapy-based techniques which have been 
previously investigated for the treatment of atherosclerotic plaques, each of which are 
described below. 
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1.5. INTRAVASCULAR PHOTOTHERAPY TECHNIQUES FOR LOCAL TREATMENT OF 
ATHEROMA 
In addition to the ongoing need for improved diagnosis of atherosclerotic lesion 
composition and vulnerability to induce an acute coronary event, an appropriate 
therapeutic strategy for such plaques, once identified, has not yet been clinically adopted 
[159]. The current strategies during percutaneous coronary intervention, including 
angioplasty, stenting and bypass grafting, are all primarily designed to restore distal 
blood flow rather than to mitigate future risk by stabilizing the underlying lesion 
composition [160]. To this end, beyond improved characterization of coronary atheroma 
and image-guidance during a clinical intervention, the IVUS/IVPA system may also offer 
the potential to be further utilized as a vehicle for delivering, and monitoring, optically-
triggered intravascular therapy. Several such optical-based therapeutic strategies have 
been investigated, including laser atherectomy, photothermal therapy, photodynamic 
therapy, and multimodal approaches.  Through both the optical delivery enabled by the 
integrated catheter and its ability to monitor optically-induced tissue responses, including 
local temperature measurements, the IVUS/IVPA imaging system is uniquely suited to be 
combined with these techniques to create a theranostic platform [161].   
1.5.1. Laser Atherectomy 
Laser atherectomy, alternatively referred to as excimer laser angioplasty, is a 
clinically approved technique which uses an intravascular catheter to deliver pulsed 
optical energy within the ultraviolet (UV) wavelength range (308 nm) in order to 
eliminate stenosis or total occlusions through photoablative effects (Spectranetics 
Corporation, Colorado Springs, Colorado). The current clinical catheter designs deliver 
optical pulses with a duration of approximately 125 ns and repetition rate of 40 Hz, 
inducing photothermal and vaporization effects within the optically-excited tissue 
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[162,163]. Because the technique uses UV illumination where all tissue components are 
both highly scattering and highly absorbing, it is unable to selectively treat specific 
lesions components, acting instead as more of a layer-by-layer etching approach to 
restore the vascular lumen. While laser atherectomy has been approved for several niche 
indications, including moderately calcified lesions, total occlusions which are traversable 
by a guidewire, and occluded vein grafts, it has not achieved widespread clinical 
adoption. This is largely attributable to clinical trials which have shown increased rates of 
perforations to the artery relative to balloon angioplasty [164] and inferior procedural 
success rates relative to the mechanical alternative, rotational atherectomy [165].  
1.5.2. Plasmonic Photothermal Therapy 
Photothermal therapy (PTT) is a therapeutic technique which relies on the 
conversion of optical energy into heat in order to induce cell death via hyperthermia or 
other thermal effects. PTT has been broadly investigated within the field of cancer 
treatment for several decades, including its use in coordination with strong optically 
absorbing contrast agents such as organic dyes [166]. The same properties that make 
plasmonic nanoparticles attractive as IVPA contrast agents, namely the enhanced optical 
absorption efficiency which results from the LSPR effect, have also led to the 
investigation of gold nanoparticles as the thermal transducers during PTT. This use of 
noble metal nanoparticles as the absorbers triggering thermal conversion within tissue has 
evolved into a subset of PTT, termed plasmonic photothermal therapy (PPTT). 
While most applications of PPTT have centered on cancer therapy [167], the 
techniques has also recently come under investigation for the treatment of atherosclerotic 
plaques [168,169]. In these investigations, the combined delivery of near-infrared 
absorbing gold nanoparticles for PPTT via either injection or local placement using an on 
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artery patch design was shown to reduce atheroma burden in both a swine model and 
first-in-man trials (NANOM FIM). Given the previously discussed ability to utilize gold 
nanoparticles as IVPA contrast agents, as PPTT continues to be evaluated as a novel 
therapeutic strategy for stabilizing atheroma, IVUS/IVPA may provide a means for 
improving the therapy guidance on several levels, including the localization of the 
delivered gold nanoparticles and the monitoring of their induced temperature rise during 
PPTT. 
1.5.3. Photoangioplasty 
Photodynamic therapy (PDT) relies on the excitation of a delivered 
photosensitizer agent using low energy (relative to PTT) optical excitation, inducing a 
cascade which leads to the production of cytotoxic singlet oxygen, 1O2. Heavily 
investigated and clinically used within the field of cancer treatment, intravascular 
photodynamic therapy, termed photoangioplasty, has also shown promise as a technique 
for treating atherosclerotic plaques. Two different photosensitizers have been most 
widely studied for photoangioplasty, MV0611 (Miravant Medical Technologies, Santa 
Barbara, California) and Lutetium Texaphyrin (Pharmacyclics Inc., Sunnyvale, 
California). Each of these photosensitizers, both of which are water soluble, have been 
shown to preferentially localize within atherosclerotic plaques in animal models of 
atherosclerosis over the course of 24 hours following systemic injection [170,171]. The 
same studies have also demonstrated a reduction in plaque area with corresponding 
increases in lumen area as well as a reduction in the number of macrophages present 
within the lesions based on histological staining of the lesions approximately one month 
following the treatment (Fig. 1.10). By comparison however, Lutetium Texaphyrin 
(LuTex) offers the advantage of being excited by illumination at 732 nm, versus the 
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excitation wavelength of 542 nm for MV0611 which overlaps with a strong absorption 
peak of oxygenated hemoglobin. Phase I clinical trials using LuTex-excited 
photoangioplasty identified safe photosensitizer and light dosages, reporting no coronary 
complications and low incidence of side effects associated with the procedure [172,173]. 
However, despite these encouraging initial human trial results, which are now over a 
decade old, photoangioplasty has not continued to progress towards clinical adoption. 
This is likely due, in large part, to the widespread adoption of drug-eluting stents for the 
prevention of restenosis, an initial clinical target for photoangioplasty. 
 
 
Figure 1.10: Reduced macrophage cell density following photoangioplasty. (A-B) 
Macrophage stain histology one month following photoangioplasty using 
MV0611 from a region which received PDT illumination (A) and one which 
did not (B). Reprinted with permission from [171]. (C-D) Macrophage 
stained histology cross sections following PDT using LuTex, from a region 
which received PDT illumination (C) and one which did not receive 
illumination (D). Reprinted with permission from [170]. 
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While fluorescence imaging of histological sections from atherosclerotic animal 
models has shown a preferential uptake of photosensitizers within atherosclerotic 
plaques, it is noteworthy that, to date, none of the prior studies evaluating 
photoangioplasty efficacy have utilized an imaging modality capable of providing image 
guidance to verify delivery of the drug prior to applying illumination for its activation. In 
the future, however, combined IVUS/IVPA imaging may offer a means for providing 
such validation as well as for a more localized drug activation scheme.  For example, the 
potential for image-guidance using IVUS/IVPA, revealing contrast agent location and 
arterial morphology, might enable activation of the drug at only the vulnerable shoulder 
regions of plaques rather than the prior practice of activating the photosensitizer 
throughout a long region (2 cm) using a diffuse optical fiber. 
1.5.4. Dual Modality Photothermal and Photodynamic Therapy 
Recently, the prospect of dual-modality nanoparticles capable of providing both 
plasmonic photothermal therapy (PPTT) and photodynamic therapy (PDT) have been 
investigated for cancer treatment applications [174-185]. Among these multifunctional 
nanoparticles, many have centered on the covalent attachment of photosensitizers to gold 
nanoparticles, while one has demonstrated the ability to embed the photosensitizer 
directly within a silica coating encapsulating a gold nanorod [180]. Interestingly, the 
combined PTT and PDT approach has been shown to provide enhanced therapeutic 
outcomes when compared to either modality independently for the treatment of various in 
vitro and in vivo cancer models [175,176,178,184]. 
The adoption of multifunctional PTT and PDT nanoparticles for the stabilization 
of atherosclerotic plaques is, therefore, a natural transition, particularly when considering 
the aforementioned preclinical demonstrations of both PPTT and photoangioplasty for the 
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treatment of atherosclerosis. With such an approach, the IVUS/IVPA imaging platform 
can provide a means of first detecting the particles and subsequently delivering the 
targeted irradiation necessary to induce a localized therapeutic effect, including both a 
photosensitizing and heating optical sources. The resulting thermal effects can then be 
monitored using IVPA imaging during the dual-modality therapy. Further investigation 
into this proposed strategy represents an overall theme of the research presented 
throughout this dissertation. 
1.6. OVERALL RESEARCH GOALS AND DISSERTATION ORGANIZATION 
The overall goal of this research is to expand the applications of the recently 
introduced intravascular ultrasound and photoacoustic (IVUS/IVPA) imaging platform by 
demonstrating the ability for detection and optically-triggered treatment of atherosclerotic 
plaques through the delivery and excitation of multifunctional nanoparticle contrast 
agents. Specifically, rod-shaped gold nanoparticles are investigated as agents for both 
IVPA contrast and vehicles for selective optically-triggered therapy delivery. 
In Chapter 2, the passive extravasation and aggregation of systemically injected 
gold nanorods (AuNR) absorbing within the near infrared tissue optical window within 
plaques of atherosclerotic rabbit models will be demonstrated. The AuNR-labeled 
atherosclerotic plaques are spectroscopically localized using ex vivo IVUS/IVPA imaging 
through both luminal saline and blood.  
In Chapter 3 and Chapter 4, the motivation for nanoparticle labeling of 
atherosclerosis is expanded from that of purely image contrast agents to vehicles for 
image-guided, dual-modality phototherapy, opening the door for a potential strategy of 
complimentary diagnosis and local treatment of atherosclerotic plaques using an 
integrated IVUS/IVPA catheter. Chapter 3 focuses on the use of the integrated 
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IVUS/IVPA imaging catheter for photothermal delivery with simultaneous IVPA 
temperature monitoring using the high optical absorption of AuNR to enable localized 
heating. In Chapter 4, the potential role for IVUS/IVPA-guided phototherapy is further 
expanded through the characterization and in vitro assessment of novel multifunctional 
theranostic nanoparticles comprised of an AuNR core with a degradable, photosensitizer-
doped silica shell.  
Finally, in Chapter 5, conclusions from the overall research are presented along 
with limitations and next steps associated with each of the preceding chapters. An overall 
assessment of the future clinical outlook for IVUS/IVPA imaging as well as the 
utilization of exogenous contrast agents for imaging contrast and/or therapy delivery is 
also presented. 
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Chapter 2: Plasmonic Gold Nanorods as Intravascular Photoacoustic 
Imaging Contrast Agents1 
2.1 MOTIVATION FOR GOLD NANORODS AS INTRAVASCULAR PHOTOACOUSTIC 
IMAGING CONTRAST AGENTS 
 Despite significant advances in preventative measures and interventional 
procedures, cardiovascular disease remains a leading cause of death within industrialized 
nations. The high mortality rate can be attributed, in part, to an inability to reliably 
differentiate atherosclerotic plaques which are prone to rupture [1]. These aptly named 
‘vulnerable plaques’ initiate at sites with a dysfunctional endothelium and progress over 
the course of years or decades through a sequence of events involving low density 
lipoprotein (LDL) infiltration, macrophage accumulation, inflammation, and 
development of a necrotic lipid rich core [2]. The ability to locate atherosclerotic lesions 
and detect compositional and functional characteristics associated with plaque 
progression, such as the extent of endothelial dysfunction, can significantly improve the 
ability to determine lesion vulnerability and therefore provide a tool for clinicians when 
choosing an appropriate treatment and assessing overall patient risk of suffering a 
subsequent acute cardiac event.  
 Current clinical intravascular imaging techniques used for diagnosing 
atherosclerosis provide a primarily morphological assessment of the vessel. Intravascular 
imaging modalities such as intravascular ultrasound (IVUS) and optical coherence 
tomography (OCT) have each been demonstrated to allow differentiation of some 
                                                 
1 Adapted with permission from D. Yeager, A. Karpiouk, B. Wang, J. Amirian, K. Sokolov, R. Smalling, S. 
Emelianov, “Intravascular photoacoustic imaging of exogenously labeled atherosclerotic plaque through 
luminal blood,”  Journal of  Biomedical Optics, 17(10), 106016, (2012). Copyright 2012 Society of Photo 
Optical Instrumentation Engineers. Contribution of the coauthors- A. Karpiouk constructed the integrated 
imaging catheter, B. Wang developed the image acquisition software algorithms, J. Amirian and R. 
Smalling provided animal care expertise, K. Sokolov provided expertise related to gold nanoparticles and 
S. Emelianov provided overall supervision of the research. 
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relevant tissue types based on variations in their respective backscatter signal intensities 
[3]. However, each of these imaging techniques has inherent limitations. OCT offers high 
spatial resolution, on the order of 10 µm, but provides limited penetration depth and the 
attenuation of blood necessitates its removal via balloon occlusion or saline flushing 
during image acquisition [4].  IVUS, on the other hand, may be utilized in the presence of 
luminal blood and offers sufficient penetration depth to image the full vessel thickness, 
but with a lower spatial resolution and contrast.  
 Recently, combined intravascular ultrasound (IVUS) and intravascular 
photoacoustic (IVPA) imaging has been introduced and characterized [5]. Combined 
IVUS/IVPA imaging provides a means of supplementing morphological information 
obtained from conventional IVUS with a co-registered assessment of atherosclerotic 
plaque composition. In photoacoustic imaging, absorption of energy from nanosecond 
duration optical pulses by endogenous tissue chromophores or exogenous contrast agents 
result in a local thermal expansion of tissues which subsequently generates a pressure 
wave that is detected and localized using an ultrasound transducer, as explained in greater 
detail in Chapter 1, section 1.3. Because the pressure is generated following optical 
absorption and localized using an ultrasound receiver, photoacoustic imaging is less 
sensitive to effects of tissue scattering and the resulting loss of optical coherence. As a 
result, the achievable penetration depth of photoacoustic imaging is significantly greater 
than conventional optical techniques. Furthermore, in the case of IVPA imaging, the 
contrast between different tissue components is partially dictated by differences in their 
wavelength-dependent optical absorption. The optical contrast enables differentiation of 
composition based on unique spectral characteristics of tissues or exogenous contrast 
agents within plaques [6,7]. Therefore, combined IVUS/IVPA imaging preserves the 
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ability of conventional IVUS to image the full arterial wall thickness while improving the 
ability to differentiate plaque composition.  
 To date, IVUS/IVPA has been heavily investigated for the detection of lipid-rich 
regions within atherosclerotic plaques [8-14] and, to a lesser extent, for the guidance and 
monitoring of stent placement [15,16], and the detection of intra-plaque macrophages 
labeled with spherical gold nanoparticles [17,18]. In the case of detecting the nanoparticle 
contrast agents, spectroscopic IVPA (sIVPA) imaging was utilized as a means of better 
differentiating the unique optical absorption spectra of the contrast agents from 
background tissue. While the labeling of plaque biomarkers with spherical gold 
nanoparticles, followed by IVUS/IVPA imaging offers the potential for cellular and 
molecular imaging of atherosclerosis, detection of such contrast agents has not been 
demonstrated in the presence of luminal blood due to their peak optical absorption 
occurring within a wavelength region where endogenous tissues, particularly oxygenated 
hemoglobin, exhibit high optical attenuation and therefore reduce the achievable signal to 
noise ratio. Modification of the optical absorption properties of delivered exogenous 
contrast agents to enable imaging through blood is desirable because it avoids the need 
for blood removal through the use of an occluding balloon or saline flush during imaging, 
a procedure which limits image acquisition time and increases the risk of ischemia and 
pulmonary edema [4].  
This chapter focuses on the extension of the use of exogenous contrast agents for 
IVUS/IVPA imaging to polyethylene glycol (PEG) stabilized gold nanorods (AuNR) 
with a longitudinal peak absorbance tuned to the near infrared (NIR) wavelength region 
where blood and endogenous tissues exhibit reduced optical absorption. The conjugation 
of PEG to the AuNR is commonly used as a means of increasing circulation time, 
reducing cytotoxicity, and preventing aggregation of the nanoparticles [19]. Several 
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groups have recently explored the potential of AuNR as exogenous contrast agents for 
photoacoustic imaging [20-22]. The current study aims to extend these uses of AuNR to 
include verification of their selective labeling of atherosclerotic plaque following 
systemic injection, enabling subsequent detection using combined IVUS/IVPA imaging.    
 The goal of this chapter is to introduce AuNR as IVPA contrast agents for 
labeling atherosclerotic plaque macrophages, including the demonstration that 
systemically-injected AuNR preferentially extravasate at sites of atherosclerotic plaque 
endothelial dysfunction and macrophage accumulation in rabbit models of 
atherosclerosis. Subsequently, the high optical absorption of AuNRs within the tissue 
optical window is utilized to evaluate the ability to detect AuNRs within atherosclerotic 
plaques in the presence of luminal saline and luminal blood using both single-wavelength 
and sIVPA imaging. The use of sIVPA, similar to prior work using spherical gold 
nanoparticle contrast agents, is implemented as a means of differentiating the AuNRs 
from background tissues. In addition, the use of single-wavelength IVPA imaging at the 
peak absorption of the AuNRs is also evaluated as a simplified imaging approach, 
capitalizing on the use of a contrast agent which strongly absorbs within the NIR region 
in which tissue produces a decreased background signal.   
2.2. CHARACTERIZATION OF GOLD NANORODS AS IVPA IMAGING 
CONTRAST AGENTS 
2.2.1. Gold Nanoparticle Synthesis and Characterization 
 Cetyltrimethylammonium bromide (CTAB) stabilized AuNRs with an 
aspect ratio of approximately 3.5 were prepared using a seed mediated growth method 
[23].  Briefly, a growth solution was prepared by adding 800 µL of AgNO3 (10 mM) and 
4 mL HAuCl4 (10 mM) to 38 mL of CTAB (200 mM, Avocado Research Chemicals) at 
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30°C and stirring at 500 rpm. A solution of 440 µL of ascorbic acid was then added to the 
growth solution, resulting in a color change from yellow-orange to colorless solution. A 
seed solution was also prepared, consisting of 500 µL of CTAB (200 mM) and 500 µL of 
HAuCl4 (0.5 mM) at 30°C. The seed solution was vigorously stirred and 60 µL of 
NaBH4 (10 mM) was added, inducing a colorless to brown color change. After 7 minutes 
of aging, 96 µL of the seed solution was added to the entire volume of the growth 
solution. The CTAB-AuNR were allowed to age over night at 30°C before being twice 
washed to remove excess CTAB via centrifugation at 18,000 rcf for 40 minutes. The 
washed CTAB-AuNR were re-suspended in deionized water at a final peak optical 
density (OD) of 15, as measured by UV-Vis spectroscopy (Synergy HT, BioTek).  
The CTAB was replaced with polyethylene glycol (5kD mPEG-SH, Creative 
PEGWorks) by adding equal volumes of mPEG-thiol (0.2 mM) and the OD 15 CTAB-
AUNR [24]. The mixture was sonicated for 10 minutes and allowed to react for four 
hours on a shaker under modest agitation. The resulting PEG-AuNR were twice washed 
via centrifuge filtration (Amicon ultra-15, Millipore, 100 kD) for 10 min at 3000 rcf and 
re-suspended in sterile phosphate buffered saline (PBS) at physiological pH. Figure 2.1A 
shows the normalized extinction of AuNR as prepared (blue), washed (red) and following 
the exchange of CTAB with PEG (green). A representative transmission electron 
microscopy (TEM, Tecnai) image of PEG-AuNR is also provided (Fig. 2.1B), revealing 
no signs of nanoparticle aggregation. Zeta potential measurements (DelsaNano C, 
Beckman Coulter) of the nanoparticles’ surface charge were also used to further verify 
the exchange of CTAB with PEG on the AuNR surface. Typical measurements of CTAB-
AuNR and PEG-AuNR were approximately +22.5 mV and -8.75 mV, respectively. 
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Figure 2.1: AuNR characterization. (A) Extinction coefficient of AuNR as prepared 
(blue), washed (red) and PEGylated (green). (B) Representative TEM image 
of PEG-AuNR. Scale bar = 100 nm. 
2.2.2. In Vitro Nanoparticle Uptake and Toxicity 
In vitro studies were performed to investigate the ability of macrophage cells to 
phagocytose PEG-AuNR and to evaluate subsequent toxicity, both with and without 
exposure of nanoparticle-labeled cells to the pulsed laser illumination required for IVPA 
imaging. First, J774A.1 murine macrophages were plated on a 96 well plate at a 
concentration of 1 x 104 cells per well in 100 µL of phenol-red free Dulbecco’s Modified 
eagle’s Medium (DMEM, ATCC) with 5% Fetal Bovine Serum and allowed to incubate 
for 24 hours at 37 °C and 5% CO2. The culture medium was then changed and an 
additional 10 µL of variable concentrations of sterilized PEG-AuNR were added to the 
cells, ranging from control cells without nanoparticles to AuNR which yielded an optical 
density of ten when dispersed with the macrophages. In total, wells containing 
macrophages with PEG-AuNR optical densities of: 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0, 1.5, 
2.0, 3.0, 5.0, and 10.0 were created in triplicate, representing a range of approximately 20 
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pM to 2 nM AuNR, or 104 to 106 AuNR per cell. The cells were incubated at 37 °C and 
5% CO2 for 24 hours, after which all cells were carefully washed with phosphate 
buffered saline (PBS) three times, followed addition of 100 µL of fresh culture media and 
further incubation of the cells for another 6 hours. The UV-Vis (Synergy HT, Biotek) 
optical extinction spectrum of the nanoparticle-labeled cells was then measured, and a 
single-step colorimetric cell viability assay was initiated by adding 20 µL of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS). The assay was allowed to progress for three hours, over which time the dye was 
reduced by an active cellular process to yield a proportional increase in optical 
absorbance at 490 nm, which was subsequently measured using the UV-Vis. Figure 2.2 
shows the relative viability of macrophages incubated with each of the different 
concentrations of PEG-AuNR (Fig. 2.2A) and representative extinction spectra of PEG-
AuNR labeled macrophages (Fig. 2.2B). No statistically significant change in any of the 
groups of PEG-AuNR labeled macrophages was measured. Furthermore, macrophages 
incubated with optical densities of 1.0 and greater PEG-AuNR were detected by the UV-
Vis spectrum.  
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Figure 2.2: In vitro PEG-AuNR labeling and subsequent viability of macrophages. (A) 
MTS Assay viability of macrophages following incubation with variable 
concentrations of PEG-AuNR. (B) Representative optical extinction of 
macrophages incubated with variable concentration of PEG-AuNR after a 
3x PBS wash. 
A parallel study was also performed in which macrophages were incubated 
without nanoparticles (negative control) or with PEG-AuNR at an optical density of 5.0 
for 24 hours before being harvested and fixed in 10% formalin. The diluted sampled of 
the fixed macrophages were then placed on a microscope slide and imaged using dark 
field microscopy (DM6000, Leica), revealing the presence of PEG-AuNR in the 
experimental group based on increased scattering of nanoparticle labeled cells (Figure 
2.3). 
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Figure 2.3: Darkfield microscopy of J774A.1 murine macrophages (A) without and (B) 
with PEG-AuNR. Scale bar = 50 µm. 
Assessment of AuNR labeled macrophage viability was further expanded to the 
investigation of potential effects of the nanosecond pulsed illumination which is required 
for IVPA imaging. Using the same experimental procedure for the MTS viability assay, 
cells were incubated with PEG-AuNR at optical densities of 2.0 and 5.0. After washing 
excess nanoparticles, the cells were illuminated with variable intensity nanosecond 
pulsed laser illumination for 200 pulses (20 seconds) using the same laser source and 
optical fiber setup designed for IVPA imaging, described in detail in Section 2.3. The 
cells were then incubated for an additional 6 hours prior to initializing the MTS assay. 
Figure 2.4 shows the relative viability of the PEG-AuNR labeled macrophages following 
pulsed laser illumination, revealing no statistically significant decline in viability across 
any of the groups. Representative bright field microscopy images of control cells without 
nanoparticles, and following incubation with optical density 2.0 and 5.0 are also provided 
in Figure 2.4B-D, respectively. 
50 µmBA
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Figure 2.4: In vitro viability of PEG-AuNR labeled macrophages following exposure to 
IVPA laser irradiation at variable intensity. (A) MTS assay as a function of 
laser fluence. (B-D) Representative microscopy images of macrophages 
with increasing PEG-AuNR labeling (40x). 
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2.3. IVUS/IVPA IMAGING: EXPERIMENTAL SETUP AND IMAGE PROCESSING 
ALGORITHMS 
2.3.1. IVUS/IVPA Imaging Setup 
 A schematic diagram of the imaging setup used for IVUS/IVPA imaging with a 
previously reported integrated catheter is provided in Figure 2.5. The output of a tunable 
OPO laser (SpectraPhysics Inc.) capable of producing 5 ns pulses at 10 Hz with a spectral 
bandwidth of 2-3 nm at NIR wavelengths was coupled to an optical fiber with a core 
diameter of 600 µm [25]. The distal tip of the optical fiber was polished at an angle 
(approximately 40°) and positioned within a gas-trapping cup to produce side-projecting 
illumination and this distal housing was coupled to a commercially available, single 
element 40 MHz IVUS imaging catheter (Boston Scientific Inc.), resulting in overlapping 
ultrasound and optical beams within the aorta lumen. With each laser pulse, the radio 
frequency IVPA signals were collected using the IVUS imaging catheter and digitized 
using a 14 bit data acquisition (DAQ) card with a sampling rate of 200 MHz 
(CompuScope 14200, GaGe Applied Technologies, Inc.). Following the triggering of 
each optical pulse, a user-defined delay of 9 µs was implemented (DPR-2515, Directed 
Energy, Inc.) after which an ultrasound pulser-receiver (5073PR, Panametrics-NDT, Inc.) 
was triggered to transmit an ultrasound pulse and subsequent receiving of an echo signal 
by the IVUS transducer. The resulting acquired data was composed of spatially co-
registered and temporally consecutive IVPA and IVUS signals in R-theta coordinates. A 
temporal separation was therefore utilized to isolate the IVPA and IVUS components of 
the signal. Furthermore, because IVPA imaging involves only one way travel of 
ultrasound, whereas IVUS signal represent a round-trip travel, the IVPA signal must be 
stretched by a factor of two using an interpolation algorithm to obtain spatially matched 
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IVUS/IVPA images. The IVUS/IVPA data was then band-pass filtered, and envelope 
detected using a Hilbert transform to base-band the raw IVUS and IVPA signals.  
 
Figure 2.5: Schematic representation of experimental setup for spatially co-registered 
ultrasound and photoacoustic imaging of ex vivo arterial samples using an 
integrated IVUS/IVPA catheter. 
 The aorta or arterial phantom sample, placed in a cuvette filled with either saline 
or blood, was secured to rotational and translational stepper-motors (T-LSR150A, Zaber, 
Inc.), allowing for generation of cross-sectional 2D images and 3D pullback images, 
respectively. Each 2D image consisted of 256 spatially co-registered IVUS/IVPA A-lines 
per rotation of the aorta sample. Four A-lines were averaged at each position prior to 
rotation. In the case of 3D pullback data acquisition, a rotation was performed to generate 
a 2D cross sectional image, followed by translation of the aorta with a step size of 500 
µm. The R-theta IVUS and IVPA data was scan converted from polar to Cartesian 
coordinates using an interpolation algorithm prior to image display in order to provide 
conventional cross-sectional views of the image target. 
 The ex vivo imaging setup allowed for imaging though saline as well as through 
blood. For imaging performed through blood, human hematocrit (The Blood Center of 
Translational Axis
Rotational 
Motor
Fluid Cuvette
(Saline or Blood)
Computer
Pulsed Laser
Pulser/ 
Receiver
Delay
Convex 
Lens
IVUS 
Catheter
Optical 
Fiber
Sample
Integrated 
Catheter
 80 
Central Texas, Austin, TX) was diluted back to the physiological concentration based on 
a packed cell volume of approximately 40 percent using saline. Additionally, in the case 
of 3D IVUS/IVPA imaging through blood, a centrifugal fluid pump was incorporated 
with the outlet aligned to produce continuous luminal blood flow through the aorta 
section to reduce ultrasound speckle from blood stasis.  
2.3.2. Image Processing Algorithms 
Prior to each experiment, the output energy of the illumination fiber was 
calibrated by adjusting the Q-switch delay to maintain an equal energy at each 
wavelength to be used for imaging. A beam splitter was positioned proximal to the fiber 
coupler to deflect a portion of the beam to a power meter (Ophir Optronics Ltd). A look-
up table was generated to relate the distal output energy to the measured energy at the 
position of the power meter. Due to the proportional relationship between local fluence 
and photoacoustic pressure, variations in the laser output energy can significantly impact 
the detected IVPA signal. During imaging, the energy of each pulse was recorded and 
subsequently used to normalize the IVPA signal to account for variation in illumination 
intensity. 
Following normalization for pulse-to-pulse energy variations,  IVPA signals over 
a fixed distance from the integrated catheter were masked-out (i.e. set to zero) to 
eliminate the effect of ringdown artifacts produced by direct excitation of the IVUS 
transducer by optical pulse reflected and scattered from tissues. Additionally, the 
intensity of each spatially co-registered IVUS image was used to generate a binary mask 
of the arterial wall where regions prior to and beyond the arterial wall were set to zero.  
This binary mask was then applied to the spatially co-registered IVPA signal to eliminate 
photoacoustic signal artifacts and signals from non-tissue (e.g., tissue holder) structures 
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associated with the experimental setup. In the case of imaging through blood, depth 
dependent fluence attenuation compensation was performed by assuming a Beer’s law 
attenuation of the illumination intensity with the appropriate wavelength dependent 
extinction coefficient of the reconstituted human blood, which was measured with the 
UV-VIS spectrophotometer prior to IVUS/IVPA imaging. A user-defined noise floor was 
then established for all IVPA images, below which signals were ignored for subsequent 
signal processing steps. Finally, the IVUS and IVPA signals were scan converted from 
polar to Cartesian coordinates to obtain the cross sectional images of the aorta, and, in the 
case of 3D pullbacks, the serial cross sections were displayed as a volume rendered 
image stack. 
 In addition to single-wavelength imaging at the peak absorption of the AuNRs, 
imaging of sample arterial cross sections was also performed at multiple wavelengths to 
enable a sIVPA imaging in order to differentiate IVPA signal which originated from 
AuNRs from those originating from endogenous absorbers or ringdown artifacts. For a 
given cross section, sIVPA imaging was performed by obtaining IVPA signals from 730 - 
830 nm wavelength in 20 nm increments. A constant optical energy was maintained 
across all wavelengths by adjusting the laser Q-switch delay. More specifically, prior to 
imaging, a look up table was created to establish the appropriate delay need to maintain 
constant optical output across the desired wavelengths. Furthermore, during imaging, the 
recorded energy of each pulse was also monitored to verify that the output energy 
remained constant during sIVPA imaging. The IVPA signals were processed as described 
above, with an identical noise floor selected across all wavelengths. Prior to scan 
conversion, the IVPA signals at each pixel of the cross sectional image were then 
normalized as a function of wavelength and compared to normalized reference spectra of 
known absorbers suspected within the intravascular environment. The reference spectra 
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considered included the extinction spectrum of the AuNRs isolated from blood at the 
time of animal sacrifice, the absorbance spectrum oxygenated hemoglobin, and an 
artificial uniform spectrum. Figure 2.6A and Figure 2.6B provide a graphical 
representation of the reference spectra and schematic representation of the IVPA data 
utilized for sIVPA analysis, respectively. The uniform spectrum was intended to account 
for IVPA signals which may have originated from artifacts such as ultrasound transducer 
ringdown or increased subsurface fluence at tissue boundaries or air bubbles within the 
fluid filled tank. These artifacts are expected to yield wavelength-independent IVPA 
signals over the wavelength range of interest.  
 
Figure 2.6: Overview of spectroscopic IVPA (sIVPA) image processing system of 
equations.  The absorption spectra of the three reference absorbers were 
normalized with respect to wavelength, (A) and the acquired IVPA signal 
intensity as a function of position and wavelength (B) was utilized to 
determine the relative concentration of each reference absorber at each 
position using a linear least squares algorithm. 
A linear least squares algorithm was then utilized to calculate the relative 
concentrations of the three reference absorbers (AuNRs, oxygenated hemoglobin and 
artifacts) at each position within the sIVPA image. More specifically, the least squares 
algorithm is intended to solve for  Equation 2.1, where the matrix A is composed of the 
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wavelengths dependent, normalized absorption coefficients of each of the three reference 
absorbers, IVPA(λ,i,j) is a three dimensional matrix composed of the obtained IVPA 
signals as a function of wavelength () and position (i,j), and C(a,i,j) represents a  matrix 
of unknown relative concentrations of the references absorbers (a) as a function of 
position, where 0≤C≤1. The unknown relative concentrations C(a,i,j) for the three 
reference absorbers is obtained by minimizing the squared residuals as expressed in 
Equation 2.2. After computing the matrix C, a relative correlation 0.6 or greater was 
selected as a threshold for identifying and displaying a pixel containing a particular 
absorber (e.g. AuNRs).  
           𝑪(𝒂, 𝒊, 𝒋) × 𝑨(𝒂, 𝝀) = 𝑰𝑽𝑷𝑨(𝝀, 𝒊, 𝒋)       Eq. 2.1 
 𝐦𝐢𝐧⁡‖𝑪(𝒂, 𝒊, 𝒋) × 𝑨(𝒂, 𝝀) − 𝑰𝑽𝑷𝑨(𝝀, 𝒊, 𝒋)‖𝟐
𝟐    Eq. 2.2 
 
2.4 IVUS/IVPA IMAGING OF AUNR-LABELED ATHEROSCLEROTIC ARTERIES 
FOLLOWING SYSTEMIC INJECTION 
2.4.1. Animal Models of Atherosclerosis 
 Two distinct rabbit models of atherosclerosis were utilized for this study. For the 
first model, a New Zealand white (NZW) rabbit was fed a high cholesterol (0.5%) chow 
diet for 25 days prior to being subjected to balloon injury within the thoracic aorta in 
order to induce endothelial denudation and inflammation. Following the balloon injury 
procedure, the rabbit was continued on the high cholesterol chow diet for an additional 8 
months prior to nanoparticle injection and ex vivo imaging.  The second atherosclerotic 
animal model utilized the Watanabe heritable hyperlipidemic (WHHL) rabbit. Due to a 
deficiency of low density lipoprotein receptors, WHHL rabbits develop 
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hypercholesterolemia and advanced atherosclerotic lesions on a normal chow diet over 
the course of one to two years [26].  
2.4.2. Validation of In Vivo AuNR-Labeling of Atherosclerotic Plaques  
 PEG-AuNRs (100 mg, O.D. 200) were injected into the rabbit ear vein and 
allowed to circulate for 26 hours, after which the animal was sacrificed and the aorta was 
harvested for ex vivo imaging. At the time of sacrifice, a blood sample was also taken to 
determine the absorption spectra of the PEG-AuNRs in order to determine the 
wavelength of peak absorption for IVPA imaging. Specifically, 5 mL of blood were 
centrifuged at 1000g for 5 minutes and the extinction spectrum of the plasma was 
measured using a spectrophotometer (BioTek). Figure 2.7 shows the normalized 
extinction spectra of as prepared CTAB stabilized AuNRs (dotted line), following 
replacement of the CTAB with mPEG-SH and re-suspension in PBS (dash-dotted line), 
and AuNRs isolated from the blood of a systemically injected atherosclerotic rabbit at the 
time of animal sacrifice (solid line). AuNRs isolated at the time of animal sacrifice show 
a 20 nm blue shift of the longitudinal absorbance peak relative to the spectrum obtained 
prior to injection as well as an increased background signal, particularly affecting the 
transverse peak. 
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Figure 2.7: Extinction spectra of systemically-injected particles as prepared (red), after 
conjugation of PEG (green), and isolated from blood following rabbit 
sacrifice (blue). 
 The excised aorta was maintained at 4°C wrapped in saline-dampened gauze to 
allow imaging of fresh, unfrozen, tissue for up to 48 hours following euthanization of the 
animals. After imaging, the tissue was fixed in 10% formaldehyde to allow for 
histological analysis and additional imaging of fixed tissue. 
 Combined IVUS/IVPA imaging was performed on atherosclerotic rabbit aortas 
subjected to systemic injection of PEG-AuNR contrast agents approximately 26 hours 
prior to excision of the arteries for ex vivo imaging. Results from both a balloon injured 
NZW rabbit and WHHL rabbit are presented.  A representative cross section of the aorta 
from the balloon injured NZW rabbit model is shown in Figure 2.8. Immunohistological 
staining and dark field microscopy images of unstained samples were utilized to evaluate 
the specificity of AuNR labeling to atherosclerotic plaques. H&E stain shows the 
presence of an atherosclerotic plaque in the region spanning from 2 o’clock to 10 o’clock 
(Fig. 2.8A). Anti-CD31 stains specific for platelet endothelial cell adhesion molecule 
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(PECAM-1), a ligand expressed by endothelial cells, macrophage, and platelets are 
provided in Figure 2.8B and 2.8C as an assessment of the arterial endothelial layer 
integrity. RAM11, a mouse monoclonal anti-rabbit macrophage antibody stain, reveals 
the presence of macrophages near the luminal surface of the plaque (Fig. 2.8D). 
Additionally, silver stain histology, used to identify the presence of heavy metals, further 
indicated the presence of AuNRs near the luminal boundary of the plaque region in 
agreement with the distribution of macrophages (Fig. 2.8E). Furthermore, dark field 
microscopy revealed the lack of a healthy endothelial layer at the luminal boundary in 
plaque regions where AuNRs were present (Fig. 2.8F).   
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Figure 2.8: Evaluation of AuNR labeling of atherosclerotic plaque.  Histological staining 
of adjacent cross sections using (A) H&E stain, (B) CD31 stain, (C) High 
resolution (10x) view of the CD31 stain of healthy region of arterial wall 
indicated by green arrow, (D) Macrophage-specific RAM11 stain, (E) Silver 
stain for labeling AuNR distribution. (F) High resolution (20x) dark field 
microscopy image of an unstained artery section revealing AuNRs (gold 
color) at the luminal boundary at the edge of a plaque which lacks a healthy 
endothelium, indicated by blue arrow. The asterisk (*) indicates arterial 
lumen. 
2.4.3. Ex Vivo IVUS/IVPA Imaging of AuNR Labeled Atherosclerotic Plaque  
 Combined IVUS/IVPA imaging was performed on AuNRs-labeled atherosclerotic 
artery sections in the presence of both luminal saline and luminal blood using the ex vivo 
imaging setup schematically shown in Figure 2.5.  IVPA and sIVPA images obtained 
from a sample cross-section of a freshly-excised WHHL aorta which was imaged in both 
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saline and blood at 750 nm with output energy of 0.5 mJ are shown in Figure 2.9.  All 
IVUS/IVPA images displayed in Figure 2.9 represent a total diameter of 22.5 mm and the 
optical path length from the integrated IVUS/IVPA catheter to the luminal boundary was 
measured to range from approximately 2.5 mm to 5.5 mm.  IVPA images are displayed 
using a 20 dB dynamic range scale (Fig. 2.9A,B). Silver stain histology from the 
corresponding cross-section is shown in Figure 2.9C.  Combined IVUS/sIVPA images 
display the IVUS signal using a 40 dB dynamic range scale with the regions of 
spectroscopically detected AuNRs overlaid in green (Fig. 2.9D,E). Examples of 
spectroscopic IVPA plots for signals determined to arise from oxygenated hemoglobin 
(HbO2) and AuNRs when imaging through saline and a region identified as containing 
AuNRs through blood are shown in Figure 2.9F with the corresponding reference spectra. 
Errors bars in Figure 2.9F represent the standard deviation of IVPA signal intensity 
calculated using a kernel size of approximately 4.5º azimuthal by 55 µm axial. The 
plotted spectroscopic response for the AuNR samples was taken from a point near the 
luminal border at approximately 9 o’clock where the images obtained through both saline 
and blood show a strong IVPA signal. Contrarily, the sample HbO2 spectroscopic signal 
was taken from the region in the adventitia at approximately 12 o’clock which was 
identified as HbO2 by the sIVPA analysis when imaging through saline. Comparison of 
the single wavelength IVPA and sIVPA signals are in agreement with one another for 
each imaging environment, saline and blood, as well as with the corresponding silver 
stain histology (Fig. 2.9C). Upon evaluation of the 2D cross-section, the IVPA signals 
obtained at the AuNRs’ peak absorbance wavelength (750 nm) show similarly high 
photoacoustic signals at the three o’clock and nine o’clock positions near the position of 
the arterial wall, which correlate with AuNR accumulation as identified by the silver stain 
histology image. However, the twelve o’clock position of the IVPA image obtained 
 89 
through blood does not reveal the high intensity signal seen in the case of imaging 
through luminal saline, and identified as a region with AuNR accumulation in the silver 
stain histology section. Additionally, the signal-to-noise ratio (SNR) of the image 
obtained through blood is noticeably reduced in the case of imaging through luminal 
blood at the same optical fluence.  As an example, the SNR of the 9 o’clock region of the 
IVPA images acquired using at 750 nm through saline and blood were calculated to be 
approximately 28 dB and 24 dB, respectively.  
 
Figure 2.9: Intravascular photoacoustic imaging of AuNR labeled atherosclerotic plaque 
cross section (color online). A,B) IVPA signal obtained from imaging at the 
AuNRs peak absorbance wavelength through saline and blood, respectively. 
IVPA images displayed with -20 dB dynamic range. C) Corresponding 
silver stain histology revealing distribution of AuNRs within the plaque.  
D,E) Intravascular ultrasound images (40 dB display dynamic range) with 
overlay of spectroscopic detection of AuNRs through saline and blood, 
respectively.  F) Comparison of representative spectroscopic IVPA signals, 
shown as dashed lines, to normalized extinction spectra of AuNRs and 
oxygenated hemoglobin (HbO2), shown as solid lines. 
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 Due to the high acoustic backscatter detected in the case of imaging through static 
luminal blood (Fig. 2.9E), a centrifugal blood pump was incorporated into the ex vivo 
imaging setup. The pump was aligned to produce a continuous luminal blood flow during 
3 dimensional data acquisition. IVUS images of an arterial cross section obtained through 
static blood (Fig. 2.10A) and luminal blood flowing at a rate of 100 mL/min (Fig. 2.10B) 
clearly demonstrate a reduction in acoustic scattering produced by flowing blood. 
 
Figure 2.10: IVUS images of an atherosclerotic artery obtained through (A) static and (B) 
flowing luminal blood. Both images are shown using a 35 dB display 
dynamic range. 
Fixed sections of a balloon injured New Zealand white rabbit aorta were 
subsequently imaged using the integrated IVUS/IVPA catheter. For all combined 
IVUS/IVPA 3D renderings shown in Figure 2.11, imaging was performed at the AuNRs’ 
peak absorbance wavelength by obtaining full serial cross sections with a step size of 500 
µm. In reconstructing a continuous rendered volume, the combined images were cropped 
to create a hemispherical view showing the morphology and AuNR distribution within a 
section of the arterial lumen. A hemispherical view of the IVUS/IVPA signal obtained 
from imaging an 8 mm arterial section with 0.7 mJ output energy in the presence of 
saline within the lumen is provided in Figure 2.11A. Following imaging, a digital 
photograph of the imaged cross section was obtained, revealing the presence and 
A B
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distribution of regions with a high density of AuNRs at the lumen surface, evident by the 
red color (Fig. 2.11B). AuNRs visible in the digital photograph are in spatial agreement 
with regions which provided high signal intensity upon IVPA imaging at the AuNR peak 
absorbance wavelength. A separate arterial section was then imaged in both saline and 
blood to further evaluate the potential to detect the AuNRs in the presence of luminal 
blood using a single optical wavelength. A 6 mm section of the artery was first imaged 
using the integrated catheter in saline with 0.7 mJ output energy (Fig. 2.11C). The saline 
was then replaced with the reconstituted human blood, which was pumped through the 
aorta lumen, and the same cross section was again imaged at the peak wavelength, but 
with output energy of 1.4 mJ (Fig. 2.11D). The similarities of localized IVPA signals 
obtained through saline and through blood suggest that the AuNRs can be detected 
through blood.  
 
Figure 2.11: Three dimensional IVUS/IVPA renderings of AuNR labeled atherosclerotic 
plaque (color online). (A) Combined IVUS/IVPA rendering of an 8 mm 
long section of atherosclerotic rabbit artery obtained through saline. (B) 
Photograph of the corresponding artery section revealing AuNR distribution 
at the luminal surface (red).  Combined IVUS/IVPA images obtained 
through saline (C), and through blood (D) of a separate 6 mm arterial 
section. Step size, 500 µm. 
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2.5 DISCUSSION AND CONCLUSIONS 
Gold nanorods (AuNR) conjugated with polyethylene glycol were investigated as 
an exogenous contrast agents to expand the use of IVUS/IVPA imaging to detect and 
characterize atherosclerotic plaques. In vitro studies demonstrated the high tolerance of 
macrophages to PEG-AuNR at concentrations ranging from optical densities of 0.1 (22.2 
pM) to 10 (2.2 nM), showing no change in cell proliferation from control cells without 
any nanoparticles (Fig. 2.2).  It was also demonstrated that exposure of PEG-AuNR 
labeled macrophages to nanosecond-pulsed illumination of variable intensity from the 
optical setup used for IVPA imaging did not result in adverse effects on cell viability 
(Fig. 2.4).  
In vivo systemic injection of PEG-AuNR was shown to result in the preferential 
labeling of sites of atherosclerosis, which were subsequently localized using ex vivo 
combined IVUS/IVPA imaging.  Histological staining of sample arterial cross sections 
was performed to assess AuNR labeling (Fig. 2.8).  AuNR accumulation was limited to 
the regions of the arterial cross section with atherosclerotic plaque formation (Fig. 2.8E).  
The nanoparticle labeling is also co-localized with the absence of a healthy, continuous 
endothelial layer and the lumen boundary (Fig. 2.8B-C) and the presence of macrophages 
(Fig. 2.8D).  While the co-localization of AuNR with macrophages near the luminal 
boundary is observed, it is unclear whether this co-localization with macrophages is due 
to phagocytosis of AuNR or if the relationship is the result of a more passive process, 
such as common sites of extravasation into atherosclerotic plaques.  The correlation 
between AuNR labeling and missing endothelial or protective fibrous cap layer suggests 
that the PEG-AuNRs are able to extravasate into the luminal margins of the plaque 
through discontinuous luminal boundaries.  The nanoparticles may also extravasate from 
the vasa vasorum, as neovasculature associated with atherosclerosis has been shown to 
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exhibit a leaky endothelium [27]. This hypothesis is further supported by recent reports 
demonstrating that PEG-AuNRs are not endocytosed by endothelial cells following 
systemic injection [28] and that injection of other contrast agents including the organic 
fluorochrome indocyanine green and perfluorocarbon nanoparticles resulted in a similar 
pattern of preferential labeling of atherosclerotic plaques [29,30].  Therefore, the present 
results are in agreement with similar studies which have found that systemically injected 
contrast agents containing no specific biological targeting moiety still tend to 
preferentially aggregate at atherosclerotic regions.  
 Additionally, the feasibility of detecting AuNR-labeled atherosclerotic plaques 
was demonstrated through the use of IVPA imaging to detect the location of contrast 
agents through within the context of spatially co-registered IVUS images of arterial 
morphology. An integrated IVUS/IVPA catheter was utilized to enable imaging in the 
presence of luminal saline as well as luminal blood in simulated in vivo imaging 
conditions.  IVPA imaging of AuNR in the presence of luminal blood is significant in 
that it simplifies an eventual clinical imaging procedure and avoids potential adverse 
effects to the patient by eliminating the need for upstream occlusion or saline flushing of 
the artery [4].  Notably, when the artery sample was imaged in static whole blood, the 
presence of blood stasis within the lumen of the aorta resulted in significant ultrasound 
speckle which reduced the ability to detect the arterial morphology (Figs. 2.9E, 2.10A).  
The enhanced IVUS speckle has previously been well documented [31]. To reduce this 
effect and better enable IVUS detection of the arterial wall morphology as is achieved in 
the case of in vivo imaging, a centrifugal pump was positioned to maintain luminal flow 
while conducting 3D pullback IVUS/IVPA imaging through blood (Figs. 2.10B, 2.11D).   
 In comparing IVPA images obtained from imaging through luminal saline to 
those obtained imaging through luminal blood, the similarity of the signals suggests that 
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the relatively low optical attenuation of luminal blood within the NIR wavelength region 
permits the detection of AuNRs (Figs. 2.9, 2.11). However, differences were noted for 
the cross sectional image between the 12 o’clock region of the IVPA signal obtained 
when imaging through saline (Fig. 2.9A) and that achieved through blood (Fig. 2.9B). 
Additionally, an overall reduction in the signal-to-noise ratio between the IVPA signals 
detected from arterial regions with AuNR labeling and using equal catheter output energy 
of 0.5 mJ was also observed. Both of these effects are likely due to the increased optical 
attenuation of blood and can be partially overcome by increasing the delivered pulse 
energy, as shown in Figure 2.11D.  
 Notably, when imaging through both saline and blood, the regions which were 
identified as consisting of AuNR using the sIVPA imaging algorithm are in close 
agreement with the IVPA signal obtained from imaging only at the AuNR peak 
absorbance wavelength (Fig. 2.9). This similarity suggests the potential for localizing 
accumulated AuNR using combined IVUS/IVPA imaging at a single NIR wavelength 
rather than across a broad spectral range. This simplification offers the potential to reduce 
both image acquisition time and IVPA imaging instrumentation costs. However,  further 
studies should be conducted to quantify the reduction in sensitivity and specificity which 
result from a single wavelength IVPA AuNR detection approach, particularly as 
integrated IVUS/IVPA catheter continue to evolve and injected AuNR doses are further 
reduced to become more clinically appealing.  
 This chapter has demonstrated that PEG-AuNRs accumulate within macrophages 
in vitro and preferentially label atherosclerotic regions following in vivo systemic 
injection. The AuNR-labeled plaques can subsequently be detected using combined 
IVUS/IVPA imaging in the presence of luminal blood. Due to the tendency of the AuNRs 
to extravasate at sites with dysfunctional endothelium, this application of IVPA imaging 
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may be utilized to identify the location of acute inflammation within atherosclerotic 
plaques, which usually locate within the cap and shoulder regions [32]. Higher aspect 
ratio AuNRs, which exhibit a longer wavelength longitudinal peak absorbance, as well as 
the addition of a silica coating, are utilized for IVUS/IVPA imaging applications 
discussed in Chapters 3 and 4 as a means of increasing the signal-to-noise ratio and 
thermal stability of the particles. The use of AuNRs can also be further expanded to 
enable the investigation of molecular IVPA imaging through the conjugation of targeting 
moieties onto the surface of the AuNR. Integration of the presented results demonstrating 
the ability of combined IVUS/IVPA imaging to localize AuNRs through luminal blood 
with prior work related to the bioconjugation of targeting moieties to nanoparticle 
surfaces suggests an avenue for molecular specific IVPA imaging of atherosclerosis 
biomarkers.  
 Additionally, the demonstrated ability to localize preferential AuNR labeling of 
atherosclerotic lesions motivates the expansion of the technique to include the 
investigation of a localized thermal therapy, whereby the AuNR themselves can serves as 
thermal sources heated by a continuous wave laser source delivered through the 
IVUS/IVPA integrated catheter following their localization. This expansion of 
IVUS/IVPA imaging using AuNR as theranostic agents is examined in greater detail in 
the remaining chapters of this dissertation, with the results presented in this chapter 
serving as the foundation for AuNR-based theranostic applications for the monitored 
treatment of atherosclerotic plaques. 
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Chapter 3: Intravascular Photoacoustics for Temperature Monitoring 
During Localized Heating of Gold Nanorods2 
3. 1 INTRODUCTION TO PHOTOACOUSTIC TEMPERATURE MONITORING DURING 
GOLD NANOROD HEATING 
Coronary heart disease remains a leading cause of death throughout industrialized 
nations, responsible for more than 7 million deaths annually throughout the world [1]. In 
the United States alone, coronary heart disease accounts for approximately one in every 
six deaths, with a coronary event occurring approximately every 25 seconds [2]. In the 
majority of cases, onset of an acute coronary event is triggered by the rupture of so-called 
“vulnerable plaques” which were undetected using conventional diagnostic procedures 
[3]. Therefore, there remains a clinical need for improved imaging modalities and 
therapeutic approaches to enable differentiation and selective, local treatment of these 
high-risk vulnerable atherosclerotic plaques.  
As reviewed in Chapter 1, Section 1.2, current clinical imaging modalities utilized 
to detect the presence of atherosclerosis lack the ability to reliably differentiate plaques 
which are vulnerable to rupture from those which are stable. Noninvasive techniques, 
such as the gold standard x-ray angiography or coronary computed tomography, lack 
sufficient resolution to visualize critical vulnerable plaque characteristics- a thin fibrous 
cap with an underlying lipid-rich necrotic core and extensive macrophage accumulation. 
Intravascular imaging modalities, including intravascular ultrasound (IVUS) and optical 
coherence tomography (OCT), offer trade-offs in terms of morphological assessment 
capabilities based on their respective imaging depths and resolutions. However, each 
                                                 
2 Adapted with permission from D. Yeager, Y.-S. Chen, S. Litovsky, and S. Emelianov, “Intravascular 
Photoacoustics for Image-Guidance and Temperature Monitoring During Plasmonic Photothermal Therapy 
of Atherosclerotic Plaques: A Feasibility Study,” Theranostics, 4(1), 36-46, (2014). Copyright 2014 
Ivyspring Internaional Publisher. Contribution of coauthors- Y.-S. Chen provided guidance for temperature 
monitoring of silica-coated gold nanorods, S. Litovsky provided experimental materials, and S. Emelianov 
provided overall supervision of the research. 
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modality is inherently limited in terms of compositional characterization due to 
similarities in the backscattered signal produced by different tissue types [4]. Virtual 
histology IVUS (VH-IVUS) seeks to expand the ability to differentiate plaque 
composition through analysis of the tissue-dependent changes in the frequency content of 
backscattered ultrasound, however the efficacy of the approach has recently been called 
into question [5,6]. Moreover, the emerging technique of diffuse reflectance near-infrared 
spectroscopy (NIRS) has been demonstrated to differentiate some plaque lipid, but the 
modality is limited by its inability to provide a depth resolved signal [7]. 
Beyond the challenge of diagnosing vulnerable plaques, an effective treatment 
strategy has not yet been clinically adopted [8]. While preventative measures and 
systemic treatments are desirable as an overall policy for atherosclerosis management, 
localized treatment strategies are likely to remain a necessary tool for effectively treating 
identified vulnerable plaques. Traditional percutaneous coronary interventions, such as 
angioplasty and stenting have focused on mechanically restoring lumen diameter in 
regions with severe stenosis rather than on stabilizing plaque composition [9]. The 
introduction of drug eluting stents has more recently introduced a dual treatment which 
adds a pharmacological agent to reduce the extent of inflammation or proliferation 
following deployment of a stent. However, even in the case of drug eluting stents, the 
treatment is not specific to atherosclerotic tissue alone, and particularly not to specific 
biomarkers of interest within vulnerable plaques.  
Several light based therapeutic strategies have also been investigated, as 
introduced in Chapter 1, Section 1.5. While these phototherapy-based approaches have 
resulted in marginal clinical approval for limited applications, none have obtained 
widespread adoption for the treatment of coronary atherosclerosis. For example, the 
clinical adoption of excimer laser atherectomy has been limited by an increased risk of 
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adverse effects which are largely related to a lack of specificity and undesirable damage 
to the vessel wall [10]. Photodynamic therapy has more recently expanded the capability 
of laser-based treatments and shown promise as a technique for stabilizing atherosclerotic 
plaques, yet has not been translated to the clinic on a large scale [11,12].  
Combined intravascular ultrasound and photoacoustic (IVUS/IVPA) imaging, 
introduced in Chapter 1, Section 1.4, has been developed as a means of supplementing 
the morphological information provided by IVUS with additional capability for assessing 
plaque composition based on unique optical absorption spectra of tissue components or 
contrast agents [13]. In Chapter 2, applications of IVUS/IVPA imaging were expanded to 
include the localization of plasmonic gold nanorods which passively label atherosclerotic 
lesions following systemic injection [14]. The strong and tunable absorption of gold 
nanorods within the near-infrared wavelength range, where endogenous tissue absorption 
is relatively low, makes gold nanorods attractive agents for photothermal therapy, 
particularly for cancer treatment applications [15-17]. This therapeutic approach, termed 
plasmonic photothermal therapy (PPTT), has more recently come under investigation as a 
tool for the localized treatment of atherosclerotic plaques, introduced in Chapter 1, 
Section 1.5.2 [18,19].   
To date, PPTT for atherosclerotic plaque treatment has required a local delivery 
of gold nanoparticles and has been limited by an inability to monitor the delivery of 
therapy. IVUS/IVPA imaging offers a means to locate gold nanoparticles following 
systemic delivery [14,20], based on unique optical absorption spectral characteristics, and 
to subsequently monitor temperature during PPTT, based on the temperature dependence 
of the generated photoacoustic signal intensity. In the case of imaging gold nanoparticles, 
it has been shown that commonly utilized 3-5 ns pulsed illumination from an Nd:YAG 
laser does not satisfy stress confinement or thermal confinement (see Chapter 1, Section 
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1.3.1 for definitions) of the metallic structures. Therefore, the general equation for 
induced photoacoustic pressure within endogenous tissues, Equation 1.6, must be 
modified to reflect a dependency on the local environment of the nanoparticles, as shown 
in Equation 3.1 (also Equation 1.7) [21]: 
 
𝑝0 ∝ 𝜂𝛤𝑒𝑓𝑓𝜎𝛷                     (3.1) 
 
In addition to the IVPA signal dependence on the local optical absorption cross 
section of the highly absorbing nanoparticle (σ), the generated photoacoustic pressure 
also exhibits a dependence on local optical fluence (Φ), the heat transfer efficiency (η) 
from the nanoparticle to its surroundings, and the effective Grüneisen parameter (Γeff) of 
the environment immediately surrounding the nanoparticle. In the case of imaging 
nanoparticles distributed within water-based tissue, the effective Grüneisen parameter is 
approximated to exhibit similar temperature dependence to that of pure water. The 
Grüneisen parameter is a function of the speed of sound, the thermal coefficient of 
volume expansion, and the isobaric specific heat capacity, all of which are temperature 
dependent properties. Therefore, the photoacoustic signal intensity generated by gold 
nanoparticles in water-based tissues is expected to result in a linear relationship with 
temperature. Therefore, photoacoustic imaging can be implemented as a tool for 
monitoring temperature within the local environment of optical absorbers of interest. To 
that end, silica-coated gold nanorods (SiO2AuNR) have been investigated as thermally 
stable nanosensors which, together with photoacoustic imaging, enable temperature 
mapping with improved sensitivity over polyethylene glycol (PEG) coated gold nanorods 
[21-23]. 
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In this chapter, the ability to utilize a modified IVUS/IVPA imaging system as a 
platform for detecting and subsequently monitoring local temperature rise during 
selective laser heating of SiO2AuNR is introduced. A single optical fiber is used to 
deliver illumination required for both IVPA signal generation, via the nanosecond pulsed 
laser, and simultaneous tissue heating, via continuous wave near-infrared illumination. 
As such, it is hypothesized that IVUS/IVPA imaging can be expanded from a purely 
diagnostic imaging-based modality to a potential theranostic platform for atherosclerotic 
plaque management.  
3. 2 SILICA-COATED GOLD NANOROD SYNTHESIS AND CHARACTERIZATION 
Cetyltrimethylammonium bromide (CTAB) stabilized gold nanorods were 
synthesized by a seed mediated growth method reported in literature and described in 
Chapter 2, Section 2.3.1 [24]. Briefly, a seed solution was prepared by adding 60 µL of 
NaBH4 (10 mM) to a vigorously stirring solution of 500 µL of CTAB (200 mM) and 500 
µL of HAuCl4 (0.5 mM) at 30°C. After 7 minutes of aging, 96 µL of the seed solution 
was added to a growth solution containing 800 µL of AgNO3 (10 mM), 4 mL HAuCl4 (10 
mM), 38 mL of CTAB (200 mM), and 440 µL of ascorbic acid at 30°C and stirring at 
500 rpm. The CTAB-AuNR were aged overnight at 30°C before being twice washed to 
remove excess CTAB via centrifugation at 18,000 rcf for 40 minutes. The washed 
CTAB-AuNR were re-suspended in deionized water at a final peak optical density (OD) 
of 15, as measured by UV-Vis spectroscopy (Synergy HT, BioTek). At this stage, it is 
possible to fine tune the longitudinal peak absorbance of the CTAB-AuNR by heating the 
solution to induce a blue shift of the peak. Figure 3.1 shows the optical absorption 
spectrum of a batch of AuNR which were heating to induce blue shifting over several 
hours prior to replacement of the CTAB with PEG. Temperature settings of the heating 
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plate for the indicated times was 120°C for all time points except for the overnight 
heating which progressed at 70°C. Note that silica coating of the AuNR results in a red 
shift of the peak absorbance wavelength of approximately 20 nm for a 20 nm silica shell 
thickness. Therefore, the CTAB-AuNR peak absorbance should be tuned such that it is 
blue shifted from the final desired absorbance peak, approximately 788 nm for a final 
absorbance peak at 808 nm. After tuning to the desired peak absorbance, the CTAB was 
replaced with polyethylene glycol (PEG, 2 kD) by adding equal volumes of mPEG-thiol 
(0.2 mM) and the OD 15 CTAB-AUNR. The mixture was sonicated for 10 minutes and 
allowed to react for four hours on a shaker under modest agitation. The resulting PEG-
AuNR were washed via centrifuge filtration (Amicon ultra-15, Millipore) for 10 min at 
3000 rcf and re-suspended in water at an OD of 10.  
 
Figure 3.1: Heat induced tuning of the AuNR peak absorbance wavelength. 
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Silica coating of the PEG-AuNR was achieved by a previously reported modified 
Stöber method [22]. In short, under vigorous stirring, 1.2 mL of the PEG-AuNR were 
added to 1.8 mL of isopropanol, followed by the addition of 40 µL of tetraethyl 
orthosilicate (TEOS) in isopropanol (100 mM). A 3.8% ammonia solution in isopropanol 
was added to adjust the solution to a pH of 11, and the solution was reacted under 
moderate stirring for 4 hours. The resulting silica-coated gold nanorods (SiO2AuNR) 
were twice washed via centrifuge filtration for 10 min at 1000 rcf and re-suspended in 
water at the desired final OD. Figure 3.2 provides optical spectra at various stages of 
synthesis of SiO2AuNR and representative transmission electron microscopy (TEM) 
images revealing the presence of AuNR/silica core-shell nanoparticles with consistent 
intra- and inter-particle silica thickness.  
 
Figure 3.2: Characterization of SiO2AuNR. TEM images of as prepared SiO2AuNR at 
(A) low and (B) high magnification. (C) Optical absorption spectra of 
AuNR prior to, during, and after SiO2 coating. 
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3. 3 IN VITRO VALIDATION OF MACROPHAGE-SPECIFIC SIO2AUNR LABELING  
In vitro nanoparticle incubation studies were conducted in order to validate 
macrophage-specific labeling of SiO2AuNR. In particular, the endothelium at the 
boundary of the arterial lumen is a critical regulator of numerous vascular processes and 
its dysfunction or damage has been shown to correlate with atherosclerosis and increased 
rates of coronary events [25]. Given their proximity to nanoparticles in circulation 
following a systemic injection, endothelial cells are also a likely cell type for unintended 
SiO2AuNR uptake. Therefore, in vitro incubation studies were performed to compare the 
tendency of endothelial cells and macrophages to phagocytose SiO2AuNR. Mouse 
monocyte-derived macrophages (J774A.1) or human umbilical vein endothelial cells 
(HUVEC) were counted using a hemocytometer and plated in a 96 well plate at a 
concentration of 1 x 104 cells/well incubated at 37°C in 5% CO2 in their respective 
culture mediums overnight. The media was then replaced and SiO2AuNR were added, 
yielding a final nanoparticle OD of 0.5 (0.1 nM). The nanoparticles were incubated with 
the cells for 18 hours before being triple washed with phosphate buffered saline (PBS) 
and imaged to evaluate nanoparticle uptake. Figure 3.3 provides microscopy images of 
J774A.1 macrophages (left) and HUVEC (right) without exposure to nanoparticles (top) 
and following incubation with SiO2AuNR and washing (bottom). Significantly greater 
SiO2AuNR labeling is observed in the macrophages than the endothelial cells.   
 108 
 
Figure 3.3: Comparison of SiO2AuNR uptake by J774A.1 macrophages and HUVEC. 
J774A.1 macrophages (A) without and (B) following SiO2AuNR exposure. 
HUVEC (C) without and (D) following SiO2AuNR exposure. Scale bars = 
50 µm. 
To further evaluate the extent of preferential macrophage uptake, SiO2AuNR 
were incubated with a co-culture containing both macrophages and HUVEC cells. 
HUVEC cells were plated in a 96 well plate at a density of 1 x 104 cells/well incubated 
overnight. Simultaneously, J774A.1 macrophages were incubated with 2 µM Rhodamine-
B isothiocyanate. The macrophages were then added to the HUVEC cells at a density of 1 
x 104 cells/well and allowed to incubate for 4 hours at 37°C in 5% CO2 to permit 
adherence of the macrophages. SiO2AuNR were then added to the co-cultured cells at a 
final OD of 0.5 (0.1 nM) and allowed to incubate overnight. Cells were then triple 
washed with PBS and imaged using bright field and fluorescence microscopy. The 
rhodamine-labeled J774 macrophages were differentiated from HUVEC cells using 
fluorescence imaging (excitation/emission: 530/590 nm). Figure 3.4 provides images of 
A
B
C
D 50 µM
50 µM50 µM
50 µM
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co-cultured macrophages without (left) and with SiO2AuNR (right). Preferential 
phagocytosis of SiO2AuNR by macrophages is confirmed by the fluorescence of 
rhodamine-labeled J774 macrophages.  
 
 
Figure 3.4: Co-culture of J774A.1 macrophages and HUVEC. (A) Brightfield and (B) 
Rhodamine fluorescence overlay revealing macrophage distribution within a 
co-culture without nanoparticle labeling. (C) Brightfield revealing 
SiO2AuNR  distribution and (D) Rhodamine fluorescence overlay revealing 
macrophage distribution within a  co-culture following nanoparticle 
labeling. Scale bar = 50 µm. 
For experiments used to validate IVPA temperature sensitivity of intracellular 
SiO2AuNR, J774A.1 macrophages were grown to 70% confluence and incubated in 
phenol free DMEM F-12 media containing 5% fetal bovine serum and SiO2AuNR with a 
final nanoparticle OD of 0.5 for 24 hours at 37°C in 5% CO2. The cells were then scraped 
and twice washed with PBS via centrifugation at 300 rcf for 5 minutes to remove excess 
nanoparticles and finally fixed in a 10% buffered formalin solution. Two separate batches 
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50 µM
50 µM
50 µM
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of SiO2AuNR were utilized for the polymethylmethacrylate (PMMA) tube imaging 
experiment and the gelatin phantom experiment described below, with peak longitudinal 
absorbance of 735 nm and 800 nm, respectively. 
3. 4 VERIFICATION OF SIO2AUNR-INDUCED INTRAVASCULAR PHOTOACOUSTIC 
SIGNAL LINEARITY VERSUS TEMPERATURE 
The combined IVUS/IVPA imaging system and the associated integrated 
IVUS/IVPA imaging catheter are described in Chapters 1 and 2 [13,26]. Briefly, an 
optical parametric oscillator (OPO) and coupled laser (PermiScan, SpectraPhysics, Inc.) 
providing nanosecond pulse duration at variable optical wavelengths. For detection of 
AuNRs, the pulsed laser optical output at wavelengths between 700 nm and 850 nm was 
focused into the 600 µm core diameter multimode optical fiber of the integrated 
IVUS/IVPA imaging catheter which also housed a commercially available, single 
element 40 MHz IVUS transducer (Atlantis SR Pro2, Boston Scientific, Inc.). The output 
energy at the distal end of the integrated catheter was maintained at approximately 0.4 mJ 
per pulse for all IVPA imaging discussed within this chapter. The resulting RF signals 
were digitized using a 14 bit, 200 MHz data acquisition card (CompuScope 14200, GaGe 
Applied Technologies, Inc.) and temporally decoupled to obtain the co-registered IVUS 
and IVPA images in R-theta coordinates. The IVUS/IVPA data was then band-pass 
filtered, and envelope detected using a Hilbert transform to baseband the raw IVUS and 
IVPA signals. For generation of 2 dimensional images of a vessel cross section, the 
integrated IVUS/IVPA imaging catheter was rotated using a stepper motor (T-
NM17A200, Zaber Technologies, Inc.) for a total of 256 co-registered IVUS and IVPA 
signal pairs per complete rotation. The R-theta data was scan converted from polar to 
Cartesian coordinates, using a bicubic interpolation algorithm, prior to image display in 
order to provide conventional cross-sectional views of the image target. 
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For initial demonstration of the temperature dependence of IVPA signal intensity, 
IVUS/IVPA imaging was performed using an experimental setup intended to model a 
SiO2AuNR labeled artery. Either colloidal SiO2AuNR (OD=20) or formalin fixed 
macrophages which had endocytosed PLL-SiO2AuNR (OD=7) were sealed within 
optically clear PMMA tubing (inner/outer diameter = 375 µm/500 µm) and aligned 
within the water tank of the IVUS/IVPA imaging system. These SiO2AuNR containing 
inclusions were oriented perpendicular to the axis of the integrated IVUS/IVPA imaging 
catheter and at a radial distance of approximately 4 mm from the transducer surface. The 
integrated catheter was fixed in a position facing the SiO2AuNR containing inclusions. 
The water tank was positioned on a heating plate, allowing the temperature of the entire 
tank and, therefore, the SiO2AuNR containing inclusions to be slowly heated and cooled, 
during which IVUS/IVPA signals were periodically recorded. 
The linearity of IVPA signal intensity change with temperature was first verified 
through a set of experiments in which the environment surrounding the imaging target 
was incrementally heated or cooled. Imaging targets ranged from SiO2AuNR at varying 
concentrations and macrophages which had phagocytosed SiO2AuNR to vessel-
mimicking phantoms and ex vivo tissue labeled with SiO2AuNR. The experimental set-up 
was subsequently modified to incorporate the addition of a continuous wave laser 
emitting at a wavelength of 808 nm and coupled into the same optical fiber of the 
integrated IVUS/IVPA imaging catheter that was used to deliver the nanosecond pulsed 
laser illumination necessary for IVPA signal generation. The ability to induce selective 
heating of the SiO2AuNR with the CW laser and to monitor the resulting targeted heating 
using IVUS/IVPA imaging was then investigated in a series of similar experiments. 
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Figure 3.5A demonstrates the change in IVPA signal intensity versus temperature. 
The presented data was recorded during cooling (blue) and subsequent reheating (red) of 
the water tank containing SiO2AuNR within PMMA tubing at an OD of 20 over a 
temperature range from approximately 29°C to 43°C. The monotonic change in measured 
IVPA signal intensity demonstrates the linearity and reproducibility of IVPA temperature 
response. Similarly, Figure 3.5B presents the percent change in IVPA signal intensity as a 
function of change in temperature for both the OD 20 SiO2AuNR (green) and a solution 
containing formalin fixed J774A.1 macrophages which had previously phagocytosed 
SiO2AUNR with a final OD of 7. The linearity of IVPA temperature response is again 
confirmed for SiO2AuNR, including both the colloidal particles and those within 
endosomes. Additionally, a change in IVPA signal of approximately 50% was measured 
for the OD 20 SiO2AuNR over a 10°C temperature change versus a 90% change in IVPA 
signal from SiO2AuNR within macrophages over the same range. This variation in 
temperature sensitivity is indicative of a variation in the effective Grüneisen parameter of 
solutions containing colloidal nanoparticles versus those aggregated within endosomes. 
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Figure 3.5: Temperature dependence of IVPA signal from SiO2AuNR within PMMA 
tubing. (A) Peak IVPA signals during cooling (blue) and subsequent 
reheating (red) of a water tank containing an inclusion of OD=20 
SiO2AuNR. (B) Percent change in peak IVPA signal versus change in 
temperature for OD 20 SiO2AUNR (green) and SiO2AuNR phagocytosed by 
macrophages (blue) at a final concentration of OD=7. Data represents the 
mean and standard deviation from 100 IVPA measurements. 
3. 5 COMPARISON OF INTRAVASCULAR PHOTOACOUSTIC IMAGING TEMPERATURE 
SENSITIVITY OF GOLD NANORODS TO ENDOGENOUS ABSORBERS: A PLAQUE-
MIMICKING PHANTOM STUDY 
A vessel-mimicking gelatin phantom was subsequently utilized to assess the 
temperature dependent IVPA signal response of more clinically-relevant tissue 
components. A solution containing 10% gelatin and 2% silica particles with an average 
diameter of 30 µm, to provide optical and acoustic scattering, was molded into a hollow 
cylindrical shape with lumen diameter and wall thickness of approximately 5 mm each. A 
piece of bovine lipid-rich tissue was implanted into the gelatin mold as the phantom 
solidified at 4°C. After solidifying, an inclusion containing additional gelatin/silica 
solution mixed with fixed macrophages loaded with SiO2AuNR at a final OD of 2.5 was 
placed on the luminal surface of the phantom adjacent to the lipid-rich tissue inclusion 
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and the phantom was again cooled to 4°C. The Vevo LAZR (VisualSonics, Inc., Toronto, 
Canada) ultrasound and photoacoustic imaging system, coupled with a 40 MHz linear 
array transducer was utilized to noninvasively confirm the orientation of the vessel-
mimicking phantom, revealing the position of both the SiO2AuNR-labeled macrophages 
and bulk lipid tissue inclusions (Fig. 3.6).  
 
Figure 3.6: Vevo LAZR ultrasound and photoacoustic validation of inclusion position 
and orientation within vessel-mimicking phantom. 
During IVUS/IVPA imaging, IVPA temperature monitoring was performed by 
slowly changing the temperature of the surrounding water tank and periodically imaging 
at the peak absorbance of the endocytosed nanoparticles (735 nm) and lipid (1720 nm) to 
differentiate the two inclusions.  Figure 3.7 demonstrates the temperature dependence of 
the IVPA signal intensity detected within the two inclusions. Imaging performed at the 
SiO2AuNR absorbance peak of 735 nm with the phantom at 11°C (Fig. 3.7A) results in a 
significantly lower signal than that detected at 26°C (Fig. 3.7B). Likewise, imaging of the 
lipid-rich tissue inclusion, performed at a lipid absorbance peak located at 1720 nm 
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which has been previously utilized for IVPA imaging of lipid-rich plaques, reveals a 
similar trend over the same temperature range (Fig. 3.7C,D). Note that the lipid-rich 
inclusion also causes a significant shadowing effect in the IVUS image within the 1-2 
o’clock region. All IVPA images are displayed on the same linear scale, overlaying IVUS 
images displayed at a dynamic range of 40 dB. 
Figure 3.7E provides a plot of the IVPA signal intensity with varying temperature 
for three regions, the SiO2AuNR loaded macrophage inclusion (12 o’clock), the adjacent 
lipid-rich tissue inclusion (1 o’clock), and a control region from within the gelatin 
phantom (9 o’clock). Data for the SiO2AuNR loaded macrophage inclusion and the 
control region were obtained from IVPA imaging at 735 nm, while the data obtained for 
the lipid-rich tissue region was obtained from IVPA imaging at 1720 nm. The plot 
reveals a linear increase in IVPA signal with temperature for all three regions, but a 
significantly greater slope for the SiO2AuNR containing inclusion. An increase in 
temperature of 10°C resulted in corresponding percent increases in IVPA signal of 
98.4%, 20.5%, and 4.4% for the SiO2AuNR loaded macrophage inclusion, lipid-rich 
tissue inclusion, and control region, respectively. This large difference in temperature-
dependent signal change further supports the use of SiO2AuNR as sensitive thermal 
sensors for IVPA imaging. 
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Figure 3.7: IVUS/IVPA imaging of a tissue-mimicking phantom with lipid and 
SiO2AuNR inclusions. IVUS/IVPA image of an inclusion with macrophages 
(M) labeled with SiO2AuNR, acquired at an imaging wavelength of 735 
nm, at temperatures of (A) 11°C and (B) 26°C. IVUS/IVPA image of an 
inclusion with lipid-rich tissue, acquired at an imaging wavelength of 1720 
nm, at temperatures of (C) 11°C and (D) 26°C. Tick marks on IVUS/IVPA 
images are spaced at 1 mm. Plot of the temperature dependence of IVPA 
signal intensity for the PLL-SiO2AuNR loaded macrophages, lipid-rich 
tissue, and a control region within the phantom (E). 
3. 6 MODIFICATION OF THE INTRAVASCULAR ULTRASOUND AND PHOTOACOUSTIC 
IMAGING SYSTEM TO ENABLE SIMULTANEOUS IMAGING AND LASER HEATING 
OF GOLD NANORODS 
To enable photothermal heating specific to the imaged vessel region, a continuous 
wave (CW) diode laser (NIR DL 808-2000, Laser Lab Components Inc.) emitting at 808 
nm was additionally focused into the optical fiber of the integrated catheter using a prism, 
aligned to serve as an optical beam combiner, positioned proximal to the focusing lens. 
CW laser output energies ranging from 60 mW to 200 mW at the distal end of the 
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integrated IVUS/IVPA catheter were used to assess photothermal heating and subsequent 
temperature dependent IVPA signal change. Reducing the output power below 200 mW 
was achieved through the addition of a neutral density filters proximal to the laser beam 
combiner. A schematic of the integrated IVUS/IVPA imaging and photothermal heating 
experimental system is presented in Figure 3.8. 
 
Figure 3.8: Schematic of IVUS/IVPA imaging system modified to incorporate continuous 
wave (CW) laser illumination within the integrated catheter to enable 
simultaneous CW laser heating and IVPA temperature monitoring. 
The need for a second optical source, separate from the nanosecond pulsed laser 
utilized for IVPA imaging, in order to induce a photothermal effect is verified by Figure 
3.9. Solutions containing 300 µL of SiO2AuNR at an optical density of 2.0 were 
illuminated using the integrated IVUS/IVPA catheter for a period of 4 minutes with 
either the pulsed laser only or both the pulsed and CW lasers with outputs measured at 
3.0 mJ and 110 mW, respectively. As expected, the externally measured temperature of 
the AuNR solutions during illumination reveals minimal heating effect using only the 
pulsed laser, while the solution also receiving CW illumination exhibited significantly 
greater bulk heating. 
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Figure 3.9: Induced temperature rise of SiO2AuNR containing solutions illuminated with 
CW and nanosecond pulsed lasers (blue) or with the nanosecond pulsed 
laser only (red). 
3. 7 EX VIVO INTRAVASCULAR PHOTOACOUSTIC IMAGING FOR LOCALIZING AND 
MONITORING OF CONTINUOUS WAVE LASER HEATING OF GOLD NANOROD 
WITHIN ARTERIAL TISSUE 
An atherosclerotic coronary artery section was directly injected with a 
concentrated colloidal solution of SiO2AuNR on the outer surface of artery between 
adventitial fat and media. After 5 minutes, the artery was thoroughly washed with PBS 
and secured in a saline-filled tank for imaging and monitored CW photothermal heating. 
IVUS/IVPA imaging was performed at 808 nm to create a cross-sectional image 
revealing the artery morphology and location of the nanoparticle inclusion. The 
integrated catheter was then oriented to detect a region of high IVPA signal from the 
nanoparticles and temperature monitoring along a single A-line was performed by 
adjusting the temperature of the saline tank as well as by inducing CW photothermal 
heating. A separate location from the cross-section which did not contain the SiO2AuNR 
inclusion was also imaged as a control. 
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The CW laser-integrated IVUS/IVPA system was utilized as a means of 
selectively heating SiO2AuNR, capitalizing on the overlap of the emission wavelength of 
808 nm with the nanoparticles’ longitudinal peak absorbance and the relatively low blood 
and tissue absorption within the tissue optical window. SiO2AuNR injected into the 
adventitial fat of a coronary artery were imaged ex vivo and utilized to demonstrate the 
ability to induce and monitor CW laser heating, Figure 3.10. The IVUS/IVPA image 
reveals the presence of the SiO2AuNR region at approximately 2 o’clock (Fig. 3.10A). 
CW laser heating with IVPA monitoring was subsequently performed along the two lines 
indicated, without rotation of the integrated catheter. Figure 3.10B reveals the peak IVPA 
signal intensity along the indicated lines, with the SiO2AuNR containing line (green) on 
the top, and the control line (blue) on the bottom. As expected from the IVUS/IVPA 
image in Figure 3.10A, the control line has a significantly lower peak IVPA signal 
intensity than that of the SiO2AuNR containing line. Additionally, an increase in the peak 
IVPA singal for the line containing SiO2AuNR can be seen while the CW laser is applied, 
indicative of heating. Conversely, no similar increase is seen from the region without 
SiO2AuNR. Further evidence of SiO2AuNR heating can be seen in Figure 3.10C, which 
provides a plot of the SiO2AuNR containing line from representative times while the CW 
laser was off (blue) and on (red). The peak IVPA signal obtained from the SiO2AuNR 
region reveals a reversible increase and proximal shift (decrease in the temporal 
occurance of the peak) while CW heating is applied.  
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Figure 3.10: Ex vivo demonstration of IVPA monitored CW laser induced heating of 
SiO2AUNR within a human coronary artery. (A) IVUS/IVPA image 
obtained at 808 nm revealing the location of SiO2AuNR at 2 o’clock. Tick 
marks are spaced at 1 mm. (B) Maximum IVPA signal along the SiO2AuNR 
containing and control lines, indicated in A, versus time. The CW laser 
initially off (blue), then turned on to induce heating (red) and back off 
(blue). (C) Section of the IVPA A-line shown in green in part A which 
containing the SiO2AuNR inclusion, revealing the reversibly induced 
increase and shift in peak IVPA intensity during CW laser heating. 
 
3. 8 QUANTIFICATION OF IVPA-MEASURED CONTINUOUS WAVE LASER-INDUCED 
HEATING  
A forward looking infrared (FLIR) thermal camera was utilized to confirm the 
extent and specificity of CW heating of SiO2AuNR relative to background tissue of the 
human coronary artery sample. The FLIR thermal camera is capable of providing only 
surface temperature measurements, so the experimental set-up was modified following 
IVPA monitored heating to enable confirmation of heating using the thermal camera. 
Specifically, the coronary artery remained fixed within the saline tank, but the saline 
level was reduced to the surface of the artery. The optical fiber from the integrated 
IVUS/IVPA catheter was then positioned outside of the artery and focused onto a region 
of interest of the coronary artery, including the SiO2AuNR inclusion and a control region 
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without SiO2AuNR. The FLIR thermal camera (FLIR A325sc, FLIR Systems, Inc.) was 
focused on the saline tank, and temperature profiles of regions of interest were recorded 
for 90 seconds (ExaminIR software, FLIR Systems, Inc.), beginning at approximately the 
same time as the start of the application of CW laser. CW laser heating was applied for 
approximately the first 45 seconds, after which the CW laser was turned off, allowing the 
artery to cool. The temporal temperature profiles were obtained from a region of interest 
within the CW laser spot on the arterial surface for three different data sets; the arterial 
region containing the SiO2AuNR inclusion which was illuminated with 200 mW laser 
output power, the arterial region containing the SiO2AuNR inclusion which was 
illuminated with 60 mW laser output power, and a control region on the arterial surface 
which did not contain SiO2AuNR but which was illuminated with 200 mW laser output 
power. Additionally, for each case, thermal images were taken after a time of 45 seconds 
of CW laser heating, just prior to the CW laser being turned off, when the laser-induced 
heating is expected to have been at its maximum. The acquired raw thermal data was then 
converted to surface temperature (°C) using a black body temperature calibration curve. 
The consistency of the IVPA signal change with respect to both changing saline 
environment temperature and CW laser induced heating of a single location containing 
SiO2AuNR within the human coronary artery is demonstrated in Figure 3.11A. The 
percent change in IVPA signal with respect to change in the saline tank temperature in 
the absence of any CW laser heating is provided in black, with a 10°C temperature rise 
resulting in an 83.6% change in measured IVPA signal intensity. At varying saline tank 
temperatures, the CW laser was also briefly turned on to produce additional heating of 
the SiO2AuNR using distinct output energies of either 60 mW (orange) or 200 mW 
(blue). Each of the plotted lines represents the total percent IVPA signal increase from 
the baseline saline tank temperature, including both the increased temperature of the 
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saline environment and the locally induced temperature rise caused by CW heating, if 
applied. By inspection of the percent change in IVPA signal induced by the CW laser, it 
is evident that the IVPA monitored heating of the SiO2AuNR amounted to average local 
temperature rises of approximately 3.0°C (21.1 % increase in IVPA signal intensity) and 
7.1°C (58.8 % increase in IVPA signal intensity) over the baseline saline and arterial 
temperature (black) for the 60 mW and 200 mW output energies, respectively. 
The FLIR images and temperature profiles presented in Figure 3.11B further 
confirm the extent of CW laser induced heating and the specificity of heating to the 
region of the human coronary artery containing SiO2AuNR. Each of the FLIR thermal 
images shown were generated following approximately 45 seconds of CW laser heating. 
The optical fiber, seen on the right of each image, was focused on a region of interest, 
either the SiO2AuNR inclusion (top and middle) or a control region (bottom) of the 
human coronary artery. Illumination of the SiO2AuNR inclusion with optical fiber output 
powers of 200 mW and 60 mW resulted in maximum temperature rises of 6.9°C (top) 
and 2.8°C (middle), respectively, as demonstrated by the temporal profile of the region of 
interest from the thermal image which corresponds to the surface of the SiO2AuNR 
inclusion. These values are in good agreement with the measured temperature rise using 
the integrated IVPA imaging catheter (Fig. 3.11A). The slight differences observed 
between the IVPA monitored temperature rise and that measured using FLIR imaging are 
likely due to the required modifications in their respective experimental set-ups and the 
fact that FLIR thermal imaging yields only a superficial temperature measurement. The 
elapsed time which was required to reach steady-state temperature during and following 
CW laser heating which was observed in the case of 200 mW power output (top) is also 
in agreement with the temporal rise and fall profiles of the recorded IVPA signal intensity 
(Fig. 3.10B). Additional FLIR thermal imaging performed with an optical fiber output 
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power of 200 mW illuminating a region of the coronary artery which did not contain 
SiO2AuNR reveals a temperature rise of less than 1.5°C (bottom), further confirming that 
background tissue heating is minimized by utilizing CW laser heating of SiO2AuNR 
strongly absorbing within the near-infrared optical wavelength range. 
 
Figure 3.11: Confirmation of IVPA temperature monitoring during heating of SiO2AuNR 
on a human right coronary artery ex-vivo. (A) The percent IVPA signal 
change versus relative baseline temperature are plotted in the absence of 
CW laser heating (black), and following CW laser heating of the SiO2AuNR 
inclusion using output energies of 60 mW (orange) and 200 mW (blue) from 
the integrated IVUS/IVPA imaging catheter. (B) FLIR thermal images and 
temporal profiles of surface temperature rise of the SiO2AuNR inclusion 
exposed to 200 mW (top) and 60 mW (middle) CW laser heating and a 
control region of the artery exposed to 200 mW CW laser heating (bottom). 
 
0 5 10 15 20
0
50
100
150
200
250
T of Saline Tank (

C)
%
 C
h
a
n
g
e
 i
n
 I
V
P
A
 S
ig
n
a
l 
In
te
n
s
it
y
IVPA Signal Change with CW Laser and Environmental Heating
 
 
CW OFF:
R
2
=0.9931
CW ON (200 mW):
R
2
=0.9960
CW ON (60 mW):
R
2
=0.9990
Temperature Increase of Saline Tank (℃)
%
 C
h
an
ge
 in
 IV
PA
 S
ig
n
al
 In
te
n
si
ty
IVPA Signal Change Induced by 
CW Laser and Environmental Heating
CW ON: 200 mW
R2=0.9931
CW ON: 60 mW
R2=0.9960
CW OFF:
R2=0.9990
7.1 ℃
3.0 ℃
A B
25            
20
15
10
5
                    5                                                      2 0 45 90
Time (s)
26.96 ℃
24.27 ℃
21.44 ℃
18.45 ℃
26.96 ℃
24.27 ℃
21.44 ℃
18.45 ℃
26.96 ℃
24.27 ℃
21.44 ℃
18.45 ℃
SiO2AuNR Region (200 mW CW)
SiO2AuNR Region (60 mW CW)
Control Region (200 mW CW)
6.9℃
2.8℃
 124 
3. 9 DISCUSSION AND CONCLUSIONS 
The linearity of IVPA signal intensity dependence on temperature was 
demonstrated on both colloidal particles and those aggregated within macrophage 
endosomes. Such a relationship was anticipated based on the sensitivity of the Grüneisen 
parameter to variations in temperature. Therefore, provided that there is adequate 
absorption to produce a photoacoustic pressure wave, IVPA provides a mechanism for 
measuring temperature variations within the local environment surrounding the 
absorbers. AuNR were previously found to preferentially accumulate within plaques of 
atherosclerotic rabbit models following systemic injection, and the ability to localize the 
nanoparticles using spectroscopic IVUS/IVPA imaging, including imaging in the 
presence of luminal blood, was recently demonstrated [20]. Herein, the ability to further 
utilize such a delivery method and the resulting AuNR contrast over surrounding blood 
and endogenous tissue within the near-infrared wavelength range for selective CW laser 
heating and IVPA temperature monitoring was introduced. By measuring the percent 
change in IVPA signal intensity versus the change in temperature, it is possible to assess 
local temperature rise independent of the local pulsed laser fluence. This method, 
therefore, effectively self-normalizes based on the change in photoacoustic signal, 
accounting for possible depth-dependent variations in both the local laser fluence and 
integrated IVUS/IVPA catheter sensitivity.  
In addition to the IVPA monitored local temperature rise, the IVUS signal can be 
used to monitor the cumulative heating along a given line due to the temperature 
dependence of the speed of sound, which affects not only the photoacoustic signal 
amplitude based on its inclusion as part of the Grüneisen parameter, but also the acoustic 
time of flight. This effect is demonstrated in Figures 3.10C and 3.10D in which proximal 
shifts (i.e., reduced acoustic time of flight) of both the IVPA and IVUS peaks are 
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noticeable as a result of the increased speed of sound during CW laser heating (red lines). 
Additionally, a qualitative comparison of the extent of IVUS peak signal shifts at the 
location of the SiO2AuNR inclusion, approximately 6.1 mm, and at the luminal boundary 
of the coronary artery, approximately 3 mm, suggests that the use of a near-infrared 
wavelength laser causes minimal diffuse heating at the lumen border. For uniform 
heating, the ratio of the signal shift to the distance from the transducer would be expected 
to remain constant, however the ratio is greater at the location of the nanoparticle 
inclusion than it is at the tissue luminal surface. This further confirms the ability to 
selectively heat the SiO2AuNR with minimal nonspecific vascular heating. 
Interestingly, results presented in Figures 3.5, 3.7, and 3.11 provide evidence that 
the slope of the IVPA signal change with temperature is dependent on more than the net 
SiO2AuNR density alone. This is particularly evident in Figure 3.7B, in which cells 
containing the nanoparticles within endosomes exhibit a significantly greater percent 
IVPA signal change with temperature change than do colloidal particles with a higher net 
OD. This apparent discrepancy, along with variability in the measured percent IVPA 
signal change per 10°C temperature rise between experiments, is presumably due to 
variations in the aggregation state and distribution of the SiO2AuNR. In the case of 
endocyosed SiO2AuNR, groups of particles are expected to be closely packed, resulting 
in an enhanced efficiency of photoacoustic signal generation for a given change in the 
local temperature based on a greater temperature sensitivity of the effective Grüneisen 
parameter. Given that variations in both SiO2AuNR concentration and distribution can 
influence a perceived temperature rise based on a measured IVPA signal change, further 
studies are needed in order to establish an understanding of the variability of CW induced 
heating as a function of nanoparticle concentration within cells, followed by a 
longitudinal study to validate the therapeutic efficacy of IVUS/IVPA-monitored PPTT of 
 126 
atherosclerotic plaques in vivo. Additionally, a recent theoretical and in vitro 
experimental study evaluating the most effective gold nanorod size for plasmonic 
photothermal therapy has proposed particles with dimensions of 28 nm by 8 nm as the 
optimal size, while particles utilized for the results presented in this chapter exhibit a size 
of approximately 50 nm by 12 nm [27]. Further studies should be conducted to evaluate if 
the proposed optimal size remains the same following the silica coating as well as what 
effect the modification of core gold nanorod size will have on the efficiency of 
photoacoustic signal generation. These future studies will seek to evaluate the minimum 
temperature sensitivity of the proposed approach based on the extent of SiO2AuNR 
loading which can be achieved within atherosclerotic plaques following systemic 
injection, as well as to establish a desirable thermal dose for optimal PPTT therapeutic 
efficacy. 
The results in this chapter have demonstrated that IVPA imaging can be used to 
monitor temperature change of the local environment surrounding SiO2AuNR based on 
the linear relationship between photoacoustic pressure generation and the temperature 
dependent Grüneisen parameter, and that such temperature change can be effectively 
achieved by incorporating near-infrared wavelength emitting CW laser illumination into 
the integrated IVUS/IVPA catheter’s optical fiber to induce preferential heating of 
SiO2AuNR contrast agents. IVUS/IVPA can, therefore, be used as a theranostic platform 
to first detect the presence of systemically injected gold nanoparticles within 
atherosclerotic plaques, as was demonstrated in Chapter 2, followed by subsequent 
IVPA-monitored, selective plasmonic photothermal heating delivered through the 
integrated imaging catheter. This method offers a potential solution to limitations of other 
intravascular laser based therapies which suffer from both a lack of specificity in the 
induced thermal damage and an inability to monitor the delivered thermal dose. The 
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tendency of gold nanoparticles to be preferentially endocytosed by macrophages (Figs. 
3.3, 3.4) further support the adoption of this contrast enhanced technique as a cellular-
specific therapeutic strategy for atherosclerotic plaques, and the future conjugation of 
targeting moieties to the SiO2AuNR surface may provide a means of cellular/molecular 
specificity beyond macrophages. 
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Chapter 4: Photosensitizer-Doped Gold Nanorods as Multifunctional 
Theranostic Agents 
4. 1 INTRODUCTION 
Coronary heart disease remains a leading global cause of mortality in the United 
States and throughout the industrialized world. In the United States alone, it is estimated 
that over 1 million people suffered a myocardial infarction in 2010, with nearly 380,000 
associated fatalities [1]. This high mortality rate can be attributed, in part, to an inability 
to adequately diagnose and treat high-risk atherosclerotic lesions such as thin-capped 
fibroatheroma (TCFA). Over the past several decades, our understanding of the cellular 
and molecular mechanisms which promote coronary plaque progression and 
destabilization has improved significantly. Advances in molecular biology have led to the 
evolution from a view of coronary atherosclerosis as sites of passive lipid accumulation 
and storage to a much more dynamic biological process involving endothelial 
dysfunction with low density lipoprotein infiltration, monocyte recruitment and 
subsequent foam cell formation, and over expression of destabilizing extracellular matrix 
proteins, all of which lead to the formation of a prothrombotic core which can induce a 
myocardial infarction and sudden cardiac death if exposed to the artery lumen [2-5]. 
Despite increased appreciation for the dynamic cellular and molecular processes 
involved in the development of a vulnerable atherosclerotic plaque, clinical diagnostic 
and interventional practices have failed to fully keep pace. Rather, the most common 
diagnostic imaging modalities, including contrast angiography, cardiac computed 
tomography, intravascular ultrasound (IVUS), and intravascular optical coherence 
tomography (OCT), provide clinicians with a view of vessel morphology, as discussed in 
greater detail in Chapter 1 [6]. As a result, diagnosis and associated decisions regarding 
intervention for a particular arterial lesion is based primarily on the severity of lumen 
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narrowing and obstruction of blood flow, with limited characterization of its underlying 
composition. The limitations associated with basing diagnoses on the extent of arterial 
narrowing are made particularly evident by studies showing that arteries exhibit positive 
remodeling to maintain lumen area as plaques develop up to a total burden of 40% wall 
[7] and that extreme narrowing of arteries in the weeks or months before a myocardial 
infarction are found in only about 15% of cases [8]. In light of the limited plaque 
information provided by clinical imaging modalities, it is not surprising that procedures 
performed during percutaneous coronary interventions are also aimed at restoring luminal 
flow, largely irrespective of potential variations in the molecular composition of the 
atherosclerotic plaque being treated.  While recent advances in the related technologies, 
such as the widespread adoption of drug eluting stents, has led to significant 
improvements in achieving their primary goal of revascularization [9], such techniques 
do not directly account for or stabilize the underlying composition of atherosclerotic 
lesions [10]. In this respect, coronary interventional practices are similar to the available, 
widely-utilized diagnostic techniques, both of which do little to account for underlying 
biological processes that drive atherosclerotic plaque destabilization. 
Recent clinical approval of an intravascular imaging modality combining near 
infrared spectroscopy with intravascular ultrasound (Infraredx Inc., Burlington 
Massachusetts) offers an improvement for assessment of atherosclerotic lesion 
composition through its ability to detect the presence of lipid. The modality is being 
implemented in clinical settings and actively evaluated in clinical trials designed to 
investigate if and how interventional treatment strategies should be affected based on the 
composition of a plaque rather than its structural features alone. For example, the 
Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow 
(CANARY) trial is investigating the presence of lipid-rich plaque as a potential indicator 
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of increased periprocedural risk which could provide an indication for distal embolic 
protection [11,12]. Such studies represent a potential step towards the adoption of novel 
diagnostic imaging modalities to tailor treatment strategies based on known 
compositional risk factors within atherosclerotic plaques. 
Combined intravascular ultrasound and photoacoustic (IVUS/IVPA) imaging has 
also been introduced and investigated within the preclinical setting as a dual-modality 
approach for complimentary assessment of arterial morphology and composition [13]. 
IVPA imaging relies on the delivery of nanosecond-pulsed optical illumination to elicit 
an acoustic response which can enable selective detection of specific endogenous 
chromophores or exogenous contrast agents (see Chapter 1 for a more thorough 
description of photoacoustic signal generation). The induced photoacoustic transients can 
then be detected and localized using an ultrasound transducer, while conventional pulse 
echo ultrasound enables the formation of an inherently co-registered assessment of 
arterial morphology. Combined IVUS/IVPA imaging has been particularly heavily 
investigated as a tool for imaging the distribution of lipid within atherosclerotic plaques 
[14-20].  
In Chapter 2, the expansion of the modality as a platform to differentiate 
systemically injected gold nanorod (AuNR) contrast agents was introduced. AuNR were 
shown to be phagocytosed by macrophages and to preferentially extravasate into 
atherosclerotic lesions in rabbit models of atherosclerosis, thereby enabling their 
localization using IVPA imaging within the near infrared tissue optical window injection 
[19]. In Chapter 3, motivation for the potential use of AuNR in characterizing 
atherosclerotic plaque was further expanded through the demonstration that the 
IVUS/IVPA imaging platform can be utilized to deliver and monitor photothermal 
heating of the plasmonic nanoparticles. The integration of light emitted from a 
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continuous wave laser source into the optical fiber of the imaging catheter was shown to 
enable heating of the local environment surrounding AuNR, with simultaneous 
monitoring of the temperature-dependent change in IVPA signal intensity plaques [21]. 
Together, Chapters 2 and 3 introduced the potential for visualizing the location of 
macrophages within atherosclerotic plaques as well as the subsequent application of 
localized and controlled photothermal treatment using the IVUS/IVPA imaging platform, 
thus enabling an improved ability for treatment strategies more specific to lesion 
composition.  
4.1.1. Motivation for Combined Plasmonic Photothermal Therapy and 
Photodynamic Therapy 
Recently, multimodality therapy using hybrid nanoparticle constructs for 
complimentary plasmonic photothermal therapy (PPTT) and photodynamic therapy 
(PDT) have come under increasing investigation as a result of the demonstrated potential 
to achieve improved therapeutic efficacy using combination therapy [22]. As discussed in 
Chapter 3, Section 3.1 and Chapter 1, Section 1.5.2, PPTT utilizes the illumination of 
highly optically absorbing plasmonic nanoparticles to induce cytotoxic photothermal 
effects. Similarly, PDT relies on the delivery and subsequent low energy illumination of a 
photosensitizing agent which induces a cascade resulting in the intracellular formation of 
cytotoxic reactive oxygen species (see Chapter 1, Section 1.5.3). Many investigational 
studies have explored the use of hybrid nanoconstructs combining photosensitizers with 
highly absorbing nanoparticles for cancer treatment applications [23-33]. Among these 
multifunctional nanoparticles, many have centered on the covalent attachment of 
photosensitizers to gold nanoparticles, while one has demonstrated the ability to embed 
the photosensitizer directly within a silica layer surrounding a gold nanorod [29]. 
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Both PDT and PPTT have been independently investigated for the treatment of 
atherosclerotic plaques. The use of gold nanoparticles for PPTT  was recently reported as 
a tool for atherosclerotic plaque treatment, including the initiation of first-in-man clinical 
trials [34,35]. Furthermore, the application of PDT for the reduction or stabilization of 
atherosclerotic plaques, termed photoangioplasty, has also been heavily investigated 
using the photosensitizers Lutetium Texaphyrin (LuTex), marketed under the trade name 
Antrin (Pharmacyclics Inc., Sunnyvale, California), and MV0611 (Miravant Medical 
Technologies, Santa Barbara, California). Each of these photosensitizers has been shown 
to preferentially localize within atherosclerotic plaques in animal models of 
atherosclerosis over the course of 24 hours following systemic injection [36,37]. These 
same studies have also demonstrated a reduction in plaque area with corresponding 
increases in lumen area as well as a reduction in the number of macrophages present 
within the lesions based on histological staining of the lesions approximately one month 
following the treatment. Phase I clinical trials using LuTex-excited photoangioplasty 
identified safe photosensitizer and light dosages, reporting no coronary complications and 
low incidence of side effects associated with the procedure [38,39].  
Despite the established potential for improved multimodal therapeutic efficacy 
and these separate investigations of PPTT and PDT for intravascular treatments, 
investigation into their combined use with a hybrid nanoparticle designed specifically for 
therapy of atherosclerotic plaques has not yet been reported. Given the prior and ongoing 
investigation of gold nanoparticles for PPTT and LuTex photosensitizers for PDT of 
atherosclerotic lesions, the combination of these exogenous agents represents a natural 
first choice for such an application. To that end, this chapter focuses on the synthesis and 
in vitro characterization of a novel multifunctional nanoparticle platform combining 
LuTex-loaded silica-coated gold nanorods (LuTex/SiO2AuNR) designed to extend the 
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utility of the IVUS/IVPA imaging platform to enable image-guided, dual PPTT-PDT 
therapy of atherosclerotic plaques.  
4. 2 SYNTHESIS AND CHARACTERIZATION OF LUTETIUM TEXAPHYRIN-LOADED 
SILICA-COATED GOLD NANORODS 
Multifunctional nanoparticles containing AuNR as strong absorbers for PPTT and 
LuTex for PDT were synthesized by directly encapsulating photosensitizers within a 
silica shell surrounding the AuNR, yielding LuTex-doped silica-coated gold nanorods 
(LuTex/SiO2AuNR) (Fig. 4.1). A standard synthesis protocol was developed based off of 
a facile modification to the method for producing SiO2AuNR, introduced in Chapter 3.  
 
Figure 4.1: Schematic of LuTex/SiO2AuNR for combined plasmonic photothermal 
therapy (PPTT) and photodynamic therapy (PDT). 
4.2.1. Multifunctional Nanoparticle Synthesis 
Cetyltrimethylammonium bromide (CTAB) stabilized gold nanorods were 
synthesized using an established seed mediated growth method which is described in 
Chapters 2 and 3 [40]. The as prepared CTAB-AuNR were then twice washed via 
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centrifugation at 18,000 rcf for 40 minutes and re-suspended in ultra-filtered deionized 
water at a final peak optical density (OD) of 15, as measured by UV-Vis spectroscopy 
(Synergy HT, BioTek). Poly ethylene glycol (PEG, 2kD) was then attached to the AuNR 
surface by adding 1 mL of mPEG-thiol (0.5 mM) per 5 mL of OD 15 CTAB-AUNR. The 
mixture was sonicated for 30 minutes and allowed to react overnight on a shaker under 
modest agitation to facilitate the replacement of CTAB with PEG. The resulting PEG-
AuNR were washed via centrifuge filtration (Amicon ultra-15, Millipore) for 10 min at 
3000 rcf and re-suspended in water at an OD of 15.  
Silica coating of the PEG-AuNR in the presence of LuTex was achieved by a 
modification to the Stöber-based approach reported in Chapter 3, Section 3.2.1 [25]. 
Under vigorous stirring, 2.0 mL of the OD 15 PEG-AuNR were added to 3.0 mL of 
isopropanol, followed by the addition of 1.2 mL of tetraethyl orthosilicate (TEOS) in 
isopropanol (3% v/v). A 3.8% ammonia solution in isopropanol was added to adjust the 
solution to a pH of 11, and the solution was reacted under moderate stirring (400 rpm) for 
20 minutes prior to the addition of the photosensitizer to initiate silica deposition on the 
AuNR surface.  
LuTex, an expanded porphyrin, was synthesized as described in the literature 
[41,42]. LuTex was dissolved in dimethyl sulfoxide (DMSO) at a concentration 1 mg/mL 
and 1mL was added to the SiO2AuNR reaction, followed by addition of the ammonia 
solution to maintain the reaction solution at a pH of 11. The solution was allowed to react 
in the dark under stirring at 400 rpm for an additional 2 hours, with the silica coating 
thickness monitored by a red shift in the longitudinal peak absorbance up to 
approximately 25 nm as measured by UV-Vis spectroscopy throughout the reaction. 
Additionally, some batches of the LuTex/SiO2AuNR were encapsulated in a PEG surface 
layer through the addition of 900 µL of 3.3 mg/mL mPEG-silane and further reacting for 
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30 minutes. The resulting LuTex/SiO2AuNR, or mPEG-LuTex/SiO2AuNR, were diluted 
2x in ultra-filtered deionized water and twice washed via centrifuge filtration (100 kD 
cut-off) for 10 min at 1000 rcf and re-suspended in water at the desired final OD. Free 
LuTex does not readily pass through the cellulose membrane of centrifuge filters. 
Therefore, residual unbound LuTex molecules were removed through a series of 3-4 
centrifugation washing steps using a bench top microcentrifuge at 8000 rcf for 10 min. 
The UV-Vis spectrum of the supernatant from each washing step was measured to 
validate the successful removal of free LuTex from the LuTex/SiO2AuNR.  
Figure 4.2A provides representative UV-Vis spectra of LuTex/SiO2AuNR 
synthesis, including the core PEG-AuNR (red), the reaction solution containing LuTex, 
silica, and AuNR prior to washing (blue) and the final washed product (green). A red 
shift in the longitudinal peak absorbance of approximately 20 nm is observed following 
the reaction, consistent with silica coting of the AuNR. Additionally, peaks at 
approximately 470 nm and 732 nm which correspond to LuTex absorbance peaks are 
clearly evident in the reaction mixture and, to a lesser extent, in the final washed product, 
indicative of successful LuTex encapsulation. Comparison of the LuTex/SiO2AuNR 
supernatant obtained following centrifugation from the final wash during the nanoparticle 
synthesis and following one week in suspension at room temperature revealed no 
indications of AuNR aggregation or LuTex leakage from the silica layer, suggesting that 
the multifunctional nanoparticles exhibit adequate shelf-life stability for further 
evaluation (Fig. 4.2B). 
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Figure 4.2: UV-Vis Spectra from a representative batch of LuTex/SiO2AuNR. (A) 
Spectra of core PEG-AuNR, reaction solution containing LuTex prior to 
washing, and resulting washed product. (B) Validation of LuTex/SiO2AuNR 
stability and low LuTex leakage in water. 
4.2.2. Qualitative Assessment of LuTex Loading Efficiency under Variable 
Reaction Conditions 
A qualitative assessment of reaction conditions on LuTex loading efficiency was 
performed to further refine the LuTex/SiO2AuNR synthesis protocol. It has been shown 
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that the thickness of the silica layer deposited on the AuNR surface can be controlled by 
adjusting both the volume of TEOS and the overall reaction time [43]. Additionally, the 
impact of reaction pH and LuTex molecular structure were evaluated. Specifically, four 
parallel reactions using the same PEG-AuNR core particles and reagent solutions were 
initiated, with the only variation being the volume percent concentration of the ammonia 
solution used during the reaction. The resulting sensitivity of LuTex loading as over a 
reaction pH range from approximately 10.5 to 11.5 is clearly indicated by the resulting 
washed LuTex/SiO2AuNR shown in Figure 4.3. The molar extinction coefficients for 
comparable AuNR dimensions and LuTex alone have been reported to be 4.4 x 109 and 
4.2x104 M-1 cm-1 at the AuNR peak wavelength and the 732 nm absorbance peak of 
LuTex, respectively [44,45]. The extinction coefficient of LuTex at 732 nm was used to 
measure the corresponding extinction coefficient at the stronger 470 nm peak, found to be 
1.2 x 105 M-1 cm-1. Using the ratio of extinction coefficients between the AuNR peak and 
the 470 nm peak of LuTex and evaluating the relative contribution of the optical 
extinction spectra for each component, the LuTex loading is estimated to range from 7 x 
102 to 7 x 103 LuTex molecules per AuNR for the pH= 10.5 and pH= 11.1 reactions.  
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Figure 4.3: Effect of reaction pH on silica coating and LuTex loading efficiency. 
The impact of the LuTex molecular structure itself was also evaluated using three 
different molecular structures, shown in Figure 4.4. The structures associated with the 
side branches R1, R2 and R3 notably vary in terms of the increasing presence from 0 to 2 
carboxylic acid groups, which are expected to be negatively charged during the high pH 
synthesis reaction.  
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Figure 4.4: Molecular structures of LuTex utilized for assessment of the impact of 
functional groups on the loading efficiency during LuTex/SiO2AuNR 
synthesis. 
Figure 4.5 shows representative products obtained using each of the three LuTex 
structures. Assessment of the UV-Vis spectra of washed LuTex/SiO2AuNR reveals an 
inverse relationship between carboxylic acid functional groups and the LuTex loading 
efficiency, with estimated LuTex molecules per AuNR ranging from 1.5 x 103 for R3 to 
3.8 x 104 for R1 (Fig. 4.5A). However, assessment of transmission electron microscopy 
(TEM) images for each molecular structure indicates a relationship between increasing 
carboxylic acid functional groups LuTex structure and increasing uniformity of silica 
coating AuNR, with a decreased tendency of LuTex/SiO2AuNR to aggregate, shown 
from top to bottom in Figure 4.5B. In fact, synthesis using the structure R1 demonstrated 
partial aggregation during initial filter centrifugation washing steps, whereas the other 
two structures were much more stable under comparable conditions. Note that different 
batches of PEG-AuNR core particles were used during synthesis with each of the LuTex 
molecular structures compared. As a result of the desired silica uniformity and particle 
stability, all subsequent results utilizing LuTex/SiO2AuNR were obtained using the 
LuTex structure R3, despite the resulting sacrifice in LuTex loading efficiency. 
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Figure 4.5: Relative loading efficiency of LuTex with different functional groups. (A) 
UV-Vis spectra normalized to the AuNR absorbance peak for functional 
groups R=1, 2 and 3. (B) Corresponding TEM images for LuTex/SiO2AuNR 
synthesized with LuTex functional groups R=1 (top), R=2 (middle), and 
R=3 (bottom). 
4. 3 SINGLET OXYGEN GENERATION 
The ability of LuTex/SiO2AuNR to generate singlet oxygen (
1O2), a cytotoxic 
product of photosensitizer excitation during PDT, was further subsequently evaluated in 
comparison to free LuTex with and without AuNR. The photochemical oxidation of 9,10-
anthracenediylbis(methylene) dimalonic acid (ABDA) by 1O2 results in a decrease in the 
ABDA absorption peak located at approximately 400 nm and its corresponding 
fluorescence efficiency [46]. To compare the 1O2 production efficiency between 
LuTex/SiO2AuNR and free LuTex using the spectral changes induced in ABDA, the 
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optical density of SiO2AuNR with either free and encapsulated LuTex, as well as free 
LuTex without AuNR were matched. Solutions containing 200 µL solutions of LuTex 
and/or AuNR at matched concentrations and 100 µL of freshly prepared 60 µM ABDA 
stock were prepared (Fig. 4.6A). Each of the four experimental solutions, water, free 
LuTex, free LuTex in the presence of PEG-SiO2AuNR and PEG-LuTex/SiO2AuNR were 
subsequently illuminated with a 735 nm LED (Thorlabs M735L3, Newtown, New Jersey) 
at a 40 mW/cm2 for a total of 8 min.  The fluorescence of ABDA (ex/em: 380/420) was 
recorded for each group in 30 second intervals during illumination (Fig. 4.6B) and the 
initial and final optical absorption spectrum were measured to confirm matching decrease 
in the ABDA absorbance spectrum (Fig. 4.6C). Subsequently, a rate constant for the 
exponential decay in ABDA fluorescence as a function of illumination time was 
calculated for each group using a previously reported approach as an approximation of 
1O2 production [47]. Following first order kinetics, the rate constant of ABDA decay can 
be determined by: 
 
[𝐴𝐵𝐷𝐴]𝑡 = [𝐴𝐵𝐷𝐴]𝑡𝑜𝑒
−𝑘𝑡    Eq. 4.1 
 
ln (
[𝐴𝐵𝐷𝐴]𝑡
[𝐴𝐵𝐷𝐴]𝑡𝑜
) =−𝑘𝑡     Eq. 4.2 
Figure 4.6D shows the linear best fit of the natural logarithm of measured ABDA 
fluorescence decay versus time. Therefore, the slope of each line is equivalent to the rate 
constant for each group, ranging from -2 x 10-4 s-1for PEG-LuTex/SiO2AuNR to -3.7 x 
10-3 s-1 for free LuTex in the presence of PEG-SiO2AuNR, indicating a significant 
reduction in the rate of 1O2 production from LuTex entrapped within silica which, 
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depending on loading efficiencies within atherosclerotic plaques, may limit the efficacy 
of PDT using the multifunctional nanoparticles. 
 
Figure 4.6: Singlet oxygen generation for LuTex and SiO2AuNR combinations. (A) 
Optical extinction spectra of experimental groups with ABDA indicator, 
validating equal concentrations of LuTex and SiO2AuNR. (B) Comparative 
decay of ABDA indicator before (solid) and after (dash) illumination for 8 
min., indicating the varying degrees of oxidative decay of ABDA. (C) 
Relative ABDA fluorescence decay versus illumination. (D) Natural 
logarithm of ABDA fluorescence decay versus illumination time including 
best linear fits as indicators of 1O2 production rate constant.  
4. 4 MULTIFUNCTIONAL NANOPARTICLE STABILITY IN PHYSIOLOGICAL 
CONDITIONS 
Stability of PEG-LuTex/SiO2AuNR in variable physiologically relevant solutions 
was evaluated to further characterize the multifunctional nanoparticles. Figure 4.7 shows 
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representative TEM images obtained following incubation of PEG-SiO2AuNR in water, 
PBS at low (endosomal) pH, PBS at neutral pH, and DMEM cell culture media with 5 % 
fetal bovine serum (FBS) at 37 ˚C for 24 hours. Particles incubated in both neutral PBS 
(Fig. 4.7C) and cell culture media (Fig. 4.7D) exhibit clear signs of reduced silica density 
or complete stripping of the silica layer from AuNR surfaces, while the particles 
incubated in low pH PBS remained stable over the same period of time. 
 
 
Figure 4.7: TEM revealing stability of PEG-SiO2AuNR following 24 hours exposure to 
37˚C: (A) H2O, (B) PBS at pH= 5.0, (C) PBS at pH=7.4, and (D) DMEM 
cell culture media with 5% FBS. 
LuTex/SiO2AuNR were then evaluated to verify similar silica degradation in cell 
culture media. TEM analysis reveals the same stripping effect of silica following 24 hour 
incubation of LuTex/SiO2AuNR in the same cell culture media (Fig. 4.8).  
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Figure 4.8: TEM images of LuTex/SiO2AuNR following 24 hour incubation in (A) H2O 
and (B) DMEM cell culture media with 5% FBS revealing the loss of SiO2 
coating. 
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4. 5 SILICA DEGRADATION KINETICS AND PASSIVE DYE RELEASE 
The kinetics of silica degradation were evaluated through the synthesis of 
fluorescein isothiocyanate (FITC)-doped SiO2AuNR. The PEG-FITC/SiO2AuNR were 
synthesized using a one-to-one exchange of the dye for the synthesis protocol of PEG-
LuTex/SiO2AuNR described in Section 4.2.1. The prepared PEG-FITC/SiO2AuNR were 
then incubated in DMEM cell culture media with 5% FBS for 12 hours. Comparison of 
the initial and final spectra of the nanoparticles presented in Figure 4.9A, a clear blue 
shift in the AuNR peak absorbance attributable to the stripping of silica is observed. 
Additionally, the fluorescence intensity of FITC from the PEG-FITC/SiO2AuNR particles 
as well as from free FITC and PEG-SiO2AuNR without the fluorescent dye in DMEM 
was tracked over the 12 hour period. In contrast to the gradual decay in fluorescence 
intensity for the free FTIC and PEG-SiO2AuNR, the fluorescence intensity from PEG-
FITC/SiO2AuNR revealed a stable signal over the first two hours of incubation in in 
DMEM culture media, followed by a 8-fold increase between 2 and 6 hours for PEG- 
FITC/SiO2AuNR (Fig. 4.9B), indicative of delayed initiation of silica decay. 
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Figure 4.9: Validation of silica degradation and cargo release using PEG-
FITC/SiO2AuNR. (A) UV-Vis spectrum taken before and after 12 hours of 
incubation in DMEM, 10% FBS culture media, revealing blue shift 
associated with loss of silica coating. (B) Kinetic study of fluorescence from 
controls and PEG-FITC/SiO2AuNR in culture media over 12 hours. 
Evaluation of LuTex/SiO2AuNR revealed similar trends to that of 
FITC/SiO2AuNR, including the blue shift in the AuNR peak absorbance following 
incubation in culture media (Fig. 4.10A). Confirmation of LuTex release following 
incubation in culture media was enabled through assessment of the supernatant by UV-
Vis spectroscopy. Specifically, LuTex/SiO2AuNR were incubated in culture media for 24 
hours after which time the entire solution was centrifuged at 8000 rcf for 10 minutes to 
spin down the colloidal AuNR. Evaluation of the supernatant reveals a significantly 
increased peak at 470 nm relative to that of the AuNR peak absorbance at approximately 
780 nm due to the increased presence of free LuTex (Fig. 4.10B). No detectable peak at 
470 nm is observed from SiO2AuNR without LuTex exposed to the same conditions. 
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Figure 4.10: Validation of LuTex release as a result of silica stripping under 
physiological conditions. (A) LuTex/SiO2AuNR in water and DMEM cell 
culture media with 5% FBS. (B) Supernatant of SiO2AuNR with and 
without LuTex following incubation in culture media. 
In light of the silica degradation which occurs under physiological conditions but 
not in water, further evaluation of 1O2 production was conducted to assess the impact of 
LuTex/SiO2AuNR pre-incubated in cell culture media for increasing amounts of time. 
Equal concentrations of LuTex/SiO2AuNR were added to DMEM media with 5% FBS in 
triplicate at intervals from 24 hours, 4 hours, 2 hours and immediately prior to initiation 
of a study again assessing ABDA fluorescence decay versus illumination time. All wells 
were subsequently illuminated (735 nm, 40 mW/cm2) for a total of 3 minutes with the 
fluorescence intensity of ABDA recorded at 30 second intervals. Figure 4.11 provides the 
resulting rate constant for 1O2 production (inverse of ABDA decay rate constant), 
indicating a gradual increase in the efficiency for increasing pre-incubation time in cell 
culture media. A total increase in the 1O2 production efficiency of approximately 68% 
was observed between the groups with 0 and 24 hours of pre-incubation time. Notably, 
the rate constant for the group which received no pre-incubation is agreement with the 
calculated rate constant for LuTex/SiO2AuNR in water. 
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Figure 4.11: Effect of pre-incubation time in DMEM cell culture media with 5% FBS on 
1O2 production by LuTex/SiO2AuNR during CW illumination. 
4. 6 IN VITRO PHOTOTHERAPY OF MULTIFUNCTIONAL NANOPARTICLE-LOADED 
MACROPHAGES 
Validation of the therapeutic efficacy of LuTex/SiO2AuNR was performed by a 
series of in vitro studies designed to compare the induced cell toxicity of both 
nanoparticle and/or photosensitizer labeled macrophages and the effect of differing 
illumination parameters. For in vitro studies, J774A.1 murine monocyte-macrophages 
were plated at a density of 1x104 cells per well of a 96-well plate in 100 µL of DMEM 
phenol-red free cell culture media with 5% FBS. Cells were allowed to incubate for 24 
hours at 37°C under 5% CO2. Desired experimental groups, comprising free LuTex, 
SiO2AuNR, and LuTex/SiO2AuNR were sterilized using 0.22 µm syringe filters and left 
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suspended in water until just prior to addition with cells, at which time 10% volume of 
sterile 10x PBS was added.  
The cells were then washed and 5 µL of the photosensitizer of nanoparticle 
solutions were added. The final optical density of wells containing AuNR, either with or 
without LuTex, was 0.5, or approximately 113 pM (6.84x109 AuNR/well), and the 
nanorods utilized exhibited a peak absorbance near 808 nm. Wells containing LuTex in 
the absence of AuNR had a final concentration of 100 nM (6.02x1012 LuTex/well). 
Nanoparticles were incubated with the macrophages at 37°C in 5% CO2 for an additional 
18 hours, after which the cell were gently washed three times with PBS and resuspended 
in fresh culture media. The cells were then exposed to the desired illumination for 3 
minutes, either dark controls which received no illumination, PPTT illumination 
conditions using a continuous wave (CW) 808 nm diode laser (NIR DL 808-2000, Laser 
Lab Components, Inc.) emitting at 1 W/cm2, PDT illumination conditions using the 735 
nm LED emitting at 40 mW/cm2, or the simultaneous combination of both optical 
sources. 
After illumination of the experimental groups, cells were allowed to incubate for 
an additional 5 hours before exposure to live/dead cell staining assays. Calcein AM is a 
green fluorescent indicator for live cell staining, capitalizing on its conversion from an 
initially non-fluorescent state to the highly fluorescent calcein upon internalization and 
hydrolysis by intracellular esterases. Propidium iodide (PI) is a red fluorescent indicator 
which is cell-impermeant for healthy cells, but readily enters damaged cell membranes to 
bind nucleic acids. Therefore, these two indictors can be used together for live/dead cell 
staining using established protocols. Briefly, the cell media was replaced with a buffer 
solution for 5 minutes before being aspirated and replaced with buffer containing 1 µM 
PI and Calcein AM solutions and incubated for 20 minutes. The cells were gently washed 
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twice with buffer before measuring the fluorescence using a UV-VIS plate reader to 
generate quantitative plots and examining the wells using fluorescence microscopy for 
qualitative comparison. 
Figure 4.12 shows the dependence of results of live/dead staining of control cells 
without any photosensitizers or nanoparticles, SiO2AuNR-labeled macrophages, and 
LuTex/SiO2AuNR-labeled macrophages after differing illumination conditions. While 
control cells and those labeled with SiO2AuNR revealed no significant changes, a marked 
reduction in the Calcein AM fluorescence intensity (Fig. 4.12A) and increase in 
propidium iodide fluorescence intensity (Fig. 4.12B) was measured using the plate reader 
for the LuTex/SiO2AuNR-labeled macrophages which were treated with PDT and 
combined PPTT/PDT illumination conditions. Figure 4.12C further confirms the trend 
through representative microscopy images including overlays of both PI and Calcein AM 
fluorescence for cells treated with LuTex/SiO2AuNR but not illuminated (left) and those 
receiving both illumination sources (right).  
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Figure  4.12: Live/Dead staining of macrophages containing control cells, SiO2AuNR, or 
LuTex/SiO2AuNR following exposure to illumination to induce PPTT, PDT 
or both. (A) Relative number of live cells, Calcein AM stain. (B) Relative 
number of dead cells, propidium iodide stain. (C) Representative 
fluorescence overlay images of LuTex/SiO2AuNR after exposure to no light 
(left) or both PPTT and PDT conditions (right), showing live (green) and 
dead (red) cells; 10x objective. 
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A separate, complimentary, in vitro study comparing live dead staining results 
following PPTT and PDT illumination of macrophages labeled with LuTex/SiO2AuNR, 
100 nM free LuTex, SiO2AuNR, or no nanoparticles (Figure 4.13). Again a reduction in 
number of live cells with a corresponding increase in dead cell staining intensity was 
measured for the LuTex/SiO2AuNR-labeled macrophages which received PPTT/PDT 
illumination. In contrast, less difference in viability between illuminated and non-
illuminated cells of the other experimental groups (free LuTex, SiO2AuNR without 
LuTex, and control cells without LuTex or AuNR). This trend is supported by the inset 
fluorescence microscopy overlay images (Fig. 4.13C). 
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Figure 4.13: Labeled macrophage response to PPTT and PDT illumination relative to 
dark controls. (A) Relative intensity of Calcein AM live cell stain with 
representative fluorescence images insets for each group, 1.25x objective. 
(B) Relative intensity of Propidium Iodide dead cell stain with overlay 
fluorescence images inset for the illuminated cells of each group showing 
live (green) and dead (red) cells, 20x objective. Provided p values are based 
on the dark control and illuminated LuTex/SiO2AuNR group.  
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4. 7 DISCUSSION AND CONCLUSIONS 
Multifunctional nanoparticles comprising photosensitizer-doped, silica-coated 
gold nanorods were synthesized and characterized in vitro. Gold nanorods are known to 
provide excellent photoacoustic imaging contrast due to their high and tunable optical 
absorption resulting from localized surface plasmon resonance, which can be tuned to the 
near-infrared tissue optical window by tuning the AuNR aspect ratio. Chapters 2 and 3 
focused on the use of AuNR as contrast agents and thermal beacons for intravascular 
photoacoustic (IVPA) imaging of atherosclerotic plaques and monitored photothermal 
heating. Herein, the incorporation of LuTex photosensitizer molecules into the 
nanoparticles platform allows for a second therapeutic modality (PPTT and PDT) in 
addition to the image contrast provided by the core particles. Several unique properties of 
the synthesized LuTex/SiO2AuNR were observed and merit further discussion and/or 
continued investigation.  
The ability to detect the presence of LuTex by its characteristic absorbance peaks 
at 470 nm and 732 nm in the presence of AuNR is in itself an indicator of high LuTex 
loading. AuNR exhibit a longitudinal peak absorbance extinction coefficient on the order 
of 109 M-1 cm-1, whereas the extinction coefficient of a single LuTex molecule is four 
orders of magnitude less (1.2x105 M-1 cm-1 at the 470 nm peak). As synthesized 
LuTex/SiO2AuNR were found to be stable in water at room temperature for several 
weeks, or several months at 4°C, no LuTex leakage detected by the UV-Vis spectrum of 
supernatants (Fig. 4.2B). However, several factors were found to influence the efficiency 
of LuTex encapsulation within silica during its growth on the AuNR surface. For 
example, the maximum loading efficiency for LuTex was found to occur at a reaction pH 
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of approximately 11, with significant deviations either above or below that value 
resulting in decreased loading (Fig. 4.3). This effect is not surprising given the expected 
effect of pH on the kinetics of silica deposition on the AuNR surface and, as a result, the 
porosity of the silica coating. However, it is interesting to note that the lowest pH 
reaction (pH=10.5) exhibited low LuTex loading while still achieving an AuNR peak 
absorbance wavelength similar to that of the other experimental groups (pH= 10.8, 11.1, 
11.5), indicating that silica was deposited on the AuNR surface.  
Additionally, the functional groups on the LuTex molecules themselves were 
found to significantly impact the relative LuTex loading efficiency and particle stability. 
In particular, under similar reaction conditions, an inverse relationship was observed 
between LuTex loading and the presence of carboxylic acid groups on the LuTex 
molecules, likely due to repulsion of the negative charges between the carboxylic acid 
functional groups and the silica-coated AuNR (Fig. 4.5A). However, the uniformity of 
the silica coating for LuTex/SiO2AuNR and stability during washing steps was also found 
to be dependent on the molecular structure of LuTex, with the more highly loaded R=1 
function group which contains no carboxylic acid groups exhibiting the most amorphous 
silica coating upon evaluation by TEM (Fig. 4.5B). Together, these trends indicate a 
molecular and environmental dependence of LuTex loading during LuTex/SiO2AuNR 
and the resulting particle structure and stability. 
Photosensitizers encapsulated within silica demonstrated a sizable reduction in 
singlet oxygen production relative to similar concentrations of free LuTex, as measured 
by the decay in ABDA fluorescence in water (Fig. 4.6). The calculated rate constant for 
ABDA decay for LuTex/SiO2AuNR was 15-fold lower than that of an equivalent 
concentration of free LuTex in the absence of SiO2AuNR and 18.5-fold lower than that of 
OD matched SiO2AuNR co-incubated with free LuTex. This reduction is in agreement 
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with other studies investigating the effect of singlet oxygen production induced by 
photosensitizers encapsulated in silica nanoparticles which reported approximately 10-
fold and 17-fold decreases for methylene blue silica nanoparticles relative to the free 
photosensitizers [47,48]. The reduction is likely due to a combination of factors 
introduced by the silica shell, including the limited lifetime and restricted diffusion of 
singlet oxygen from within the silica layer as well as increased optical scattering within 
the silica which reduces the potential for photosensitizer excitation. 
Potential reduced efficiency of singlet oxygen production from LuTex entrapped 
within silica is likely avoided through the demonstrated biodegradation of the silica layer 
surrounding the AuNR within physiological conditions. PEG-SiO2AuNR were found to 
be stable in acidic salt solutions, while the silica was stripped in PBS at pH=7.4 and in 
cell culture media with 10% FBS (Fig. 4.7). Assessment of the TEM imaging for 
degraded silica particles in PBS and DMEM reveal a heterogeneous distribution of 
particles in which some PEG-SiO2AuNR appear to remain intact while others are 
completely stripped after 24 hours of incubation. Many of the particles also appear to 
have a lower silica density on the interior of the silica than at its periphery, indicating that 
the degradation may occur from the inside out rather than etching away at the outer 
surface of the silica layer. Each of these observations is likely due, at least in part, to 
incomplete and heterogenous PEG coating of the surface of the silica. Previous reports 
including an in vitro assessment of silica nanoparticles found differences in the kinetics  
of  degradation based on the particles shape, surface properties and porosity [49]. These 
dependencies were similarly investigated as a means of creating silica xerogel materials 
with controlled release properties [50].   
In order to better understand the kinetics silica degradation under physiological 
conditions, PEG-FITC/SiO2AuNR were synthesized as a proxy for LuTex/SiO2AuNR. 
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FITC is a highly fluorescent dye with similar charge to that of LuTex. The observed 
sigmoidal curve of FITC fluorescence intensity capitalizes on the fact that FITC 
entrapped within silica is quenched, but will fluoresce upon its release from the AuNR 
surface (Fig. 4.8B). By comparison, a separate report which utilized FITC-loaded silica 
nanoparticles prepared using the Stöber method in the absence of a metal nanoparticle 
core were shown to exhibit a drastic increase in particle degradation and FITC release 
between 4 and 17 hours in the same culture media [51]. 
Given the tendency for nanoparticles to exhibit long circulation times, the 
question remains whether or not the LuTex/SiO2AuNR can be adequately delivered to 
intended treatment sites, such as atherosclerotic plaques, prior to degradation of the silica 
and LuTex release. It was recently shown that perfluorocarbon core nanoparticles with a 
diameter of approximately 250 nm showed a similar extent of extravasation within 
atherosclerotic lesions within 2 hours to what was measured after 6 hours of circulation, 
indicating that the majority of passive plaque labeling may occur within the first few 
hours following injection [52]. This reported timescale of in vivo labeling kinetics in 
atherosclerotic rabbit models suggests that the release kinetics observed for the 
FITC/SiO2AuNR (Fig. 4.8B) may allow for sufficient time to label plaques before 
significant silica degradation occurs. Future work is needed to confirm if such in vivo 
kinetics and silica degradation kinetics hold true for LuTex/SiO2AuNR or if further 
development of stabilizing surface conjugations will be required for appropriate in vivo 
delivery. Interestingly, free LuTex has been shown to localize primarily within lysosomes 
following cellular uptake [53]. This is also the expected fate of AuNR internalized by 
macrophages, indicating that LuTex/SiO2AuNR are not expected to significantly alter the 
ultimate intracellular distribution of photosensitizers.  
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Together, the results from in vitro studies provided in Figures 4.12 and 4.13 
indicate the therapeutic potential for dual PPTT/PDT using the synthesized 
multifunctional nanoparticles. Increased numbers of dead cells and reduced live cell 
fractions for experimental groups illuminated with both 732 nm PDT and 808 nm PPTT 
conditions relative to changes observed from other experimental groups was observed, 
including an enhanced therapeutic efficacy for combined PPTT/PDT over PPTT and PDT 
alone (Figs. 4.12B and 4.13B). This enhanced effect for combined photothermal and 
photodynamic therapy is in agreement with several recent reports investigating such 
combined approaches for cancer therapy applications [26-28,32,33]. 
As the multifunctional nanoparticle platform transitions from in vitro 
characterization to in vivo validation, several inter-related factors must be considered to 
help further refine the optimal nanoparticle design. For example, Adili et. al. 
demonstrated a wide range of biological responses which can be achieved through 
variations in the drug-light dosage in treatment intended for the treatment of intimal 
hyperplasia in the carotid artery of rats [54]. As the administered drug concentration and 
optical fluence were increased, therapeutic effects ranging from incomplete cell 
eradication following the treatment, to the desirable complete cell eradication with 
inhibited hyperplasia at two weeks following treatment, to rapid thrombus formation with 
vascular occlusion were all observed. This wide range of physiological effects suggests 
the importance of monitoring both drug delivery and light dosage prior to and during 
treatment. Once a desirable drug-light dosage has been established, the incorporation of 
intravascular photoacoustic (IVPA) imaging to verify and assess multifunctional 
nanoparticle delivery and to monitor the temperature rise induced by combined 
PPTT/PDT. 
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In conclusion, this chapter has focused on the introduction of novel 
multifunctional nanoparticles comprised of photosensitizer-doped, silica-coated gold 
nanorods. Encapsulation of LuTex photosensitizers onto gold nanorods was specifically 
chosen based on the prior research investigating each component individually for 
intravascular diagnostic and/or therapeutic applications. The synthesized 
LuTex/SiO2AuNR have been characterized and shown to release the LuTex cargo within 
physiological media and increased in vitro therapeutic efficacy of combined PPTT/PDT 
of LuTex/SiO2AuNR-labeled macrophages relative to either SiO2AuNR or LuTex alone 
was demonstrated, supporting their continued investigation. In the context of prior 
research within this dissertation, the multifunctional nanoparticles provide a potential for 
improved control of therapy delivery under the guidance of combined IVUS/IVPA 
imaging.  
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Chapter 5: Conclusions and Future Directions 
5.1. SUMMARY OF COMPLETED RESEARCH 
The pathophysiology associated with progression and destabilization of 
atherosclerotic plaques is a multifaceted process which leads to characteristic changes in 
arterial morphology and composition. Combined intravascular ultrasound and 
photoacoustic (IVUS/IVPA) imaging is a novel modality currently in preclinical 
development which seeks to expand upon the ability of clinically utilized intravascular 
ultrasound (IVUS) imaging to assess vessel anatomy by adding improved sensitivity to 
image the underlying cellular and molecular composition through intravascular 
photoacoustic (IVPA) imaging. The motivation for IVUS/IVPA imaging lies in this 
ability to provide complimentary vessel information, capitalizing on the unique capability 
of IVPA imaging to yield optical contrast at significantly deeper penetration depths than 
other optical techniques. Such contrast can be obtained from endogenous chromophores 
within atherosclerotic plaques, such as lipid, or through the delivery of exogenous 
contrast agents designed to localize within atherosclerotic plaques and provide high 
IVPA signal contrast relevant to molecular and cellular composition of plaques.  
The present work has focused on methods of expanding the applications of IVPA 
imaging using exogenous contrast agents, plasmonic gold nanorods, to enable the 
detection and subsequent optically-triggered therapy of atherosclerotic plaques. The 
passive extravasation and aggregation of systemically injected plasmonic gold nanorods 
absorbing within the near infrared tissue optical window within plaques of atherosclerotic 
rabbit models was demonstrated, along with the ability to localize the contrast agents 
using ex vivo IVUS/IVPA imaging. The motivation for nanoparticle labeling of 
atherosclerosis was then expanded from that of purely image contrast agents to vehicles 
for image-guided, dual-modality phototherapy.  
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In Chapter 2, the potential for using polyethylene glycol conjugated gold 
nanorods (PEG-AuNR) as contrast agents for IVUS/IVPA imaging of atherosclerosis was 
evaluated. Biocompatibility of the nanoparticle contrast agents was evaluated in vitro, 
showing no signs of reduced viability of macrophages following their incubation and 
labeling with PEG-AuNR, including after application of nanosecond pulsed laser 
illumination of intensity comparable to that required for IVPA signal generation. 
IVUS/IVPA imaging of atherosclerotic rabbit aortas following systemic injection of 
PEG-AuNR with peak absorbance within the tissue optical window was performed. Ex 
vivo imaging revealed a high photoacoustic signal from localized AuNRs in regions with 
atherosclerotic plaques, with corresponding histological staining further confirming the 
preferential extravasation of AuNR in atherosclerotic regions with compromised luminal 
endothelium and acute macrophage accumulation. The ability to detect AuNRs using 
combined IVUS and photoacoustic imaging in the presence of luminal saline and luminal 
blood was evaluated using spectroscopic IVPA imaging.  
Chapter 3 further introduced IVUS/IVPA imaging as a tool for localized 
temperature monitoring during plasmonic photothermal therapy.  The temperature 
dependent change in IVPA signal intensity of silica coated gold nanorod (SiO2AuNR) 
contrast agents absorbing within the near infrared wavelength range is evaluated and 
shown to have a linear relationship, with a slope greater than that of endogenous tissue.  
A continuous wave laser was subsequently incorporated into the IVUS/IVPA integrated 
catheter and utilized to selectively heat the nanoparticles with simultaneous IVPA 
temperature monitoring.  As a result, IVUS/IVPA provides a platform for detection and 
therapy monitoring of atherosclerotic plaques through the selective heating of plasmonic 
gold nanoparticle contrast agents. 
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The theranostic potential of coupling the optical delivery enabled by the 
IVUS/IVPA imaging system with selectively delivered nanoparticles was further 
expanded in Chapter 4 through the synthesis and characterization of multifunctional 
nanoparticles designed to enable combined plasmonic photothermal therapy (PPTT) 
using illumination at 808 nm and photodynamic therapy (PDT) using lower intensity 
illumination at 735 nm. SiO2AuNR doped with the photosensitizer lutetium texaphyrin 
(LuTex/SiO2AuNR) were shown to passively release the photosensitizer after a delay of 
several hours, resulting in an improved efficiency of cytotoxic singlet oxygen production 
during PDT. In vitro studies further confirmed an increased therapeutic efficacy of 
combined PPTT/PDT for macrophages labeled with LuTex/SiO2AuNR than was 
observed using either PPTT or PDT alone. 
Together, the results presented within this dissertation provide a framework for 
ongoing research into the expansion of IVUS/IVPA imaging as a platform for 
complimentary diagnosis and local treatment of atherosclerotic plaques using 
multifunctional theranostic nanoparticle contrast/therapeutic agents. 
5.2. FUTURE DIRECTIONS  
5.2.1. Outlook for Clinical Translation of Intravascular Ultrasound and 
Photoacoustic Imaging: Characterizing Lipid-Rich Plaques 
Translation of combined IVUS/IVPA imaging into the catheterization laboratory 
is dependent on several factors, including existing technical hurdles, safety concerns, and 
the extent of demonstrated advantages of IVUS/IVPA imaging over existing diagnostic 
modalities. The established correlation of lipid distribution within atherosclerotic plaques 
and the risk of acute coronary events, as well as the ability of IVPA imaging to detect 
lipid without introducing exogenous contrast agents, make lipid imaging a likely first 
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clinical application of IVUS/IVPA imaging [1-3]. This section, therefore, focuses on 
factors effecting the clinical translation of IVUS/IVPA imaging for that initial 
application, while additional considerations brought about by the introduction of 
exogenous contrast and/or therapeutic agents are discussed in Section 5.2.2. 
5.2.1.1. Technical Hurdles  
The primary technical hurdles restricting clinical translation of IVUS/IVPA 
imaging relate to the required laser sources for development of a real-time system and 
miniaturization of the integrated catheter. To date, the majority of applications of IVPA 
imaging have utilized commercially available US transducers and illumination from Q-
switched Nd:YAG lasers coupled with optical parametric oscillators (OPO). Such optical 
systems are attractive in preclinical settings because they offer high pulse energies, on the 
order of tens of millijoules (mJ), over a broad range of wavelengths, allowing optical 
tuning for IVPA detection of a wide range of absorbers of interest. The versatility of 
these laser sources, however, is available at the expense of pulse repetition frequency 
(PRF), which is on the order of 10 Hz.  
Whereas OPO lasers may be adequate for some US/PA applications which utilize 
array transducers to capture full two dimensional images with a single laser pulse, 
intravascular imaging using mechanically scanned single element ultrasound transducer 
provides an extreme case for optical source requirements if real-time imaging is to be 
achieved. Using an integrated IVUS/IVPA catheter which is mechanically rotated and 
pulled back to enable three dimensional imaging, an optical source operating at several 
kilohertz (kHz) and providing approximately 1 mJ/pulse would be required to maintain 
real-time IVPA imaging capabilities. For imaging lipid within plaques the requirements 
for the optical source are further restricted based on the need for an output wavelength 
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which matches an optical absorption peak of lipid, approximately 1210 nm or 1720 nm. 
Such sources are becoming commercially available. However, real-time IVUS/IVPA 
imaging has not yet been demonstrated. Further progression of IVPA towards the 
initiation of clinical trials hinges on the development of such systems; their completion 
will enable validation of in vivo IVUS/IVP lipid detection in large sample sizes of animal 
models of atherosclerosis and excised human coronary arteries. While in vivo 
IVUS/IVPA imaging has been demonstrated on rabbit models of atherosclerosis (see 
Figure 1.7), characterization of the received IVPA signal was restricted to qualitative 
comparison with histology sections and the small sample sizes have not allowed 
quantification of the sensitivity and specificity of IVPA-based lipid imaging. 
In addition to the need for real-time IVUS/IVPA imaging systems, continued 
improvements to the overall integrated imaging catheter design are still needed before 
clinical translation can occur. Results presented within this dissertation have all utilized a 
catheter design with an outer diameter of approximately 2 mm and an inflexible region at 
the distal tip of approximately 5 mm. Future designs should exhibit comparable physical 
dimensions and flexibility to existing clinical catheters. To date, the smallest diameter 
IVPA catheter which has been reported is comprised of a rigid distal tip and an outer 
diameter of approximately 1.25 mm [4]. Additionally, our lab is currently working on 
developing and characterizing catheter prototypes which are assembled within a drive 
cable with an outer diameter of 1 mm. However, clinically used, mechanically rotated 
IVUS catheters rotate within a sheath that has an outer diameter of approximately 700 
µm and with a rigid segment surrounding the transducer of less than 1 mm. Combined 
IVUS/IVPA catheters must meet similar criteria prior to its clinical adoption. While such 
a miniaturization is conceptually feasible, it is yet to be demonstrated, and the 
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effectiveness of light delivery for PA signal generation from the small optical fibers that 
would be required remains a potential obstacle. 
5.2.1.2. Safety of IVPA Imaging 
Beyond remaining technical challenges, the clinical acceptance of IVPA imaging 
will also require a more thorough investigation into its safety. In particular, the desire for 
achieving enhanced signal-to-noise (SNR) from the imaging target (e.g. lipid) should be 
balanced with the potential for unintentional laser-tissue interactions which may lead to 
tissue damage during IVPA imaging. The American National Standards Institute (ANSI) 
has established wavelength dependent laser fluence exposure limits, ranging from 20 
mJ/cm2 in the visible range to 100 mJ/cm2 in the near infrared range, which can be used 
as a benchmark for predicting laser safety during IVPA signal generation [5,6]. While 
these limits were primarily set in place for considerations of safety to ocular exposure as 
well as that of skin, which is significantly more absorbing than other tissues due to the 
pigment/melanin content, they are treated as a conservative benchmark in predicting 
safety for all tissue exposure. For IVPA imaging, continued miniaturization of the 
integrated IVUS/IVPA catheter to a size acceptable for clinical use in human coronary 
arteries, ≤ 1 mm, will necessitate the use of an optical fiber with a diameter on the order 
of 300 µm, resulting in a high optical fluence at the distal end of the integrated catheter. 
Pulse energy of 0.5-1.0 mJ equate to fluences of several hundred mJ/cm2, potentially 
resulting in local heating during imaging and well over the ANSI standard at any 
wavelength [7,8]. While optical diffusion will rapidly reduce fluences further away from 
the catheter and natural blood flow will help to mitigate any potential for heat buildup 
during imaging, ongoing studies are needed to evaluate the potential negative effects 
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which can result from IVPA imaging through luminal blood, particularly the presence 
and extent of optically-induced hemolysis. 
5.2.1.3. Motivation for Clinical Adoption 
If existing technical challenges are met and IVUS/IVPA imaging is shown to be 
well tolerated, the extent and rate of its adoption will be highly dependent on the effect 
which it has on clinical practice. In the short term, the question is how additional 
information provided by the coupling of IVPA imaging will impact existing 
interventional practices. Currently, intravascular imaging is reserved primarily for 
providing guidance of revascularization during percutaneous coronary intervention (PCI) 
and aiding in the diagnosis of lesions of unclear severity upon angiographic assessment 
[9,10]. Therefore, the immediate impact of combined IVUS/IVPA imaging will be 
largely determined by the ability to demonstrate improved therapeutic outcomes achieved 
through changes in clinical standards of care that are enabled by the new information 
provided by the imaging modality. While this remains to be demonstrated specifically by 
IVUS/IVPA imaging as it is translated into the clinic, several recent and ongoing clinical 
trials provide evidence of the potential impact that it may have on existing treatment 
strategies and outcomes.  
First, the Providing Regional Observations to Study Predictors of Events in the 
Coronary Tree (PROSPECT) study has confirmed two critical points which support the 
expanded use of intravascular imaging modalities which are capable of accurately 
assessing atherosclerotic plaque composition in addition to its morphology- the 
demonstrations that angiography alone is not a good predictor of future coronary events 
and that plaque composition plays a significant role in determining the underlying risk 
profile for a given lesion [11,12]. Using virtual histology IVUS, the accuracy of which 
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has recently been questioned, to assess lesion composition, the PROSPECT trial found 
significantly higher incidence rates among patients with thin-cap fibroatheroma (TCFA) 
than in those with no identified TCFA plaques (Fig. 5.1) [11].  
 
Figure 5.1: Event Rates for Lesions That Were and Those That Were Not Thin-Cap 
Fibroatheromas, at a Median Follow-up of 3.4 Years. Event rates associated 
with 595 nonculprit lesions that were characterized as thin-cap 
fibroatheromas (TCFA) and 2114 that were not by means of radiofrequency 
intravascular ultrasonographic imaging are shown according to minimal 
luminal area (MLA) and plaque burden (PB) as detected on gray-scale 
intravascular ultrasonography. The inset shows an example of a thin-cap 
fibroatheroma imaged by radiofrequency ultrasonography. Data on 
prevalence are for one or more such lesions per patient. Lesions in patients 
with indeterminate events were excluded. Reproduced with permission from 
[11]. 
In addition, Infraredx Inc. (Burlington, MA), the company which has 
commercialized near-infrared spectroscopy for the detection (albeit not depth-resolved) 
of lipid-rich plaques has led additional clinical trials investigating the role of lipid 
detection in guiding coronary intervention. For example, the Coronary Assessment by 
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Near-infrared of Atherosclerotic Rupture-prone Yellow (CANARY) trial is actively 
investigating criteria for defining lipid core plaques which are at increased risk of 
rupturing and inducing intra-procedural complications during PCI [13,14]. From a more 
long term perspective, Infraredx has also initiated the Chemometric Observations of 
Lipid Core Plaque of Interest in Native Coronary Arteries (COLOR) registry to be used 
for assessment of the varieties of lipid-rich plaques and their long-term clinical 
significance and responses to available therapies as well as the large scale Lipid-Rich 
Plaque Study trial which is intended to assess whether their imaging modality can be 
utilized as a predictor of future coronary events [15].  Combined IVUS/IVPA imaging is 
well positioned to capitalize on the results from each of these clinical trials.  
Experimental results shown to date support the hypothesis that image guidance by 
IVUS/IVPA will provide the only imaging technique capable of localizing the 
distribution of lipid during PCI guidance and will, therefore, lead to a more complete 
understanding of the relationship between lipid-rich plaques and periprocedural 
complications as well as an improved ability to identify such lesions during therapy 
guidance. 
This dissertation has focused on applications of IVUS/IVPA imaging for novel 
diagnostic and therapy guidance applications through the delivery of exogenous agents, 
the clinical translation of which are, in all likelihood, more long term and admittedly 
higher risk techniques to be translated into clinical practice. The introduction of 
exogenous agents will require an additional layer of safety concerns to be addressed in 
preclinical trials, while the therapeutic approaches which served as the motivation for 
Chapters 3 and 4 of the dissertation are at early stages of development and represent 
significant deviations from current PCI standards of care. Each of these factors will 
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necessitate substantial preclinical and clinical testing to validate safety and efficacy in 
comparison with existing alternatives. 
5.2.2. Outlook for the Clinical Use of Noble Metal Nanoparticles as Imaging 
Contrast Agents and Therapeutic Vehicles 
Plasmonic nanoparticle contrast agents provide great promise as tools for 
expanding the cellular/molecular sensitivity of IVPA imaging, as demonstrated through 
the labeling of phagocytically active macrophages throughout this dissertation. However, 
the long-term safety of such contrast agents is not yet fully understood. It has been shown 
in systemically-injected animal models, for example, that metallic nanoparticles larger 
than 6 nm do not ever fully clear the body and that high percentages of the initial 
injection are retained within the liver and spleen. However, particles smaller than 6 nm 
are quickly cleared from circulation and therefore may not allow enough time for 
sufficient accumulation within the desired targets [16]. In an effort to address these 
conflicting restrictions, biodegradable clusters of nanoparticles with suitable PA 
properties have been developed which are comprised of cross-linked 4 nm primary 
particles that form larger initial sizes until exposed to reduced pH values within 
intracellular lysosomes [17-19]. While such an approach which increases the likelihood 
of contrast agent clearance is ideal in the clinical setting, the overall safety of metallic 
nanoparticle contrast agents, including gold and gold/silica nanoparticles, which are 
greater than 6 nm are also being studied in ongoing FDA clinical trials for applications 
within and beyond cardiovascular medicine (Table 5.1) [20]. While the majority of 
inorganic nanoparticles already approved and currently in clinical trials in Europe and the 
United States are focused on cancer imaging and therapy, it is noteworthy that three of 
the nanoparticle platforms utilize gold nanoparticles. These studies are paving the way 
for clinical adoption of nano-gold. It is also notable that each of the gold nanoparticles in 
 179 
clinical trials is being investigated for therapeutic applications rather than merely as 
imaging contrast agents. Most importantly, one of the nanoparticles under development 
involved the use of gold nanoparticles for plasmonic photothermal therapy (PPTT) of 
atherosclerotic plaques in first-in-man clinical trials, the NANOM FIM trial [21]. While 
there is limited preclinical research into the use of gold nanoparticles for PPTT of 
coronary atherosclerosis, the preliminary results seem to support its continued 
investigation and have, in part, motivated the coupling of such a strategy with the use of 
gold nanoparticles for contrast during IVPA imaging [22]. Together, these studies will 
help guide future research utilizing metallic nanoparticle contrast agents by 
demonstrating their biological interactions and potential toxicity. Such relationships will 
likely need to be further investigated to assess potential additional effects, such as local 
heating, which can result from the interaction between the nanoparticles and nanosecond-
pulsed optical illumination during IVPA imaging.  
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Table 5.1: Inorganic nanoparticles on the market and in clinical trials, Adapted with 
permission from [20]. 
 
Beyond demonstrations of nanoparticle safety and regulatory approval, the use of 
plasmonic nanoparticles for intravascular contrast and therapy also presents unique 
constraints beyond that of many other applications, most notably the need for delivery of 
the nanoparticles within a suitable timeframe for intravascular imaging. Given that 
intravascular imaging is, at present, utilized during PCI for clarification of uncertainties 
arising from the use of other diagnostic approaches, it may be difficult to plan which 
Commercial name Compound Function Target disease Development stage
Feridex I.V.® Dextran-coated SPIO
MRI contrast 
agent
Liver tumors
FDA approval in 
1996
GastroMARK™ Silicone-coated SPIO
MRI contrast 
agent
Gastrointestinal 
forms of cancer
FDA approval in 
1996
Resovist®
Carboxydextrane-
coated SPIO
MRI contrast 
agent
Liver tumors
EU approval in 
2001
Acticoat Silver nanoparticles
Antimicrobial 
barrier dressing
Wound healing
FDA approval in 
2005
NanoTherm
Aminosilane-coated 
SPIO
Magnetic 
thermotherapy
Brain tumors
Prostate and 
pancreatic 
carcinoma
EU approval in 
2010
Phase I
NBTXR3
Hafnium oxide 
nanoparticle
Radiation therapy Soft-tissue sarcoma Phase 1
-
Silica-gold 
nanoparticles
Photothermal
ablation of 
atherosclerotic 
plaques
Atherosclerosis Phase 1/phase 2
AuroShell®
Gold@silica 
nanoshells
Photothermal 
therapy
Refractory head 
and neck cancers
Primary and 
metastatic tumors 
in the lung
Phase 1
Approved by FDA 
for clinical trials in 
2012
Aurimmune
TNF-α-bound 
PEGylated colloidal 
gold particles
Targeted delivery 
of TNF-α
Solid tumors Completed phase 1
Cornell dots
Silica nanoparticles 
embedded with 
fluorophores or 
radioactive iodine
Fluorescence/PET 
contrast agents
Cancer
Approved by FDA 
for clinical trials in 
2011
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patients will benefit from an injection of contrast agents far in advance of the time at 
which imaging is performed. Therefore, the use of long circulating nanoparticles, such as 
nanoparticles with the circulation times of > 24 hours utilized for systemic injection in 
animal models of atherosclerosis, may limit their future clinical impact. Achieving 
similar plaque- and macrophage- specific labeling of the nanoparticles within a time span 
of a few hours following injection should, therefore, be a goal moving forward. Ideally, 
agents would be modified to enable rapid labeling following delivery directly into the 
coronary tree though a flushing port during the intervention, similar to the injection of 
contrast for angiography. This would limit both effective lead time for contrast enhanced 
IVPA imaging and reduce concerns of system toxicity by significantly limiting the 
injected dose. 
5.2.3. In Vivo Response to Macrophage-Specific Therapy 
Chapters 3 and 4 of this dissertation have focused on introducing therapeutic 
approaches which are complemented by combined IVUS/IVPA imaging using exogenous 
theranostic agents. The feasibility of IVPA temperature monitoring during PPTT using 
gold nanorods (AuNR) and in vitro characterization of multifunctional nanoparticles for 
combined IVPA contrast, PPTT and photodynamic therapy (PDT) have been introduced 
and serve as a foundation for continued research into the utilization of an IVUS/IVPA 
imaging system for combined diagnostics and optically-triggered, local therapy under 
image guidance. Moving forward, a key topic to investigate are the immediate and long 
term effects following in vivo application of the proposed therapeutic approach.    
Within advanced atherosclerotic lesions, it has been well established that 
endothelial cells and smooth muscle cells provide plaque stability while macrophages 
contribute to plaque destabilization [23,24]. Therefore, macrophage-specific therapy and 
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elimination within atherosclerotic plaques has been proposed using numerous techniques 
such as delivery of the mammalian target of rapamycin (mTOR) inhibitor everolimus or 
cytotoxic clodronate-containing liposomes [24-27]. Due to adverse effects of systemic 
drug delivery, however, these approaches are restricted to local delivery, such as through 
their incorporation within drug eluting stents [28]. It has also been shown that phagocytic 
clearance of apoptotic macrophages is compromised in advanced atherosclerotic lesions, 
leading to questions of the in vivo response which will result from therapeutic approaches 
designed to selectively deplete plaque macrophages in vulnerable lesions [29]. This 
concern is difficult to test using experimental models of atherosclerosis because such 
models tend to more closely resemble early atherosclerotic lesions in which the clearance 
of apoptotic cells is still effective. 
With regard to the phototherapy approaches investigated within this dissertation, 
experimental investigations utilizing either PPTT or PDT for the treatment of 
atherosclerotic plaques have demonstrated encouraging results, including reduction in 
atheroma burden following PPTT and a reduction in inflammatory macrophages coupled 
with reduced plaque volume following PDT [21,22,30,31]. However, the mechanisms 
involved in creating such an effect are yet to be fully defined.  
Studies evaluating the mechanisms of PDT host tissue response have primarily 
focused on the treatment and response of cancerous tumors [32]. In this case, it has been 
shown that the tissue injury induced during PDT treatment invokes an innate immune 
response characterized by an immediate inflammatory response with accompanying 
neutrophil infiltration followed by efferocytosis, or removal of dead cells from the treated 
site. If a similar process is maintained in the treatment of atherosclerotic tissue, the 
magnitude and effect of the short term inflammatory response is important for therapeutic 
outcome, particularly for the case of treating unstable atherosclerotic plaques. The 
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efficiency of efferocytosis in advanced lesions is also critical for achieving favorable 
therapeutic outcome. It has been well established that inefficient clearance of apoptotic 
and necrotic macrophages plays a role in destabilizing advanced atherosclerotic lesions 
[33]. Uncertainty regarding how atherosclerotic plaques, and particularly advanced 
lesions, will respond to the inflammatory response and subsequent need for efficient 
clearance is supported by a report demonstrating a variable range of therapeutic responses 
achieved for the PDT treatment of rat carotid arteries at different drug and light dosages 
[34].  
In the case of PPTT, investigations into the underlying nanoparticle-cellular 
interaction have demonstrated that cell apoptosis is initiated by disruption of the plasma 
membrane [35,36]. The same study also showed that a 10 fold reduction in laser energy is 
required for similar cell death if the nanoparticles are attached to the cell membrane 
versus internalized within the cytoplasm, as well as a 10 fold reduction in energy required 
when using a femtosecond pulsed laser rather than a continuous wave laser source [35].  
These findings offer insights into important considerations related to both the 
instrumentation utilized for PPTT and nanoparticle targeting strategies. Combination of 
PPTT and PDT for the treatment of atherosclerotic plaques will require several areas of 
ongoing research to evaluate whether each of these mechanisms holds true for 
atherosclerotic tissue. 
5.2.4. Modifications and Alternatives for Exogenous Contrast or Therapeutic 
Agents 
Continued development of IVUS/IVPA imaging for diagnosis and image-guided 
treatment of atherosclerosis offers several avenues for ongoing research, particularly 
regarding the design and delivery of contrast and/or theranostic agents. The expansive 
field of nanobiotechnology offers a huge array of potential designs which may offer 
 184 
advantages for future integration of nanomaterials with diagnosing and treating 
atherosclerosis; this section focuses on a few specific applications which are of particular 
interest given the scope of this dissertation. 
5.2.4.1. Modifications to Silica-Coated Plasmonic Multifunctional Nanoparticles 
Tailoring Degradation and Photosensitizer Release Kinetics 
One area of further development and modification to the doped-silica coated 
nanoparticle design rests in the refinement of the release kinetics of photosensitizing 
agents, or other therapeutics, from within the silica. A few initial potential avenues for 
tailoring the release have been investigated, but additional techniques merit further 
development. For example, the PEG-FITC/SiO2AuNR utilized within Chapter 4 required 
the quenching of SiO2 through the addition of 0.1 mg of 5 kD mPEG-silane per OD·mL 
of core AuNR. To investigate the effect of PEG on the release kinetics of FITC in cell 
culture media, a second PEGylation step was performed, whereby the PEG-
FITC/SiO2AuNR were reacted at a pH of 11 in isopropyl alcohol for four hours with 1 
mg per OD·mL PEG-silane. Surprisingly, the FITC release from the higher density PEG 
layer was found to occur on a faster time scale than that of the initial PEGylation 
protocol, indicating that they may exhibit more rapid silica degradation under 
physiological conditions (Fig. 5.2). 
 185 
 
Figure 5.2: Effect of PEG Density on cargo release for PEG-FITC/SiO2AuNR. 
The effect of optical pre-treatment using either the continuous wave (CW) or 
nanosecond pulsed laser on the release kinetics of PEG-FITC/SiO2AuNR was also 
investigated. Exposure of PEG-FITC/SiO2AuNR in cell culture media to 3 min of 10 
mJ/cm2 nanosecond pulsed irradiation at the AuNR peak absorbance wavelength was 
ineffective in directly inducing silica disruption and FITC release into the supernatant 
(Fig. 5.3A). A separate study evaluated the potential for CW or nanosecond pulsed laser 
irradiation to result in annealing of the silica layer as a means of elongating the release 
kinetics. Figure 5.3B demonstrated that no significant change was observed in the FITC 
release temporal profile from a dark control (green), and PEG-FITC/SiO2AuNR exposed 
to either 1 W/cm2 CW illumination (orange) or 2 mJ/cm2 nanosecond pulsed illumination 
(red) for 3 min. prior to incubation in culture media. A slight decay in the FITC 
fluorescence measurement over time was observed for the control group with only cell 
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culture media (blue) as well as all three experimental groups following the silica 
degradation and FITC release (after approximately 8 hours) due to photobleaching of 
fluorophores from the culture medium itself as well as FITC. 
 
Figure 5.3: Evaluation of laser induced modification of silica cargo release. (A) 
Fluorescence of supernatant before and after exposure of PEG-
FITC/SiO2AuNR to 10 mJ/cm
2 nanosecond pulsed illumination for 3 min at 
800 nm. (B) Release kinetics of PEG-FITC/SiO2AuNR pre-treated with no 
illumination (green), 1 W/cm2 808 nm continuous wave illumination 
(orange), or 2 mJ/cm2 nanosecond pulsed illumination (red) for 3 min. 
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Mesoporous Silica 
Utilizing the same fundamental structure as the multifunctional nanoparticles 
discussed in Chapter 4, comprising a noble metal nanoparticle core with a therapeutic 
agent doped in a silica shell, several notable modifications merit further investigation. For 
example, mesoporous silica particles have been widely investigated as high-payload drug 
carriers which can be modified to enable pH-triggered or thermally-trigger cargo release 
[37]. The direct doping of photosensitizing agents into an amorphous silica layer may be 
modified through the introduction of a templated mesoporous silica layer. In an initial 
attempt to create a mesoporous silica shell covering existing silica-coated gold nanorods, 
5 mL of SiO2AuNR were mixed with 250 µL of ammonia, 25 µL of 
tetraethylorthosilicate (TEOS) and 10 µL of octadecyltrimethoxysilane (ODTMS) and 
stirred for 3 hours before being triple washed. In order to ensure that the organic 
templating molecules, in this case ODTMS, are efficiently removed, the resulting 
particles were then resuspended in ethanol and vacuum dried overnight prior to being 
heated to 250 ˚C for one hour. Figure 5.4, however, shows a resulting TEM revealing 
that the core AuNR particles were broken apart during heating, further evidenced by a 
color change from red-orange to purple to teal blue. While classic mesoporous silica 
nanoparticle synthesis protocol utilize similar approaches for template removal, two 
recently reported applications utilizing mesoporous silica coated AuNR utilize only 
washing via centrifugation [38,39]. These approaches merit further investigation, as they 
may open the door for more easily controlled loading of photosensitizers and additional 
therapeutic agents. 
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Figure 5.4: Mesoporous silica coated SiO2AuNR at (A) low and (B) high resolution, 
revealing the breaking apart of core AuNR particles during organic template 
removal.  
Silver Nanoplate Core Particles 
Additionally, the AuNR core particles can be replaced with silver nanoplates 
(AgNP) which can also be tuned to absorb in the near infrared wavelength range for high-
contrast photoacoustic imaging [40]. AgNP were synthesized and tuned to a peak 
absorbance near 800 nm utilizing an established protocol and then coated with LuTex-
doped silica using the same procedure detailed in Chapter 4 (Fig. 5.5). The prepared 
silver-based multifunctional nanoparticles had an edge length of approximately 160 nm 
with a silica thickness of approximately 12 nm which degraded following incubation in 
cell culture media, suggesting that similar characteristics to the multifunctional AuNR 
discussed in Chapter 4 can be achieved using AgNP. The use of silver nanoparticles is of 
interest due to their known antibacterial and anti-inflammatory characteristics [41]. 
However, at this stage, the effect that such particles would have for intravascular 
applications seems to remain controversial, with conflicting reports regarding their 
interactions within the vasculature [42]. On one hand, silver nanoparticles have been 
1 µm 100 nmA B
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linked to endothelial cell dysfunction via oxidative stress as well as platelet aggregation 
and enhanced thrombus formation [43,44]. Contrarily, silver nanoparticles were also 
demonstrated to exhibit antiplatelet and anti-clot formation properties [45,46]. Clearly 
further investigation as to the true nature of their vascular interactions is needed. 
However, if the antiplatelet properties are verified, silver nanoparticles may provide an 
advantage over gold-core nanoparticles whereby the core particles themselves provide a 
localized vaso-protective effect following silica shell degradation and cargo release. The 
use of silver may have an additional long term advantage in that the gradual release of 
silver ions from the core particles may enable the entire multifunctional nanoparticle 
platform to exhibit biodegradability, although the kinetics of the core particle 
biodegradation should be carefully evaluated [47]. 
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Figure 5.5: Multifunctional silver nanoplates. (A) Optical extinction spectra at different 
stages of synthesis. (B) Validation of temporal stability of 
LuTex/SiO2AgNP in water and SiO2 degradation in cell culture media. (C) 
Representative TEM images of LuTex/SiO2AgNP as prepared (left, center) 
and following silica degradation in culture media for 72 hours (right). 
5.2.4.2. Alternative Nanoparticle Surface Functionalization Schemes 
Another consideration of nanoparticle design which should be investigated in 
greater detail is the surface functionalization. This dissertation has focused exclusively on 
the use of polyethylene glycol (PEG) stabilized nanoparticles, utilizing nonspecific 
phagocytosis of macrophages for selective, or at least preferential, cell labeling. In 
Chapter 3 the preferential phagocytosis of silica coated nanoparticles by macrophages 
relative to endothelial cells was demonstrated in vitro. However, the incorporation of 
macrophage-specific ligands may help further improve cellular specificity and 
1 µm 100 nm 100 nm
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
400 600 800 1000
N
o
rm
al
iz
e
d
 E
xt
in
ct
io
n
 (
a.
u
.)
Wavelength (nm)
Stability of LuTex/SiO2AgNP
LuTexSiO2-AgNP: As Prepared
LuTex/SiO2-AgNP: 2 weeks
LuTex/SiO2-AgNP: in DMEM,  4hr
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
400 600 800 1000
N
o
rm
al
iz
e
d
 E
xt
in
ct
io
n
 (
a.
u
.)
Wavelength (nm)
LuTex/SiO2-AgNP Synthesis
As Prepared AgNP
PEG-AgNP
LuTex/SiO2-AgNP
A B
C
 191 
nanoparticle phagocytosis kinetics. One potential alternative is the polysaccharide 
dextran, which enables nanoparticles to be efficiently endocytosed by interaction with 
scavenger receptors [48,49].  To demonstrate this potential, AuNR were coated with a 10 
kD dextran using a modification of the protocol utilized for AuNR PEGylation. Two 
milliliters of 10 mg/mL Dextran containing 10% Rhodamine-B Isothiocyanate 
conjugated dextran was mixed with 10 mL of AuNR at an optical density of 10, sonicated 
for 30 minutes and left on a shaker under modest agitation for four hours. The particles 
were then triple washed with water, resuspended in phosphate buffered saline, and passed 
through a 200 nm syringe filter for sterilization. The dextran-conjugated AuNR were then 
incubated with macrophages at variable nanoparticle concentrations under similar 
experimental conditions to those reported in Chapter 2 using PEG-AuNR. Figure 5.6 
reveals the resulting J774A.1 murine macrophage uptake following 18 hours of 
incubation as well as the maintained cell viability the day following nanoparticle 
incubation. In comparison to macrophage uptake of comparable concentrations of PEG-
AuNR, previously shown in Figures 2.2 and 2.4, higher labeling is achieved using 
dextran-AuNR.  
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Figure 5.6: J774A.1 murine macrophage uptake of dextran-stabilized gold nanorods and 
subsequent viability. (A) Brightfield (left) and fluorescence overlay (right) 
revealing extent of dextran-AuNR uptake for cells incubated with optical 
density 0, 0.5, 0.75, and 1.5 nanoparticles (top to bottom). Scale bar = 50 
µm. (B) Resulting cell viability as assessed by MTS assay the day following 
nanoparticle incubation with cells. 
In addition to the use of PEG or dextran to enable selectivity towards macrophage 
labeling, more sophisticated nanoparticle functionalization strategies may also be 
evaluated to enable expanded molecular-specific IVPA imaging. There are numerous 
biomarkers within atherosclerotic plaques which could be targeted at various stages of 
atherosclerotic plaque destabilization, ranging from vascular adhesion molecules to 
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matrix metalloproteinases to thrombin. For example, a cyclic peptide containing an 
arginine-glycine-aspartic acid (RGD) sequence was conjugated to AuNR using an 
established protocol involving the attachment of carboxylic acid functionalized PEG to 
the AuNR surface followed by the use of carbodiimide (EDC) chemistry to conjugate the 
peptide via an exposed amine group [50]. Figure 5.7 shows the AuNR optical spectra at 
various stages of synthesis and bioconjugation as well as the significantly enhanced 
uptake of the nanoparticles with RGD (right) as compared to PEGylated nanoparticles 
(left) in cells expressing a receptor for RGD peptide sequences. One such receptor is the 
integrin αvβ3, which is highly expressed in neovasculature of the vasa vasorum in 
advanced atherosclerotic lesions. Therefore, continued investigation into this and other 
targeting moieties may serve to expand the cellular and molecular specificity for IVPA 
imaging as well as targeted therapy.  
 
Figure 5.7: RGD peptide-conjugated AuNR. (A) Optical spectra of AuNR as prepared, 
PEGylated, and conjugated with RGD peptides. (B) 20X darkfield 
microscopy images of αvβ3 expressing MDA-MB-435 cells following 
incubation with PEG-AuNR (left) and RGD-PEG-AuNR (right). 
Another approach for improve cellular specificity utilizes a significant deviation 
in the nanoparticle design. Biomimetic nanoparticles which resemble high density 
lipoprotein (HDL) in size, shape and surface chemistry have recently been evaluated as 
contrast agents for magnetic resonance imaging and computer tomography [51-54]. Due 
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to the limited size of natural HDL, this particle design necessitates the use of smaller, 
spherical gold nanoparticles, approximately 5 nm, encompassed in a phospholipid shell 
with apolipoprotein A1 (Apo-A1), the protein natural found on the surface of HDL 
particles, embedded. HDL-mimicking gold nanospheres (AuNS) were prepared according 
to an established protocol, with the nanoparticle schematic and resulting negative stain 
TEM revealing gold core and phospholipid coating provided in Figures 5.8A and 5.8B, 
respectively [52]. Figure 5.8C demonstrates that incubation of phospholipid coated AuNS 
lacking Apo-A1 protein (left) and HDL-mimicking AuNS (right) with J774A.1 murine 
macrophages for 12 hours resulted in significantly higher HDL-mimicking nanoparticle 
uptake, as seen in the bright field images (top) and fluorescence images revealing the 
distribution of Rhodamine-labeled phospholipid which was incorporated into the 
particles. This result is expected based on the direct recognition of Apo-A1 by 
macrophage scavenger receptor A.  
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Figure 5.8: HDL-mimicking AuNS design and labeling efficiency. (A) Schematic design 
of biomimetic nanoparticles. (B) Negative stain TEM revealing AuNS core 
(dark) and phospholipid core (light). (C) Brightfield and fluorescence 
imaging of J774A.1 incubated with phospholipid-AuNS (left) and HDL-
mimicking-AuNS (right). Scale bar = 100 µm. 
The HDL-mimicking AuNS design offers a tradeoff between the inherent optical 
properties and the nanoparticle biodistribution. On the one hand, the small size of the 
core AuNR may enable their eventual clearance, as it has been demonstrated that 5 nm 
nanoparticles can be cleared through renal filtration [16]. This advantage may become 
significant if larger nanoparticles are shown to induce adverse long term effects following 
delivery into the vasculature. However, the potential for clearance has not been 
demonstrated specifically for the HDL-mimicking AuNS. The potential advantage is also 
offset by the less desirable optical characteristics of AuNS relative to AuNR. The optical 
absorption peak of AuNS falls at approximately 520 nm, which overlaps with strong 
hemoglobin absorption. While plasmon resonance coupling of AuNS within intracellular 
endosomes is known to cause a red shift and significant broadening of the absorbance 
peak, the extent of such coupling for macrophage labeled with HDL-mimicking AuNS 
25 nm
A
B C
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does not appear to provide contrast within the tissue optical window of the near infrared 
wavelength region, as assessed by hyperspectral microscopy (Fig. 5.9). Therefore, the use 
of AuNS-based nanoparticles is expected to provide low contrast than AuNR for IVPA 
imaging applications, and imaging through luminal blood is likely not an option. 
 
Figure 5.9: Plasmon resonance coupling of intracellular HDL-mimicking AuNS. (A) 40X 
brightfiled microscopy image of two HDL-mimicking AuNS labeled 
J774A.1 macrophage cells. (B) Brightfield hyperspectral analysis of the two 
cells shown in A, revealing little optical absorption beyond 650 nm. 
5.2.4.3. Indocyanine Green as a Contrast Agent for Intravascular Photoacoustic 
Imaging  
The use of metallic nanoparticles can be altogether eliminated through the use of 
organic chromophores such as indocyanine green (ICG). ICG is widely investigated as a 
biomedical optical contrast agents because it has already been approved for clinical use 
for limited indications [55]. Among these investigation applications is a recent report 
demonstrating that systemically injected ICG preferentially co-localizes with 
atherosclerotic plaques in animal models of atherosclerosis, similar to the labeling pattern 
shown in Chapter 2 for AuNR [56]. The organic fluorophore also is known to yield a 
concentration depended optical absorption spectrum, presenting both a challenge and 
potential means of quantification of contrast delivery using IVPA imaging. Figure 5.10 
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demonstrates an initial investigation into the sensitivity of IVPA to detect ICG at carious 
concentrations, revealing a minimum detectable concentration of approximately 500 µM.  
 
Figure 5.10: IVPA imaging of an ICG phantom. (A) Photograph of ICG in plasma at 10 
mM, 5 mM, 1 mM, 500 µM, 100 µM, 50 µM, 10 µM and 0 µM. (B) 
IVUS/IVPA image of cylindrically oriented inclusions containing the ICG 
concentrations shown in A. (C) Spectroscopic IVPA signal for inclusions in 
which ICG was detected, ≥ 500 µM. 
Continued development of IVPA imaging of ICG represents an attractive 
alternative to the use of metallic nanoparticles, primarily because of the rapid clearance 
of ICG. However, elimination of the metallic core particles will greatly reduce specificity 
for photothermal heating over background tissue due to the lower extinction coefficient 
of organic fluorophores in comparison to metallic nanoparticles. Therefore, alternative 
therapeutic strategies should also be investigated in parallel with studies evaluating the 
use of ICG for IVPA imaging contrast. 
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5.3. CONCLUSIONS 
Combined intravascular ultrasound and photoacoustic (IVUS/IVPA) imaging is 
actively being developed as a tool for improved characterization of high-risk 
atherosclerotic plaques. The use of exogenous contrast agents offers the potential for 
expanding the cellular and molecular specificity of IVPA imaging as well as the 
introduction of optically-triggered, local therapy of identified lesions. This dissertation 
has focused on introducing methods for expanding the IVUS/IVPA imaging platform to 
enable theranostics of atherosclerotic lesions using image-guided excitation of exogenous 
contrast agents delivered to macrophages within atherosclerotic lesions. While the overall 
approach needs continued refinement as it is translated to in vivo imaging and therapeutic 
applications, the potential for providing a new standard of interventional therapy that is 
cell-specific and locally-delivered merit its continued investigation.  
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